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Abstract 
The work described in this thesis investigates the actions of hypothalamic neuropeptides 
involved in the control of energy homeostasis and reproduction. 
Cerebellin 1 (Cbln1) is a 16-amino acid peptide abundantly expressed in the cerebellum and the 
hypothalamus. I have shown that Cbln1 increases food intake when administered centrally to 
rats, and that this effect may be partly mediated by neuropeptide Y. I have also demonstrated that 
Cbln1 mRNA expression within the ventromedial nucleus of the hypothalamus is up-regulated 
following a 48-hour fast, suggesting that Cbln1 may have a physiological role in the control of 
food intake.  
In addition to hypothalamic centres, the reward system has an important role in the control of 
feeding. The melanocortin system has a well characterised role in the homeostatic control of 
food intake. My work suggests that the melanocortin system may also have a previously 
unknown role within the ventral tegmental area (VTA) in the hedonic control of feeding. Intra-
VTA administration of a melanocortin agonist reduced, whereas an antagonist increased, food 
intake in rats. My work suggests that the VTA melanocortin system may act upstream of 
dopamine signalling to influence feeding.  
Kisspeptin is a hypothalamic neuropeptide with a crucial role in reproduction. The hypothalamus 
contains two populations of kisspeptin neurones, located in the arcuate nucleus (Arc) and in the 
anteroventral periventricular nucleus. The physiological role of these two populations is 
unknown. I used recombinant adeno-associated virus (rAAV) to suppress kisspeptin expression 
within the Arc in female rats. Animals injected bilaterally into the Arc with rAAV-kisspeptin 
antisense had significantly fewer oestrous cycles, and an increase in oestrous cycle length, 
compared to controls.  
In summary, these studies have identified novel roles for Cbln1 and the melanocortin system in 
the control of food intake, and have demonstrated the importance of Arc kisspeptin signalling in 
the regulation of reproduction. 
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1.1. The endocrine system 
Maintenance of a stable internal environment is essential for the survival of most organisms. In 
mammals, this stability is primarily achieved by two systems: the autonomic nervous system 
(ANS) and the endocrine system. Whilst the ANS signals rapidly via neural impulses and 
neurotransmitter release, the endocrine system communicates via chemical messengers, or 
hormones. Hormones are secreted by endocrine glands directly into the bloodstream and are 
transported to their often distant specific target cells. The endocrine system is therefore slower 
and less localised than the ANS.  
Although distinct, the ANS and endocrine system overlap in function and each influences the 
other. The hypothalamus is a key interface between both systems and can be considered a 
neuroendocrine organ, as it contains neurones which can release neurosecretions either across 
synapses, or directly into the bloodstream.  
The hypothalamus controls the release of hormones from the pituitary gland into the systemic 
circulation, which act upon target cells in peripheral tissues. Together, the hypothalamus and 
pituitary regulate numerous functions including reproduction, metabolism, growth and the stress 
response. An important characteristic of the endocrine system is its ability to regulate itself via 
negative feedback. Hormones released from peripheral endocrine organs act at the hypothalamus 
and pituitary to inhibit the stimuli for their own release, hence ensuring that the activity of the 
endocrine system remains within certain limits. 
 
1.2. Energy homeostasis and reproduction 
Body weight and fertility are closely linked. Pubertal onset and normal functioning of the 
reproductive axis are dependent on adequate body energy stores, and energy deficiency resulting 
from under-nutrition or excessive exercise results in a reduction in reproductive capacity in both 
humans and animals (Klentrou and Plyley, 2003; De Souza et al., 1998; Glass et al., 1976; Terry 
et al., 2005). At the opposite end of the spectrum, obesity is also linked to disorders of fertility 
(Rachon and Teede, 2010).  
The hypothalamus plays a crucial role in the regulation of both energy homeostasis and 
reproduction. By responding to and integrating numerous metabolic signals, the hypothalamus 
couples energy reserves with fertility. One such metabolic signal, which has a vital role in the 
control of both energy homeostasis and reproduction, is the adipokine leptin.  
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1.3. Leptin 
Leptin is a peptide hormone encoded by the ob gene and secreted by white adipose tissue (Zhang 
et al., 1994). Leptin circulates at levels proportional to body fat stores (Maffei et al., 1995; 
Considine et al., 1996) and  is able to cross the blood-brain barrier by a saturable process (Banks 
et al., 1996). Although leptin is generally thought to be a signal of long-term energy stores, 
circulating levels may become temporarily dissociated from body adipose tissue levels. For 
example following a 48 hour fast, serum leptin levels rapidly decrease and rise following re-
feeding in rodents (Ahima et al., 1996; Frederich et al., 1995).  
Mice genetically deficient in leptin (ob/ob) or the leptin receptor (db/db) are severely obese and 
hyperphagic. Additionally, male and female ob/ob mice do not enter puberty and are infertile 
(Swerdloff et al., 1976).  Leptin administration to ob/ob mice reduces food intake and body 
weight (Halaas et al., 1995), and restores fertility (Chehab et al., 1996). This suggests that leptin 
has a key role in the regulation of both energy homeostasis and reproduction. 
Peripheral and central administration of leptin to rodents reduces food intake and body weight, 
and increases energy expenditure (Halaas et al., 1995; Campfield et al., 1995; Van Heek et al., 
1997). Although cases of leptin deficiency resulting in severe early-onset obesity have been 
identified in humans (Montague et al., 1997), most obese people have elevated serum leptin 
compared to lean controls (Considine et al., 1996). This suggests that common obesity is 
associated with leptin resistance. Accordingly, diet-induced obese mice and obese humans are 
insensitive to the anorectic effect of peripherally administered leptin (Van Heek et al., 1997; 
Heymsfield et al., 1999).  
Leptin signals via the long form of the leptin receptor, ObRb, a member of the type 1 cytokine 
receptor family (Tartaglia et al., 1995). ObRb is expressed in hypothalamic and non-
hypothalamic sites including the reward system and the brainstem (Hakansson et al., 1998; 
Mercer et al., 1996b; Munzberg, 2008).  
Starvation induces neuroendocrine changes designed to conserve energy stores and aid survival. 
These include a reduction in reproductive capacity and thyroid hormone-induced thermogenesis. 
These changes are also observed in ob/ob mice, suggesting that a lack of leptin signalling 
induces these adaptations. Leptin administration corrects the neuroendocrine abnormalities 
observed in food-deprived mice (Ahima et al., 1996). The severe phenotype induced by leptin 
deficiency, and the apparent lack of effect of excess leptin in obesity, suggest that the main role 
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of leptin is to signal starvation, rather than nutrient excess, to the CNS. This signalling is 
primarily mediated via the hypothalamus. 
 
1.4. The hypothalamus 
The hypothalamus is present in the brain of all vertebrates. It is located in the ventral part of the 
diencephalon and lies inferior to the thalamus, surrounding the third ventricle. The hypothalamus 
regulates several functions including body temperature, reproduction, electrolyte balance and 
circadian rhythm. By detecting and responding to internal and external stimuli, the hypothalamus 
plays an integral role in maintaining bodily homeostasis. 
The hypothalamus can be divided into three distinct zones: the periventricular, medial, and 
lateral zones (Berthoud, 2002). Each zone contains numerous discrete collections of neuronal 
cell bodies, or nuclei (Figure 1.1).  
 
1.5. Hypothalamic regulation of food intake and energy expenditure 
A role for the hypothalamus in energy homeostasis was first suggested in the mid-20th century, 
when it was discovered that bilateral lesions of the lateral hypothalamus resulted in anorexia in 
rats, whereas destruction of the ventromedial hypothalamus led to obesity and hyperphagia 
(Hetherington and Ranson, 1940; Anand and Brobeck, 1951). The lateral hypothalamus was 
therefore designated the ‘feeding centre’ and the ventromedial nucleus the ‘satiety centre’. The 
‘dual centre’ hypothesis is now considered too simplistic and it is instead thought that circuits 
between and within discrete hypothalamic nuclei communicate via specific neurotransmitters to 
regulate food intake and energy expenditure. Additionally, many extra-hypothalamic areas 
including the brainstem, reward centres and higher cortical areas are now known to be involved 
in the control of feeding (Berthoud, 2002). 
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1.5.1. Arcuate nucleus 
The Arcuate nucleus (Arc) of the hypothalamus is an elongated collection of neuronal cell bodies 
which lies adjacent to the floor of the third ventricle (Schwartz et al., 2000). The Arc is situated 
directly above the median eminence, a circumventricular organ which lacks a complete blood-
brain barrier, and is thus ideally situated to detect and respond to circulating signals of short- and 
long-term nutritional status (Broadwell and Brightman, 1976). Numerous peripheral signals act 
at the Arc to influence energy homeostasis, including adipokines such as leptin (Glaum et al., 
1996), insulin (Wilcox et al., 1989), gut hormones, such as ghrelin (Hewson and Dickson, 2000), 
and metabolites, such as glucose (Lynch et al., 2000).  
The Arc contains two major groups of neurones which influence energy homeostasis. Located 
medially are a subpopulation of neurones which co-express the orexigenic peptides neuropeptide 
Y (NPY) and agouti-related protein (AgRP) (Hahn et al., 1998). A second, lateral sub-population 
co-express the anorexigenic peptide cocaine-and amphetamine-regulated transcript (CART), and 
the precursor protein pro-opiomelanocortin (POMC), which is cleaved to produce the anorectic  
alpha-melanocyte stimulating hormone (α-MSH) (Elias et al., 1998a). In addition to exerting 
opposing actions, a small population of NPY neurones directly inhibit adjacent POMC/CART 
neurones via local release of gamma-aminobutyric acid (GABA) (Cowley et al., 2001).  
Both NPY/AgRP and POMC/CART neurones express the leptin receptor (Mercer et al., 1996a; 
Cheung et al., 1997). Leptin inhibits the activity of NPY/AgRP neurones and stimulates the 
activity of POMC/CART neurones, hence promoting a state of negative energy balance (Elias et 
al., 1998a; Elias et al., 1999). 
NPY/AgRP co-expressing neurones of the Arc project to various hypothalamic nuclei implicated 
in the control of food intake, including the paraventricular nucleus (PVN), lateral hypothalamus 
(LH) and dorsomedial nucleus (DMN). Additionally, extra-hypothalamic targets include the 
ventral tegmental area (VTA), the amygdala, and the bed nucleus of the stria terminalis (BNST) 
(Broberger et al., 1998). POMC/CART co-expressing neurones also project widely to 
hypothalamic and extra-hypothalamic sites (Elias et al., 1998a; Elias et al., 1998b).   
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1.5.2. Paraventricular nucleus 
The PVN is situated adjacent to the superior part of the third ventricle and contains two 
functionally distinct cell divisions. Magnocellular neurones synthesise arginine vasopressin 
(AVP) and oxytocin and project to the posterior lobe of the pituitary gland. Parvocellular 
neurones produce corticotrophin releasing hormone (CRH) and thyrotrophin releasing hormone 
(TRH) and project to other hypothalamic nuclei, the brainstem, and the median eminence 
(Swanson and Kuypers, 1980). At the median eminence, parvocellular nerve terminals release 
CRH and TRH into the pituitary portal circulation (Swanson and Sawchenko, 1983). CRH and 
TRH regulate the hypothalamo-pituitary-adrenal (HPA) and hypothalamo-pituitary-thyroid 
(HPT) axes respectively.  
The PVN plays a crucial role in energy homeostasis. Bilateral lesions of the PVN cause 
hyperphagia (Fukushima et al., 1987) and intra-hypothalamic administration of either CRH or 
TRH reduces food intake and increases energy expenditure (Suzuki et al., 1982; Arase et al., 
1988). CRH and TRH neurones in the PVN are hypothesised to act downstream of Arc 
NPY/AgRP and POMC/CART neurones (Schwartz et al., 2000). NPY/AgRP and POMC/CART 
neurones project to the PVN, and intra-PVN administration of NPY stimulates, whereas α-MSH 
inhibits, food intake in rats (Stanley and Leibowitz, 1984; Giraudo et al., 1998).  
The PVN receives inputs from hypothalamic nuclei including the Arc, DMN and VMN, and 
from extra-hypothalamic sites such as the brainstem and cortico-limbic structures (Berthoud, 
2002). In addition to projecting to the posterior pituitary and median eminence, the PVN also has 
direct inputs to sympathetic and parasympathetic pre-ganglionic neurones (Jansen et al., 1997). 
The PVN is therefore able to integrate information from a variety of sources to initiate 
appropriate endocrine and autonomic responses.  
 
1.5.3. Ventromedial nucleus 
The VMN lies superior to the Arc and has reciprocal connections with the brainstem and most 
hypothalamic nuclei involved in the regulation of food intake (Canteras et al., 1994). It was 
originally designated the ‘satiety centre’ of the brain, as bilateral lesions of the VMN induce 
obesity and hyperphagia in rats (Anand and Brobeck, 1951). It has since been suggested that the 
observed phenotype may have been caused by damage to the neighbouring Arc and PVN 
(Aravich and Sclafani, 1983). However, mice lacking steroidogenic factor 1 (SF1), a relatively 
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VMN-specific transcription factor, have abnormal VMN cellular morphology (Dellovade et al., 
2000) and are obese (Majdic et al., 2002). VMN SF1 neurones are leptin-responsive and loss of 
leptin signalling in SF1 neurones causes obesity (Dhillon et al., 2006).  
Brain-derived neurotrophic factor (BDNF), a neurotrophin essential for brain development, is 
highly expressed within the VMN (Xu et al., 2003). BDNF is a potent anorexigenic factor; 
central infusion of BDNF reduces food intake, induces weight loss and improves glucose 
homeostasis in diabetic db/db mice (Pelleymounter et al., 1995; Ono et al., 1997). BDNF mRNA 
expression within the VMN is reduced by fasting (Xu et al., 2003) and mice heterozygous for the 
BDNF gene are heavier and eat more than their wild-type littermates (Kernie et al., 2000). 
BDNF is hypothesised to act downstream of the melanocortin system to reduce food intake, as 
VMN BDNF mRNA expression is down-regulated in MC4R knockout mice, and administration 
of an MC4R agonist rescues fasting-induced suppression of BDNF expression (Xu et al., 2003). 
 
1.5.4. Dorsomedial nucleus 
The dorsomedial nucleus of the hypothalamus (DMN) is located immediately dorsal to the 
VMN. Unlike the VMN, ablation of the DMN causes hypophagia and reduced body weight gain 
(Dalton et al., 1981). The DMN receives afferent inputs from hypothalamic nuclei including the 
Arc, and from the brainstem (Thompson and Swanson, 1998). Projections from the DMN are 
largely intra-hypothalamic; the PVN is particularly densely innervated (Thompson et al., 1996).  
The DMN contains a population of NPY-expressing neurones, and DMN NPY expression is up-
regulated in states of energy deprivation, for example following intense exercise, food restriction 
or lactation (Lewis et al., 1993; Smith, 1993). The DMN contains a high density of the leptin 
receptor ObRb and is highly responsive to peripheral leptin administration  (Elmquist et al., 
1998a). 
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1.5.5. Lateral hypothalamic area 
The lateral hypothalamic area (LH) is a large, heterogeneous region located lateral to the VMN. 
It has reciprocal connections with hypothalamic nuclei including the Arc and PVN and projects 
widely to the hippocampus, thalamus and amygdala (Saper et al., 1979; Elias et al., 1998b). The 
LH was originally termed the ‘feeding centre’ of the brain, as early studies demonstrated that 
bilateral lesions resulted in hypophagia (Anand and Brobeck, 1951). Subsequently, it was 
discovered that the LH is the site of production of two groups of orexigenic neuropeptides: 
melanin-concentrating hormone (MCH) and the orexins. Both MCH and orexin-expressing 
neurones receive dense innervations from arcuate NPY/AgRP and α-MSH fibres (Elias et al., 
1998b) and hence indirectly signal downstream of leptin. 
In mammals, MCH-expressing neuronal cell bodies are found exclusively in the zona incerta and 
lateral hypothalamus (Skofitsch et al., 1985). ICV administration of MCH acutely stimulates 
feeding (Qu et al., 1996) and reduces energy expenditure by suppressing the HPT axis (Kennedy 
et al., 2001). Furthermore, hypothalamic MCH expression is up-regulated by fasting and is 
elevated in leptin deficient ob/ob mice compared to wild-type controls (Qu et al., 1996).  Mice 
lacking MCH are lean and hypophagic (Shimada et al., 1998). 
A distinct neuronal population within the LH express prepro-orexin, which is processed to 
produce orexin A and orexin B. Prepro-orexin mRNA expression is increased by fasting and ICV 
administration of orexin A or B increases food intake (Sakurai et al., 1998). Orexin knockout 
mice have a phenotype very similar to human narcolepsy (Chemelli et al., 1999) and the orexins 
are hence thought to be important mediators of sleep and wakefulness. The effects of the orexins 
on appetite may therefore be at least partly secondary to effects on wakefulness. 
The LH is also hypothesised to coordinate the homeostatic control of food intake and the 
rewarding, hedonistic aspect of feeding. The LH has reciprocal connections with the limbic 
system (Saper et al., 1979; Usuda et al., 1998) and the effects of the mesocorticolimbic dopamine 
system on food intake may be mediated by LH neurones (Stratford and Kelley, 1999).  
 
 
 
26 
 
1.6. Extra-hypothalamic regions involved in the control of energy homeostasis  
 
1.6.1. The brainstem 
The brainstem, consisting of the midbrain, pons and medulla, is a site of convergence for meal-
related satiety signals. It plays a vital role in the control of energy homeostasis and is able to 
regulate food intake even when severed from the forebrain in rats (Grill and Smith, 1988). 
The nucleus tractus solitarius (NTS) of the brainstem is particularly important in the control of 
energy homeostasis. The NTS lies along the length of the medulla and receives afferent input 
from the glossopharyngeal, trigeminal, and facial nerves, which convey taste and sensory 
information from the tongue and face. The NTS is also the termination site of vagal sensory 
neurones originating in the gastrointestinal tract. These neurones relay information regarding 
visceral chemo- and mechanosensation. Many gut hormones, including cholecystokinin (CCK) 
and ghrelin mediate their effects on food intake partly via vagal signalling to the brainstem 
(Smith et al., 1981; Date et al., 2002). 
The NTS lies in close proximity to the area postrema (AP), a circumventricular organ which, like 
the Arc, lacks a complete blood-brain barrier. The AP is therefore able to detect meal-related 
blood-borne signals and, due to the rich projections from the AP to the NTS, relay this 
information directly to the NTS.  
The NTS also has reciprocal connections with the forebrain and projects particularly strongly to 
the PVN and DMN (Ter Horst et al., 1989). Neuronal populations expressing POMC, NPY and 
glucagon-like peptide 1 (GLP-1) are located in the NTS and project widely to the forebrain.  
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1.6.2. The mesocorticolimbic pathway 
In addition to homeostatic circuits in the hypothalamus and brainstem, the cortico-limbic 
structures involved in cognition, emotion and reward also play an important role in the control of 
feeding. This is particularly relevant in today’s obesogenic environment in which there is a 
surplus of easily available palatable food. There is extensive cross-talk between the 
hypothalamus and areas involved in the non-homeostatic control of feeding. It has been 
suggested that these pathways allow cognitive and emotional factors to override homeostatic 
signals, and hence promote food intake even in the absence of an energy deficit (Berthoud, 
2006).  
Dopaminergic neurones projecting from the ventral tegmental area (VTA) in the midbrain to the 
nucleus accumbens (NAc), olfactory tubercle, hippocampus and pre-frontal cortex comprise the 
mesocorticolimbic dopamine pathway (Ikemoto, 2007) (Figure 1.2). This pathway is an 
important component of the CNS motivational circuitry and has a major role in mediating the 
rewarding properties of substances including palatable food and drugs of abuse.  
Rewarding stimuli, including cocaine, opiates and palatable food, increase dopamine release 
within the NAc (Pettit and Justice, Jr., 1989; Wilson et al., 1995; Di Chiara and Imperato, 1988). 
The reinforcing effect of extracellular dopamine release in the NAc is demonstrated by the 
finding that rats will repeatedly self-administer the dopamine-releasing agent amphetamine into 
the NAc (Hoebel et al., 1983).   
Over time, repeated stimulation of reward pathways induced by chronic drug use induces 
neuroadaptations within the mesocorticolimbic dopaminergic pathway (Volkow et al., 2004). 
Repeated ingestion of palatable food may induce similar changes and contribute to compulsive 
over-eating and obesity (Wang et al., 2001). 
Dopamine has long been known to influence energy homeostasis. Dopamine depletion within the 
ventrolateral striatum disrupts feeding behaviour, and dopamine-deficient mice are severely 
hypophagic (Zhou and Palmiter, 1995). The dopamine transporter (DAT) mediates dopamine 
clearance from the synaptic cleft, and hence terminates dopamine signalling. DAT mRNA 
expression levels are altered in the VTA following food restriction (Patterson et al., 1998), 
further supporting a role for mesocorticolimbic dopamine in the control of food intake.  
It is well known that food deprivation enhances the rewarding attributes of drugs of abuse (Bell 
et al., 1997; Carroll and Meisch, 1981). Starvation induces a series of metabolic changes 
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including hypoleptinaemia and hypoinsulinaemia. Recent work has suggested that low levels of 
both insulin and leptin may mediate the effect of food deprivation on reward circuitry. Food-
conditioned place preference can be abolished by peripheral leptin treatment to food restricted 
rats (Figlewicz et al., 2001), and ICV administration of leptin or insulin reduces sucrose self-
administration in rats (Figlewicz et al., 2006). However, this effect is blunted if animals are fed a 
high fat diet for several weeks prior to the study (Figlewicz et al., 2006), suggesting that high fat 
feeding induces central resistance to leptin and insulin.  
ICV insulin administration increases DAT mRNA expression and hence reduces dopaminergic 
signalling within the VTA (Figlewicz et al., 1994). Insulin and leptin receptors are localised on 
VTA dopaminergic neurones (Figlewicz et al., 2003), suggesting that in addition to acting at the 
Arc to reduce food intake, leptin and insulin may also act  directly on the mesocorticolimbic 
dopamine system to reduce the rewarding properties of food. Additionally, hypothalamic 
neuropeptides including the melanocortins (Tracy et al., 2008; Davis et al., 2010) and the orexins 
(Zheng et al., 2007) may influence food intake by modulating reward pathways. 
In addition to dopamine, other neurotransmitters including glutamate and GABA are implicated 
in reward and reinforcement. GABAergic interneurones within the VTA tonically inhibit 
dopaminergic neurones (Matthews and German, 1984; David et al., 1997). In contrast, excitatory 
glutamatergic inputs to the VTA from cortical structures and the brainstem increase VTA 
dopamine transmission (Carter, 1982).  
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Figure 1.2: Sagittal section of the rat brain showing the mesocorticolimbic dopaminergic 
pathway, which originates in the ventral tegmental area (VTA) and projects to the 
nucleus accumbens (NAc) and prefrontal cortex (PFC). The VTA also has reciprocal 
connections with the tegmental pedunculopontine nucleus (TPP). Taken from (Laviolette and 
van der Kooy, 2004).  
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1.7. Central regulators of energy homeostasis 
 
1.7.1. NPY 
NPY is one of the most widely distributed neurotransmitters in the central nervous system (Allen 
et al., 1983) and is an extremely potent stimulator of food intake (Levine and Morley, 1984). 
Within the hypothalamus, NPY-expressing neurones are most abundant in the Arc and mainly 
project to the ipsilateral PVN (Bai et al., 1985). Arcuate NPY neurones are stimulated by ghrelin 
(Kohno et al., 2003) and inhibited by leptin and insulin (Wang et al., 1997b; Schwartz et al., 
1991).  
Intra-PVN administration of NPY to rats acutely induces carbohydrate-specific hyperphagia 
(Stanley et al., 1985). Additionally, chronic administration of NPY into the third ventricle or 
directly  into the PVN increases food intake, reduces energy expenditure and ultimately causes 
obesity (Stanley et al., 1986; Billington et al., 1991; Zarjevski et al., 1993). The reduction in 
energy expenditure is partly mediated by a reduction in brown adipose tissue (BAT)-mediated 
thermogenesis (Egawa et al., 1991). Chronic ICV administration of NPY also induces 
hyperinsulinaemia and hepatic lipogenesis, independently of changes in food intake (Zarjevski et 
al., 1993).  
Levels of NPY expression and release in the rodent hypothalamus reflect nutritional status, by 
increasing during fasting and decreasing after re-feeding (Kalra et al., 1991; Brady et al., 1990). 
Additionally, long-term down-regulation of Arc NPY expression using anti-sense RNA reduces 
body weight gain and food intake in adult rats (Gardiner et al., 2005). This suggests that NPY 
has a physiological role in the control of food intake.  
NPY is a member of the pancreatic polypeptide family, which also includes peptide tyrosine 
tyrosine (PYY) and pancreatic polypeptide (PP). These peptides bind to members of the Y 
receptor family, of which there are at least 6 members (Y1-Y6). NPY binds preferentially to Y1 
and Y5 receptors, and ICV administration of a Y1 or Y5 antagonist inhibits NPY-induced and 
nocturnal food intake (O'Shea et al., 1997; Daniels et al., 2002). 
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1.7.2. Melanocortin system 
Within the CNS, POMC is synthesised exclusively in neurones of the Arc and NTS of the 
brainstem (Young et al., 1998). However, POMC-expressing fibres project widely throughout 
the forebrain and brainstem (Joseph et al., 1985). POMC can be post-translationally cleaved to 
produce several bioactive peptides including adrenocorticotrophic hormone (ACTH) and α, β 
and γ-melanocyte stimulating hormone (MSH).  
ICV α-MSH administration reduces food intake in fasted rats (Tsujii and Bray, 1989) and arcuate 
POMC mRNA expression levels are reduced by fasting and increased following leptin 
administration or re-feeding (Schwartz et al., 1997). In addition to suppressing food intake, α-
MSH stimulates the hypothalamo-pituitary-thyroid (HPT) axis and hence increases energy 
expenditure. Alpha-MSH nerve fibres terminate in close proximity to thyrotrophin-releasing 
hormone (TRH) neurones in the PVN (Fekete et al., 2000), and ICV administration of an α-MSH 
analogue increases plasma levels of  thyroid-stimulating hormone (TSH) (Kim et al., 2000b). 
Additionally, central α-MSH administration increases sympathetic nerve activity in BAT and 
increases BAT temperature (Yasuda et al., 2004).  
To date, five melanocortin receptors (MC1R-MC5R) have been cloned. Alpha-MSH exerts its 
effects on energy homeostasis via the melanocortin 3 receptor (MC3R) and melanocortin 4 
receptor (MC4R).  
The MC4R is widely expressed in the brain, particularly in hypothalamic nuclei involved in the 
control of feeding such as the PVN, DMN and LH (Mountjoy et al., 1994). ICV administration 
of MC4R agonists potently reduces food intake, whereas MC4R antagonists stimulate food 
intake (Benoit et al., 2000). Inactivation of the MC4R results in hyperphagia, obesity, and 
hyperinsulinaemia in mice and humans (Huszar et al., 1997; Yeo et al., 1998). 
The role of the MC3R is less well defined. MC3R mRNA is abundant throughout the 
hypothalamus, particularly in the Arc (Roselli-Rehfuss et al., 1993). Although mice lacking the 
MC3R have increased fat mass, they are not hyperphagic (Chen et al., 2000). However, mice 
lacking both the MC3R and MC4R are heavier than those lacking only the MC4R, suggesting 
that the two receptors have distinct roles in the control of energy homeostasis (Chen et al., 2000).  
Two endogenous antagonists of the melanocortin system have been identified: agouti and AgRP. 
Expression of agouti is usually restricted to hair follicles, whereas AgRP is located almost 
exclusively within NPY neurones of the Arc (Shutter et al., 1997). AgRP is a selective 
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MC3R/MC4R antagonist (Ollmann et al., 1997). ICV administration of AgRP blocks the 
anorexigenic effect of  α-MSH and can elicit an increase in food intake which lasts for 24 hours 
or longer  (Rossi et al., 1998; Small et al., 2003). Additionally, recent work using optogenetic 
techniques has demonstrated that stimulation of Arc AgRP neurones is sufficient to induce 
feeding independently of melanocortin receptor antagonism (Aponte et al., 2011). Chronic ICV 
AgRP administration for 7 days reduces oxygen consumption and  energy expenditure, leading 
to an increase in body weight (Small et al., 2003). Mice engineered to over-express AgRP are 
obese and hyperphagic (Ollmann et al., 1997).  
 
1.7.3. Cocaine and Amphetamine Related Transcript 
Cocaine and amphetamine related transcript (CART) is widely distributed throughout the central 
and peripheral nervous system, and is abundantly expressed in hypothalamic nuclei involved in 
the control of food intake including the Arc, PVN, DMN, SON, and VMN (Douglass et al., 
1995). In the Arc, over 90% of CART neurones co-express POMC mRNA (Elias et al., 1998a).  
ICV administration of active CART peptide fragments inhibits basal and starvation-induced food 
intake in rats (Lambert et al., 1998; Kristensen et al., 1998). ICV injection of antiserum raised 
against CART stimulates feeding, and CART mRNA within the Arc is down-regulated in fasted 
animals, suggesting that endogenous CART is a physiological anorectic agent (Lambert et al., 
1998; Kristensen et al., 1998). CART mRNA expression is increased following leptin 
administration, therefore, similarly to POMC, CART expression is positively regulated by leptin 
(Kristensen et al., 1998).  
Despite these findings, ICV CART administration has been noted to induce a movement-
associated tremor in rats, implying that its effects on food intake may be secondary to 
behavioural changes (Kristensen et al., 1998). Additionally, injection of CART into specific 
hypothalamic nuclei including the Arc and PVN acutely increases food intake in non-diabetic 
(Abbott et al., 2001) and diabetic  (Hou et al., 2010) rats, suggesting that the role of CART in the 
control of energy homeostasis is more complex than originally thought. 
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1.8. Energy expenditure 
Under most conditions, homeostatic mechanisms ensure that energy intake closely matches 
energy expenditure to maintain body weight at a relatively constant level. However, if energy 
intake exceeds energy expenditure, weight gain and obesity develop.  
Energy expenditure can be subdivided into obligatory thermogenesis, which refers to the loss of 
heat resulting from all metabolic processes that support life; physical activity; and adaptive 
thermogenesis. Adaptive thermogenesis is heat production in response to environmental 
temperature or diet. The HPT axis is an important mediator of adaptive thermogenesis.  
 
1.8.1. The hypothalamo-pituitary-thyroid axis 
The HPT axis plays a vital role in the control of metabolism and energy expenditure.  
TRH is a tri-peptide primarily produced by neurones in the parvocellular PVN, although it is also 
present in other areas of the CNS (Winokur and Utiger, 1974). TRH-expressing neurones 
terminate in the median eminence in close proximity to capillaries of the hypothalamo-
hypophyseal portal system. TRH is transported by this capillary plexus to the adenohypophysis, 
where it stimulates the biosynthesis and release of TSH (Harris et al., 1978).  
TSH binds to receptors on the thyroid gland and increases the synthesis and release of the 
thyroid hormones, thyroxine (T4) and the more biologically active tri-iodothyronine (T3). T4 is 
converted to T3 in peripheral tissues by the iodothyronine deiodinase enzyme type 2 deiodinase. 
T3 and T4 exert negative feedback at the hypothalamus and pituitary gland to inhibit the release 
of TRH and TSH respectively. 
T3 and T4 increase the basal metabolic rate of many tissues, thus increasing oxygen 
consumption. Thyroid hormones also stimulate adaptive thermogenesis, the heat production 
observed following cold exposure or consumption of an energy-dense meal. One mechanism by 
which T3 drives thermogenesis is by increasing the expression and activity of uncoupling protein 
1 (UCP-1) in brown adipose tissue (Branco et al., 1999). UCP-1 uncouples the mitochondrial 
proton gradient from ATP production, leading to the release of energy as heat.  
Starvation suppresses the HPT axis to decrease energy expenditure and hence conserve 
resources. This down-regulation is characterised by reduced prepro-TRH mRNA expression 
within the PVN, low TSH and reduced circulating T3 and T4 (Blake et al., 1991; Connors et al., 
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1985). The fall in circulating leptin during fasting is thought to play a key role in mediating this 
down-regulation, as leptin administration to fasted animals restores plasma thyroid hormones to 
fed levels (Ahima et al., 1996). Leptin acts directly at TRH neurones to increase pro-TRH 
biosynthesis, and indirectly via arcuate NPY/AgRP and POMC neurones. Both NPY/AgRP and 
POMC/CART- expressing neurones project to TRH neurones within the PVN (Fekete et al., 
2000; Legradi and Lechan, 1999; Toni et al., 1990). Alpha- MSH increases, whereas NPY and 
AgRP reduce plasma TSH and thyroid hormones (Kim et al., 2000b; Fekete et al., 2001). 
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1.9. Hypothalamic regulation of reproduction 
In mammals, reproductive function is controlled by the hypothalamo-pituitary-gonadal (HPG) 
axis. The hypothalamus is the location of neuronal cell bodies expressing gonadotrophin-
releasing hormone (GnRH), a neuropeptide which drives the release of the gonadotrophins 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary 
gland. LH and FSH act at the gonads to regulate steroidogenesis and gametogenesis (Figure 1.3).  
The hypothalamus also contains neurones expressing kisspeptin, a 54-amino acid peptide which 
has a crucial role in the control of the HPG axis. Loss of function of either kisspeptin or its 
receptor, GPR54, results in impaired pubertal development and infertility (Seminara et al., 2003; 
de Roux N. et al., 2003; d'Anglemont de Tassigny et al., 2007). Kisspeptin is hypothesised to act 
upstream of GnRH to regulate reproduction (Irwig et al., 2004; Matsui et al., 2004; Pielecka-
Fortuna et al., 2008).  
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Figure 1.3: The hypothalamo-pituitary-gonadal (HPG) axis. GnRH is released by 
hypothalamic neurones into the portal circulation and stimulates the release of LH and FSH 
from the adenohypophysis. LH and FSH act at the gonads to stimulate steroidogenesis and 
gametogenesis. In males, testosterone exerts negative feedback at the pituitary gland and 
hypothalamus. In females, depending on the stage of the cycle, oestrogen exerts negative or 
positive feedback to inhibit or stimulate activity of the HPG axis respectively. Abbreviations: 
GnRH, gonadotrophin-releasing hormone; LH, luteinizing hormone; FSH, follicle-stimulating 
hormone.  
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1.10. Central regulators of reproduction 
 
1.10.1. Gonadotrophin-releasing hormone 
The decapeptide GnRH is the primary drive for the HPG axis in adult mammals and is crucial in 
initiating the onset of puberty. GnRH cell bodies are not localised within a discrete nucleus but 
are scattered throughout the anterior hypothalamus, in particular the preoptic and medial basal 
areas (Silverman et al., 1987), from where they project to the median eminence. GnRH is 
released in a pulsatile fashion into the pituitary portal circulation. This pulsatility is essential for 
normal reproductive function; exposure to continuous exogenous GnRH disrupts gonadotrophin 
secretion (Belchetz et al., 1978; Clayton et al., 1982). The generation of GnRH pulses is 
incompletely understood. Immortalised hypothalamic GnRH neurones are able to secrete GnRH 
in a synchronised, pulsatile fashion, demonstrating that these neurones have an intrinsic firing 
properties (Wetsel et al., 1992). However, it is thought that external factors also modify and 
coordinate GnRH pulses. Steroid hormones, leptin (Lebrethon et al., 2000) and neurotransmitters 
including NPY (Crowley and Kalra, 1987) and glutamate (Bourguignon et al., 1989) are known 
to regulate GnRH neuronal activity. Over the last decade, a critical role for the kisspeptins in 
GnRH release has also been described (Irwig et al., 2004). 
GnRH binds to receptors on gonadotroph cells in the adenohypophysis and stimulates the 
pulsatile release of LH and FSH into the systemic circulation. Circulating gonadotrophins act 
upon the gonads. In males, LH binds to Leydig cells of the testes and regulates the synthesis of 
testosterone. In females, LH acts at thecal cells of the developing follicle and stimulates the 
production of androgens, primarily androstenidione. The mid-cycle LH surge in females also 
stimulates ovulation. 
In males, FSH acts at Sertoli cells and regulates spermatogenesis. In females, FSH induces the 
aromatisation of androgens produced by thecal cells to oestrogens in neighbouring granulosa 
cells.  
Gonadal steroids exert negative feedback at the hypothalamus and pituitary to suppress activity 
of the HPG axis. Additionally, in specific stages of the female reproductive cycle, oestrogen 
exerts positive feedback at the hypothalamus and pituitary to potentiate its own secretion. This 
positive feedback leads to a peak in circulating oestrogen and LH, which is crucial in initiating 
ovulation. However, the mechanism by which gonadal steroids exert negative and positive 
feedback at the hypothalamus is unclear, as GnRH neurones appear to lack oestrogen and 
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androgen receptors (Shivers et al., 1983). Recently, kisspeptin has emerged as a potential 
mediator of sex steroid feedback.  
 
1.10.2. Kisspeptin 
Kisspeptin is a 54-amino acid peptide encoded by the KiSS-1 gene. Although originally 
identified as a metastasis-suppressor, kisspeptin is now known to have an essential role in the 
control of reproduction. 
In humans the KiSS-1 gene encodes a 145-amino acid product (Ohtaki et al., 2001; Muir et al., 
2001) which is processed to generate kisspeptin-54, corresponding to residues 68-121 of the full 
length translation product (Ohtaki et al., 2001). Shorter fragments of 10, 13 and 14 amino acid 
residues have also been isolated (Kotani et al., 2001; Bilban et al., 2004). Collectively these 
peptides are termed the kisspeptins. All share a common C-terminal decapeptide which is 
essential for receptor binding and activation (Kotani et al., 2001).  
The kisspeptins bind to and activate the G-protein coupled receptor GPR54 (Ohtaki et al., 2001; 
Kotani et al., 2001; Muir et al., 2001). KiSS-1 and GPR54 mRNA expression is highest within 
the placenta but both are also reported to be expressed in the pituitary, brain, testis, ovary, liver, 
pancreas and small intestine (Ohtaki et al., 2001; Kotani et al., 2001). Within the CNS, KiSS-1 is 
highly expressed in the hypothalamus and basal ganglia (Muir et al., 2001) and GPR54 mRNA is 
abundant in the hypothalamus and amygdala (Lee et al., 1999).  
A role for kisspeptin and GPR54 signalling in the control of reproduction was first suggested 
when it was discovered that loss of function mutations within the GPR54 gene are associated 
with hypogonadotrophic hypogonadism, defined as impaired pubertal development and 
reproductive function due to defective pituitary LH and FSH secretion (Seminara et al., 2003; de 
Roux N. et al., 2003; Semple et al., 2005). Similarly, mice lacking either GPR54 or KiSS-1 are 
infertile and display abnormal sexual maturation (Seminara et al., 2003; Funes et al., 2003; 
d'Anglemont de Tassigny et al., 2007; Lapatto et al., 2007).  
Central and peripheral administration of kisspeptin potently increases LH and FSH release 
(Thompson et al., 2004; Matsui et al., 2004; Gottsch et al., 2004) and can stimulate ovulation in 
primed rats (Matsui et al., 2004). Strong evidence suggests that the effect of kisspeptin on the 
HPG axis is mediated via hypothalamic GnRH. KiSS-1 immuno-reactive fibres are located in 
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regions of the forebrain where GnRH neurones reside, including the medial preoptic area 
(MPOA), the anterior hypothalamic area and the Arc (Brailoiu et al., 2005). Over 75% of GnRH 
neurones co-express GPR54 mRNA (Irwig et al., 2004) and kisspeptin is able to directly 
depolarize and increase firing rates of GnRH neurones (Pielecka-Fortuna et al., 2008). 
Additionally, pre-treatment with a GnRH antagonist abolishes the effect of kisspeptin on 
gonadotrophin release in vivo (Matsui et al., 2004; Gottsch et al., 2004). In rodents, kisspeptin 
neuronal cell bodies located in the Arc and anteroventral periventricular nucleus (AVPV) have 
received particular attention as both areas are known to project heavily to forebrain areas 
containing GnRH neurones (Simonian et al., 1999). 
Forebrain kisspeptin neurones are hypothesised to relay gonadal steroid feedback to GnRH 
neurones. Most kisspeptin neurones within the Arc and AVPV express receptors for oestrogen, 
progesterone and androgens, suggesting they are direct targets for sex steroids (Smith et al., 
2006b; Smith et al., 2005b; Clarkson et al., 2008). Hypothalamic KiSS-1 mRNA expression is 
regulated by circulating steroids. Interestingly, in rodents this regulation is nucleus-specific. 
Following castration or ovariectomy, KiSS-1 mRNA expression dramatically increases in the 
Arc, but decreases in the AVPV (Smith et al., 2006b; Smith et al., 2005b). This suggests that the 
two nuclei may relay gonadal steroid hormone negative feedback (in both males and females) 
and positive feedback (in females only) to GnRH neurones respectively.  
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1.11. Energy homeostasis and reproduction are co-regulated 
Although essential for propagation of the species, reproduction is not essential for the survival of 
an individual and so mechanisms have evolved to allow the reproductive axis to be switched off 
in times of energy insufficiency. Body energy stores must be adequate to permit pubertal onset 
and normal functioning of the HPG axis. In humans, under-nutrition and extreme exercise induce 
menstrual irregularities, amenorrhoea and infertility (Klentrou and Plyley, 2003; De Souza et al., 
1998). In rats, food deprivation suppresses circulating LH and sex steroid levels (Badger et al., 
1985; Castellano et al., 2005), delays puberty (Glass et al., 1976) and prevents normal 
reproductive function (Terry et al., 2005). 
Leptin has long been known to influence the HPG axis. Leptin-deficient ob/ob mice are infertile 
and their fertility can be restored with leptin replacement (Chehab et al., 1996). Leptin increases 
GnRH pulse frequency in vitro (Lebrethon et al., 2000) and stimulates LH release in vivo (Finn 
et al., 1998). However, GnRH neurones do not express the leptin receptor ObRb (Hakansson et 
al., 1998) and hence the mechanism by which leptin influences the HPG axis must be indirect. 
Recently, it has been suggested that leptin conveys metabolic information to the HPG axis via 
hypothalamic kisspeptin neurones. Kisspeptin neurones within the Arc co-express ObRb mRNA, 
and ob/ob mice have significantly lower hypothalamic KiSS-1 mRNA levels than wild type 
controls (Smith et al., 2006a). Leptin replacement rescues KiSS-1 expression in these animals 
(Smith et al., 2006a). Similarly, food deprivation, resulting in low circulating leptin levels, 
decreases hypothalamic KiSS-1 mRNA in pre-pubertal rats (Castellano et al., 2005). Central 
kisspeptin administration restores vaginal opening and increases circulating gonadotrophins in 
chronically under-fed female rats that would otherwise not progress through puberty (Castellano 
et al., 2005). Additionally, the LH response to exogenous kisspeptin is preserved in food-
deprived animals, suggesting that even in a state of negative energy balance, kisspeptin is able to 
activate the HPG axis (Castellano et al., 2005). However, it has recently been found that male 
and female mice lacking the leptin receptor specifically on hypothalamic kisspeptin neurones 
progress through puberty and are fertile, suggesting that direct leptin signalling in kisspeptin 
neurones is not essential for normal reproductive function (Donato et al., 2010). 
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1.12. Aims of this thesis 
In order to develop new strategies for the treatment of obesity or cachexia, it is important to 
characterise endogenous factors which regulate energy homeostasis and understand the pathways 
involved in appetite regulation. Cerebellin 1 (Cbln1) is a hypothalamic neuropeptide expressed 
in areas of the brain involved in appetite regulation. In chapter 2 of this thesis I describe the 
effects of Cbln1 on food intake.  
The reward system plays a crucial role in the control of appetite, yet little is known about the 
mechanisms by which it modulates food intake. In chapter 3 of this thesis I have investigated the 
mechanisms by which reward pathways, specifically within the VTA, may affect energy 
homeostasis.  
Reproduction and food intake are intimately linked, and the hypothalamus has a vital role in the 
control of both systems. Hypothalamic kisspeptin neurones are essential regulators of 
reproduction, and relay metabolic signals to GnRH neurones. In chapter 4 of this thesis I have 
investigated the role of kisspeptin signalling, specifically in the Arc, in the control of 
reproduction.   
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Chapter 2: Investigating the role of 
Cerebellin 1 in the regulation of 
energy homeostasis and 
neuroendocrine function 
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2.1. Introduction  
2.1.1. Cerebellin 1 
Cerebellin1 (Cbln1) is a highly conserved 16-amino acid protein (Yiangou et al., 1989) 
originally isolated from rat cerebellum (Slemmon et al., 1984). The amino acid sequence of 
Cbln1 is shown in Figure 2.1 (Slemmon et al., 1984). 
 
S-G-S-A-K-V-A-F-S-A-I-R-S-T-N-H 
 
 
 
Cbln1 is widely distributed throughout the CNS and peripheral tissues (Burnet et al., 1988; Satoh 
et al., 1997). Pre-Cbln1 mRNA (Miura et al., 2006) and Cbln1 peptide (Burnet et al., 1988) are 
highly expressed within the hypothalamus, in particular in the VMN (Segal et al., 2005; Miura et 
al., 2006).  
 
2.1.2. Pre-Cerebellin1 
Cbln1 is a proteolytic cleavage product of Pre-Cerebellin1 (Pre-Cbln1), a 193-amino acid 
peptide (Urade et al., 1991). Pre-Cbln1 is a member of the Pre-Cerebellin gene family of which 
there are four members (Pre-Cblns1-4) (Urade et al., 1991; Pang et al., 2000). These peptides 
share 60-80% sequence homology and are located on different chromosomes (Pang et al., 2000).  
The Pre-Cblns are part of the C1q/tumour necrosis factor superfamily which also includes 
adiponectin and collagen X (Kishore et al., 2004). The C-terminal two-thirds of these family 
members share significant homology with the globular domain of the B chain of the complement 
subunit C1q (Urade et al., 1991) and have a similar three-dimensional structure to tumour-
necrosis factor-α (TNF-α) (Shapiro and Scherer, 1998).  
The Pre-Cblns form homomeric and heteromeric, hexameric complexes in vitro (Pang et al., 
2000; Bao et al., 2005) which can affect their secretory profiles (Iijima et al., 2007). The C1q 
Figure 2.1: Amino acid sequence of Cbln1. S: Serine; G: Glycine; A: Alanine; K: Lysine; 
V: Valine; F: Phenylalanine; I: Isoleucine; R: Arginine; T: Threonine; N: Asparagine; H: 
Histidine. 
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motif permits trimer formation and the amino terminus is essential for the formation of higher 
order complexes (Iijima et al., 2007; Pang et al., 2000; Bao et al., 2005).  
Mice lacking Pre-Cbln1 are ataxic and have impaired motor coordination (Hirai et al., 2005). 
This is thought to be due to impaired matching and maintenance of synapses between parallel 
fibres and Purkinje cells within the cerebellum (Hirai et al., 2005). Injection of recombinant Pre-
Cbln1 temporarily rescues the ataxia in these mice (Ito-Ishida et al., 2008). The phenotype of 
Pre-Cbln1 knockout mice is very similar to that of mice lacking the orphan glutamate receptor 
delta-2 subunit (GluD2) (Hirai et al., 2005) and it has recently been suggested that Pre-Cbln1 
may interact with GluD2 to modulate cerebellar synaptic integrity (Matsuda et al., 2010).  
 
2.1.3. Localisation of Pre-Cbln1 and Cbln1 
Within the cerebellar cortex, Pre-Cbln1 mRNA is localised in granule cells, which form synapses 
with Purkinje cells via parallel fibres (Hirai et al., 2005; Miura et al., 2006). However, Cbln1 
peptide is mainly located within the cell body and dendrites of Purkinje cells (Slemmon et al., 
1985). Pre-Cbln1 may therefore be secreted pre-synaptically, bind to Purkinje cells and be 
internalised and processed to produce Cbln1 (Bao et al., 2005).  
In addition to the cerebellum, Pre-Cbln1 mRNA and Cbln1 peptide has been detected in 
numerous regions of the CNS including the dorsal cochlear nucleus (Mugnaini and Morgan, 
1987), hypothalamus (Burnet et al., 1988; Satoh et al., 1997; Miura et al., 2006), thalamus, 
hippocampus and spinal cord (Satoh et al., 1997; Miura et al., 2006). Within the mouse 
hypothalamus, the main site of Cbln1 expression is the VMN (Segal et al., 2005; Miura et al., 
2006), an area important in food intake, body weight and glucose homeostasis.  
Pre-Cbln1 mRNA and Cbln1 peptide has also been detected peripherally, although at lower 
levels than in the CNS. Cbln1 is located in numerous tissues including the thyroid gland, anterior 
pituitary gland, testis, ovaries, pancreas (Rucinski and Malendowicz, 2009), adrenal gland (Satoh 
et al., 1997), heart, and stomach (Burnet et al., 1988). Additionally, Cbln1 has been located in 
several human tumour tissues including phaeochromocytomas and cortisol-producing 
adrenocortical adenomas (Satoh et al., 1997). 
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2.1.4. Function of Cbln1 
As yet, the biological functions of Cbln1 are poorly characterised. Cbln1 is enriched in 
synaptosomes (Slemmon et al., 1984) and is released upon depolarisation in a calcium-dependent 
manner, suggesting it may have neuromodulatory properties (Burnet et al., 1988). The receptor 
for Cbln1 has not yet been elucidated.  
Cerebellar Cbln1 levels rise in parallel with post-partum development, in particular migration of 
granule cells and Purkinje cell maturation (Slemmon et al., 1985; Morgan et al., 1988). Mice 
with mutations affecting cerebellar development, for example the ‘wheeler’, ‘reeler’ and 
‘staggerer’ have reduced Cbln1 content within the cerebellum (Slemmon et al., 1988). 
Additionally, patients suffering from cerebellar degenerative diseases such as 
olivopontocerebellar atrophy and Shy-Drager syndrome have significantly reduced Cbln1 
content in the cerebellum (Mizuno et al., 1995). This, together with the observed phenotype of 
the Pre-Cbln1 knockout mouse, suggests that Pre-Cbln1 and/or Cbln1 may have an important 
physiological role in cerebellar development, particularly synaptic development and 
maintenance.  
Cbln1 stimulates catecholamine, aldosterone and corticosteroid release from human and rat 
adrenal glands in vitro (Mazzocchi et al., 1999; Albertin et al., 2000). Chronic subcutaneous 
administration of Cbln1 to rats increases corticosterone and aldosterone secretion independently 
of adrenocorticotropic hormone (ACTH) (Hochol et al., 2001). 
In addition, Cbln1 has an insulinostatic effect on pancreatic islets in vitro, and subcutaneous 
administration of Cbln1 to rats decreases plasma insulin concentrations (Strowski et al., 2009). It 
should be noted that Cbln1 immunoreactivity is not present in the circulation (Satoh et al., 1997) 
and therefore any endogenous effects of Cbln1 are likely to be mediated via local autocrine or 
paracrine mechanisms.  
  
2.1.5. The effect of Cbln1 on energy homeostasis and endocrine function 
The presence of Cbln1 within the hypothalamus suggests it may have an endogenous role in the 
control of food intake and energy expenditure. Additionally, its localisation within peripheral 
endocrine organs and its effects on the adrenal gland and pancreas suggest Cbln1 may have a 
role in endocrine function.  
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2.1.6. Hypothesis 
I hypothesise that Cbln1 plays a role in the regulation of food intake and endocrine function.  
 
2.1.7. Aims 
To determine the role of Cbln1 in the regulation of feeding I will investigate: 
 
- The effect of ICV Cbln1 administration on food intake in fasted and ad libitum fed male 
Wistar rats. 
- The effect of ICV Cbln1 administration on behaviour in male Wistar rats. 
- The effect of chronic ICV administration of Cbln1 on food intake and body weight in 
male Wistar rats. 
- Possible mechanisms underlying the actions of Cbln1 on food intake, by determining the 
effect of Cbln1 on hypothalamic neuropeptide release ex vivo. 
- The effect of nutritional status on Pre-Cbln1 mRNA expression within the rat 
hypothalamus. 
 
I will also investigate the effect of ICV Cbln1 administration on plasma anterior pituitary 
hormones and corticosterone in male Wistar rats. 
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2.2. Methods 
2.2.1. Materials 
Cbln1, angiotensin II and neuropeptide S (NPS) were purchased from Bachem (St Helens, 
Merseyside, UK). BIBP 3226 trifluoroacetate (BIBP 3226) was purchased from Tocris 
Bioscience (Bristol, UK).  
 
2.2.2. Animals 
Male Wistar rats (specific pathogen free; Charles River, Margate, Kent, UK) weighing 250-300g 
were maintained in individual cages with a solid floor and wire mesh lid under controlled 
temperature (21-23°C) and light (12:12 light-dark cycle) conditions with ad libitum access to food 
(Rat and Mouse 1 (RM1) diet, Special Diet Service Ltd, Witham, Essex, UK) and water. Cage 
dimensions were 245 (width) x 415 (length) x 18.5 (depth) mm.  
All animal procedures undertaken were approved by the British Home Office Animals (Scientific 
Procedures) Act 1986 (Project License 70/6402). 
 
2.2.3. Intracerebroventricular cannulation and injection 
Rats were anaesthetised with 2L/minute oxygen and 4% inhaled isoflurane (Abbott Laboratories 
Ltd, Queenborough, Kent, UK). Animals were placed in the induction chamber until they lost the 
pedal reflex. Once anaesthetised, animals were administered intra-peritoneal prophylactic 
antibiotics (amoxycillin (37.5mg/kg) and flucloxacillin (37.5mg/kg)) to prevent post-operative 
infection. Rats were positioned on a stereotactic frame (David Kopf Instruments, supplied by 
Clark Electromedical Instruments, Reading, Berkshire, UK) with the incisor bar 3mm below the 
interaural line. The head was cleaned with 10% w/v povidone/iodine solution (Ecolabs Ltd, 
Leeds, Yorkshire, UK) and a 1.5cm longitudinal incision made in the scalp. A hole was drilled 
using a stereotactically mounted electric drill (Department of Medical Engineering, Imperial 
College London, UK). Stereotactic coordinates calculated from the Rat Brain Atlas (Paxinos and 
Watson, 2007) were as follows: 0.8mm posterior to the bregma in the midline and 6.5mm below 
the surface of the skull. A permanent 22-gauge stainless steel cannula (Plastics One Inc., 
Roanoke, Virginia, USA) projecting to the third cerebral ventricle was implanted. Dental cement 
(Associated Dental Products Ltd, Swindon, Wiltshire, UK) was used to hold the cannula in 
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position and seal the wound; this was anchored by three stainless steel screws inserted into the 
skull. Animals were administered subcutaneous buprenorphine (45mg/kg, Schering-Plough Corp, 
Welwyn Garden City, Hertfordshire, UK) for post-operative analgesia and rehydrated with 0.9% 
sodium chloride (5ml/rat). A plastic-topped wire cap (Plastics One Inc.) was inserted into the 
cannula to prevent blockage. 
After a seven day recovery period, animals were handled daily and acclimatised to the injection 
procedure. To ensure cannulae were correctly positioned, rats received ICV 50ng angiotensin II 
in a 5µl volume between 09:00 and 10:00. Following injection, animals were observed for a 
prompt drinking response. Those that did not respond were given a second angiotensin II 
injection three days later.  
Peptides or vehicle were administered to conscious, freely moving rats in a volume of 5μl via a 
28-gauge stainless steel injector placed into, and projecting 1mm below, the tip of the cannula. 
The injector was connected by polythene tubing to a Hamilton syringe (Fisher Scientific, 
Loughborough, Leicestershire, UK) in a Harvard infusion pump (Harvard Apparatus, 
Massachusetts, USA). The tubing was filled with water and an air bubble drawn up to separate 
the experimental compound from the water. 
Each experimental group was injected by a single individual to reduce cross-contamination of 
peptides between injections and to permit all animals to be injected within a relatively short time 
period (less than 1 hour), minimising the effect of daily fluctuations in food intake. The 
minimum washout period between injections was 72 hours. Animals which were considered 
unwell, or had reduced bodyweight or low food intake, were excluded from studies. 
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2.2.4. The effect of ICV Cbln1 administration on food intake in fasted rats in the early light 
phase 
As the effects of ICV Cbln1 administration on food intake were unknown, the initial study was 
carried out in fasted rats. Fasting induces an exaggerated re-feeding response and so the 
anorectic effect of an administered peptide can be easily observed.  
Male Wistar rats were ICV cannulated as described in section 2.2.3 and fasted for 24 hours prior 
to the study. Rats were randomised into groups by body weight and ICV injected with saline or 
Cbln1 at doses of 3, 10 or 30nmol per rat (n=9 per group) in the early light phase (08:00-10:00).  
Following injection rats were returned to their home cage with a pre-determined amount of food 
and free access to water. Food was re-weighed at 1, 2, 4, 8 and 24 hours post-injection. 
 
2.2.5. The effect of ICV Cbln1 administration on food intake in ad libitum fed rats in the 
early light phase 
Rats were ICV cannulated as described in section 2.2.3. As the results from study 2.2.4 
suggested that Cbln1 may induce an orexigenic effect, the second study was carried out in ad 
libitum fed rats in the early light phase. The light phase is not the usual feeding period for rats so 
an orexigenic effect is easier to observe.  
Ad libitum fed rats were randomised into groups by body weight and ICV injected with either 
saline or 1, 3, 10 or 30nmol Cbln1 (n=9 per group) in the early light phase (08:00-10:00). 
Following injection rats were returned to their home cage with a pre-determined amount of food 
and free access to water. Food was re-weighed at 1, 2, 4, 8 and 24 hours post-injection. 
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2.2.6. The effect of ICV Cbln1 administration on behaviour in ad libitum fed rats in the 
early light phase 
Behaviour was monitored following ICV administration of Cbln1 to determine whether the 
effects of Cbln1 on food intake were secondary to behavioural changes. Rats were ICV 
cannulated as described in section 2.2.3. Ad libitum fed rats were ICV injected with saline, 
10nmol Cbln1 or 30nmol Cbln1 (n=10-12 per group) in the early light phase and returned to 
their home cages. These doses of Cbln1 were chosen because they significantly increased food 
intake in study 2.2.5. NPS was used as a positive control as it is known to induce behavioural 
abnormalities, and was injected ICV at a dose of 10nmol per rat (Smith et al., 2006c).  
Behaviour was continuously monitored for one hour by two observers blinded to the 
experimental treatment using methods adapted from Fray et al (Fray et al., 1980; Scott et al., 
2005). Each rat was observed for fifteen seconds every five minutes. Each fifteen second period 
was sub-divided into three five second periods and the behaviour of the rat was noted in each 
time period. Behaviour was classified into the following categories: feeding, drinking, rearing, 
locomotion, grooming, burrowing, head down, sleeping and pica (Table 2.1, adapted from (Scott 
et al., 2005)). 
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Behaviour 
 
Description 
Feeding 
 
Animal feeding at hopper or feeding from 
food held in paws 
Drinking Animal licking at water spout 
 
Rearing Animal with front paws off the ground 
 
Locomotion Animal moving around the cage with all 
four legs moving 
 
Grooming 
 
Animal scratching, licking or biting itself 
Burrowing Animal scratching at sawdust bedding 
 
Head down Animal with nose lowered 
 
Sleeping Animal sleeping 
 
Pica 
 
Animal eating non-nutritive substance 
 
 
 
 
 
 
Table 2.1: Description of behaviour types observed following ICV administration of 
Cbln1. 
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2.2.7. The effect of Cbln1 on neuropeptide release from hypothalamic explants 
Materials 
Artificial cerebrospinal fluid (aCSF) equilibriated with 95% oxygen and 5% carbon 
dioxide (Appendix I) 
Potassium-enriched aCSF equilibriated with 95% oxygen and 5% carbon dioxide 
(Appendix I) 
 
Methods 
Ad libitum fed male Wistar rats were killed by decapitation in the early light phase. The whole 
brain was immediately removed, mounted ventral surface uppermost onto a pre-cooled block and 
placed in a vibrating microtome (Microfield Scientific Ltd., Dartmouth, Devon, UK). A 1.9mm 
slice was taken from the basal hypothalamus and dissected free. The hypothalamic slice taken 
included the MPOA, SON, PVN, DMN, VMN, LH and Arc.  
Hypothalamic slices were transferred to individual tubes containing 1ml aCSF. Tubes were 
placed on a platform in a water bath maintained at 37ºC. After an initial two hour equilibration 
period, hypothalami were treated with 600μl aCSF for 45 minutes (basal period), followed by 
treatment with 600μl aCSF supplemented with 10, 100 or 1000nM Cbln1 for 45 minutes (test 
period, n=9-12 hypothalamic slices per group). Tissue viability was confirmed by incubating 
slices in 600μl aCSF containing 56mM KCl for 45 minutes. Isotonicity was maintained by 
substituting K+ for N+. Explants which failed to show increased peptide release in response to 
aCSF supplemented with KCl compared to basal levels were excluded from analysis.  
Artificial CSF was collected at the end of each period and stored at -20ºC until measurement of 
NPY, AgRP, CART and α–MSH by radioimmunoassay (RIA) (section 2.2.8.).  
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2.2.8. Radioimmunoassay 
2.2.8.1. Principles of radioimmunoassay 
Radioimmunoassay (RIA) is a technique used to detect small quantities of substances in tissue or 
plasma samples. The principle of RIA is based on competition between a known amount of 
radio-labelled antigen and unlabelled antigen in the sample for binding to a known concentration 
of antibody. The concentration of the antibody is limiting, so antigen binding will be finite. An 
increase in the concentration of unlabelled antigen will decrease the number of binding sites 
available for labelled antigen, and hence the amount of antibody-bound labelled antigen is 
inversely proportional to the quantity of unlabelled antigen. A standard curve is constructed 
using known concentrations of peptide to calculate the percentage of labelled peptide bound for 
each concentration of pure unlabelled peptide.  
Antibody-bound antigen can be separated from unbound antigen by several methods. The two 
used in this work were separation by adsorption with charcoal, or by using a primary 
antibody/secondary antibody complex. 
For charcoal separation, dextran was added to a charcoal suspension (Appendix I) to block large 
holes in the charcoal. 4mg charcoal was added to each RIA tube, where it trapped unbound 
antigen. Tubes were then centrifuged for 20 minutes at 1500g and the supernatant and pellet 
separated by aspiration. 
For secondary antibody separation, the secondary antibody is derived from an animal species 
different from that in which the primary antibody is generated. The secondary antibody used in 
this work was sheep or goat anti-rabbit solid phase second antibody (Pharmacia Diagnostics, 
Uppsala, Sweden). Samples were pre-incubated for 60 minutes with 100µl of secondary 
antibody. Immediately prior to centrifugation, 500µl of 0.01% Triton-X-100 solution and 100µl 
of 10% polyethylene glycol was added to each tube. Samples were then centrifuged at 1500g at 
4°C for 20 minutes. Bound and free label were separated by aspiration. 
For both methods, bound and free label were counted in a gamma counter (model NE1600, 
Thermo Electron Corporation, Ohio, USA) and peptide concentrations in samples calculated 
using a non-linear plot (RIA Software, Thermo Electron Corporation).  
All samples were assayed in duplicate. Non-specific binding (NSB) tubes, which did not contain 
antibody, were included at the beginning of each assay. Tubes containing half and twice the 
standard volume of radio-labelled antigen were included to check quality of the radiolabel. 
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Tubes with no sample (zero tubes) were interspersed throughout the assay to measure baseline 
drift.   
All peptides used for RIAs in this work were iodinated by Professor M. Ghatei using the iodogen 
method (Bryant, 1982). Reaction products were purified by high performance liquid 
chromatography (HPLC) (Gilson 321-H1) using a C18 column (Waters, Milford, Connecticut, 
USA). Fractions were tested by RIA and used at 1500 counts per minute/tube (cpm/tube). 
Antisera were raised in rabbits immunized with each peptide conjugated to Freund’s adjuvant as 
previously described (White, 1963).  
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2.2.8.2. Hypothalamic neuropeptide RIAs 
All assays were performed using 0.06M phosphate buffer (Appendix I). Standard curves for each 
assay were prepared using synthetic peptide made up to varying concentrations in assay buffer and 
added in duplicate at volumes of 1, 2, 3, 5, 10, 15, 20, 30, 50 and 100µl.  
 
2.2.8.2.1. NPY RIA 
NPY peptide was purchased from Bachem (UK) Ltd. Standard curves prepared for the NPY assay 
were made up to 1pmol/ml in assay buffer. The assay was carried out in 0.06M phosphate buffer 
with 1% bovine serum albumin (BSA) and 0.02% Tween 20. Sample volume of hypothalamic aCSF 
was 150µl and samples were assayed in duplicate in a total volume of 350µl, containing rabbit anti-
NPY antibody at a final dilution of 1:120,000 and 1500cpm/tube of iodinated NPY. The antiserum 
showed full cross reactivity to synthetic NPY. The assays were incubated at 4°C for 72 hours, before 
free and antibody bound peptide were separated using a secondary antibody. The sensitivity of the 
assay was 1fmol/ml. The intra- and inter-assay variation was 7% and 8% respectively. 
 
2.2.8.2.1. AgRP RIA 
AgRP was measured using a commercially developed RIA from Phoenix Pharmaceuticals Inc. 
(Burlingame, California, USA). The AgRP (82-131)-NH2 assay utilises 125I-labelled AgRP and 
AgRP antiserum to determine the level of AgRP in samples. Reagents were supplied and 
reconstituted according to the protocol. Standards, quality controls and samples (all 100μl) were 
added in duplicate. One hundred microlitres of primary antibody (rabbit anti-serum containing an 
antibody specific for AgRP) was added to all tubes except those measuring NSB. The assay was 
incubated for 24 hours at 4ºC. Following this incubation period, 100μl of 125I-AgRP (10000 cpm 
per 100μl) was added to all tubes. The assay was incubated for a further 24 hours at 4ºC. 
Following this incubation, 100μl of goat anti-rabbit secondary antibody and normal rabbit serum 
were added to all tubes. The assay was incubated at room temperature for 90 minutes prior to the 
addition of 500μl of assay buffer. 
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2.2.8.2.3. Alpha-MSH RIA 
Alpha-MSH peptide was purchased from Bachem (UK) Ltd. Standard curves prepared for the α-
MSH assay were made up to 0.2pmol/ml in assay buffer. The assay was carried out in 0.06M 
phosphate buffer containing 0.3% BSA. Sample volume of hypothalamic aCSF was 100µl and 
samples were assayed in duplicate in a total volume of 400µl, containing a rabbit anti-α-MSH 
antibody at a final dilution of 1:20000 and 1500cpm/tube of iodinated α-MSH. The antiserum 
showed full cross reactivity to synthetic α-MSH but no cross reactivity to any other POMC product. 
The assays were incubated at 4°C for 72 hours, before free and antibody bound peptide were 
separated by charcoal adsorption of the free fraction. The sensitivity of the assay was 1fmol/ml. The 
intra- and inter-assay variation was 7% and 8% respectively. 
 
2.2.8.2.4. CART RIA 
CART peptide was purchased from Bachem (UK) Ltd. Standard curves prepared for the CART 
assay were made up to 1pmol/ml in assay buffer. The assay was carried out in 0.06M phosphate 
buffer containing 0.3% BSA and 0.02% Tween 20. Sample volume of hypothalamic aCSF was 
20µl and samples were assayed in duplicate in a total volume of 350µl, containing a rabbit anti-
CART antibody at a final dilution of 1:80000 and 1500cpm/tube of iodinated CART. The assays 
were incubated at 4°C for 72 hours, before free and antibody bound peptide were separated by 
charcoal adsorption of the free fraction. The sensitivity of the assay was 1.25fmol/tube. The 
intra- and inter-assay variation was 8% and 9% respectively. 
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2.2.9. The effect of ICV Cbln1 administration on food intake following pre-treatment with 
a Y1 receptor antagonist in the early light phase 
My results from study 2.2.7 showed that treatment of hypothalamic explants with Cbln1 induced 
a significant increase in NPY release. I therefore hypothesised that the orexigenic effect of Cbln1 
may be mediated via NPY. In order to investigate this further I co-administered Cbln1 with 
BIBP 3226, a Y1 receptor antagonist which has been shown to attenuate the orexigenic effect of 
NPY but have no effect on food intake when administered alone (O'Shea et al., 1997). 
Rats were ICV cannulated as described in section 2.2.3. Ad libitum fed rats (n=10-12 per group) 
were given ICV injections at time 0, and 30 minutes later, in the early light phase. The following 
injection regimen was used: vehicle/saline, vehicle/Cbln1 (10nmol), BIBP 3226 (60nmol)/saline, 
BIBP 3226 (60nmol)/Cbln1 (10nmol). As BIBP 3226 is insoluble in saline, the vehicle 
administered for the first ICV injection was 70% ethanol, which has previously been shown to 
have no effect on food intake (O'Shea et al., 1997).  
After the second injection rats were returned to their home cage with a pre-determined amount of 
food and free access to water. Food was re-weighed at 1, 2, 4, 8 and 24 hours.  
 
2.2.10. The effect of chronic ICV Cbln1 administration on food intake and body weight 
Rats were ICV cannulated as described in section 2.2.3. Ad libitum fed rats (randomised by body 
weight, n=8-10 per group) received twice daily ICV injections (at the beginning of the light 
phase and just prior to the onset of the dark phase) of saline or 10nmol Cbln1 for four days. This 
dose of Cbln1 was chosen because it was the lowest dose to significantly increase in food intake 
in study 2.2.5. 
Following each injection rats were returned to their home cage with a pre-determined amount of 
food and free access to water. Food intake and bodyweight were measured daily for the duration 
of the study. 
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2.2.11. The effect of nutritional status on hypothalamic Pre-Cbln1 mRNA expression 
I decided to use in situ hybridisation to detect and semi-quantify Pre-Cbln1 mRNA within the 
hypothalamus of rats either fed ad libitum or fasted for 48 hours. In situ hybridisation relies on 
binding of a probe, usually radio-labelled, to target mRNA in tissue. Probe binding can then be 
visualised using autoradiography.   
In order to do this I first constructed a probe corresponding to nucleotides 63-381 of rat Pre-
Cbln1 cDNA. The cDNA fragment was produced by reverse transcription and amplified by 
polymerase chain reaction, then ligated into a plasmid. Following bacterial transformation, small 
scale and large scale amplification of plasmid DNA were performed.  Plasmid DNA was purified 
and sent for sequence analysis, prior to use as a template for the production of a radio-labelled 
RNA probe.  
 
2.2.11.1. Construction of a Pre-Cbln1 probe 
2.2.11.1.1 Reverse transcription 
Materials 
Rat whole brain RNA (5mg/ml) 
5x reverse transcriptase buffer (Promega, Madison, Wisconsin, USA) 
10mM deoxynucleoside triphosphates (dNTPs) (GE Healthcare, Amersham, Bucks, UK) 
Oligo dT 200ng/μl (GE Healthcare) 
Reverse transcriptase (RT) 10U/µl (Promega) 
 
Methods 
The reaction was set up in a total volume of 20μl containing 20μg RNA, 1x reverse transcription 
buffer, 1mM dNTPs and 10mg/ml oligo dT and heated to 60°C for five minutes. The solution 
was left at room temperature for thirty minutes before the addition of 10U reverse transcriptase. 
The reaction was heated to 42°C for one hour then used in PCR. 
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2.2.11.1.2. Polymerase chain reaction (PCR) 
Materials 
10x Taq buffer (Sigma-Aldrich, Gillingham, Dorset, UK) 
20μM oligonucleotide primers (Table 2.2) 
10mM dNTPs (GE Healthcare) 
Taq DNA polymerase (5U/μl) (Sigma-Aldrich) 
Phenol/chloroform (VWR) 
2M sodium acetate (NaAc) (Appendix I) 
Ethanol (VWR) 
 
5’ primer GCAGAATGAGACAGAAGCCA 
  3’ primer GGATGGTCTGTCTGTTGTAG 
  Base pairs 318 
  Accession number NM_001109127 
  Restriction enzymes BamH1 and EcoR1 
 
 
 
Methods 
10μl of the reverse transcription reaction was added to a tube containing 10μl Taq buffer, 200nM 
oligonucleotide primers and 0.2mM dNTPs. The reaction was heated to 95°C for three minutes. 
Five units Taq DNA polymerase was then added and the reaction cycled twenty two times 
through the following program: 95°C for thirty seconds, 55°C for thirty seconds and 72°C for 
thirty seconds. After completion, 10µl PCR product was visualised by gel electrophoresis (see 
section 2.2.11.1.3).  
The remaining PCR products were purified with an equal volume of phenol/chloroform, mixed 
well and centrifuged for two minutes at 12,300g. The aqueous phase was removed to a new tube. 
DNA was purified by ethanol precipitation; 1/10 sample volume of 2M sodium acetate was 
added, the sample mixed, then 2.5 volumes ice cold 100% ethanol added. The reaction was 
Table 2.2: Primer sequences used in polymerase chain reaction (PCR) to detect Pre-
Cbln1. The expected size of the product is in base pairs. Accession numbers refer to those 
published in the Nucleotide Sequence Database. 
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stored at -20°C for one hour then centrifuged for eight minutes at 12,300g. The supernatant was 
removed and the pellet re-suspended in 20μl glass distilled water (GDW). 
 
2.2.11.1.3. Agarose gel electrophoresis 
Materials 
Agarose, type II-A medium EEO (Sigma-Aldrich) 
50x Tris-acetate-EDTA buffer (TAE) (Appendix I) 
Ethidium bromide (10mg/ml) (VWR, Leicester, Leicestershire, UK) 
DNA marker (1kb ladder) (Invitrogen, Paisley, UK) 
Gel loading buffer (Appendix I) 
 
Methods 
A 1% (w/v) agarose gel was made by dissolving 1.5g agarose in 1x TAE using a microwave 
oven. Once the gel had cooled to 37°C, ethidium bromide was added to a final concentration of 
0.5μg/mg.  
Once the gel was set it was placed in an electrophoresis tank containing 0.5x TAE and 0.5μg/mg 
ethidium bromide. Ten microlitres of PCR product were run with three microlitres of gel loading 
buffer. Samples were electrophoresed at 120mV and visualised using UV light (300nm).  
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2.2.11.1.4. Restriction endonuclease digestion of PCR products and plasmid 
PCR products and the plasmid into which they were inserted were cut with the same restriction 
endonucleases in order for them to be joined in a ligation reaction. 
Materials 
PCR products 
 pBluescript plasmid DNA (Stratagene Ltd, Amsterdam, The Netherlands)  
10x restriction buffer (New England Biolabs, Hitchin, Herts, UK) 
100x bovine serum albumin (BSA) (New England Biolabs) 
Restriction endonucleases: BamHI and EcoRI (New England Biolabs) 
Shrimp alkali phosphatase (SAP) 4U/µl (GE Healthcare) 
 
Methods 
Two separate restriction digest reactions were set up in a total volume of 100μl containing 10μg 
DNA (either PCR products or plasmid), 1x restriction buffer, 1x BSA, and restriction 
endonucleases in equal proportion to make up to 8% of total volume. The reactions were 
incubated at 37°C for at least one hour. Eight units of SAP was added to the pBluescript reaction 
30 minutes before the end of the incubation. 
Following restriction digestion, phenol/chloroform extraction and ethanol precipitation were 
repeated. Purified DNA was re-suspended in 20μl GDW. 
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2.2.11.1.5. Electroelution of DNA fragments 
This procedure was performed to remove contaminating fragments and purify the fragment of 
interest. DNA was separated on an agarose gel and the appropriate fragment electroeluted. 
Materials 
1% TAE agarose gel (prepared as described in section 2.2.11.1.3) 
Dialysis tubing 
DNA marker (Invitrogen) 
50x TAE (Appendix I) 
Gel loading buffer (Appendix I) 
 
Methods 
A 1% agarose gel was prepared as described in section 2.2.11.1.3. The precipitated DNA was 
added to 0.3 volumes of gel loading buffer. DNA marker was dissolved 1:10 and added to 0.3 
volumes gel loading buffer. Samples were electrophoresed at 120mV. After visualisation with 
UV illumination, the band of interest was excised and placed in a piece of dialysis tubing with 
400μl 0.5x TAE. Air bubbles were excluded and the ends clipped. DNA was removed from the 
gel by electrophoresis at 200mV for twenty minutes then the current was reversed for forty 
seconds. The TAE in the tubing was removed, purified with phenol/chloroform and the DNA 
extracted by ethanol precipitation. 
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2.2.11.1.6. Ligation of PCR product into plasmid 
DNA ligase is a virus-derived enzyme which catalyses the formation of phosphodiester bonds 
between the 5’ phosphate end of one nucleotide and the 3’ hydroxyl end of another. 
Materials 
20ng cut pBluescript plasmid 
PCR product  
10x ligase buffer (New England Biolabs) 
T4 DNA ligase, 6U/μl (New England Biolabs)  
 
Methods 
Twenty nanograms of cut plasmid were added to a four-fold molar excess of insert and 1x ligase 
buffer. Six units of ligase enzyme were added and the volume made up to 10μl with GDW. The 
reaction was incubated overnight at 16°C then used in transformation. 
 
2.2.11.1.7. Production of competent bacteria 
In order to take up plasmid DNA, gram negative bacteria such as E. Coli must be rendered 
competent. This can be achieved by incubation in the presence of divalent cations, a method was 
originally described by Hanahan et al (Hanahan, 1983). Production of competent bacteria was 
carried out by Dr James Gardiner. 
Materials 
Lysogeny broth (LB) (Appendix I) 
Tetracycline (Sigma-Aldrich) 
Transformation buffer I (TFB I) (Appendix I) 
Transformation buffer II (TFB II) (Appendix I) 
XL1-B cells (ATCC, Middlesex, UK) 
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Methods 
One hundred millilitres of LB supplemented with 5mg/ml tetracycline (LBtet) was inoculated 
with a colony of XL1B cells and incubated overnight at 37°C with vigorous shaking. One 
millilitre of this culture was taken and incubated in LBtet at 37°C with vigorous shaking, until the 
bacteria were in log phase growth (OD550 = 0.4-0.5). The bacteria were recovered by 
centrifugation for 15 minutes at 800g. Bacteria were re-suspended in 40ml ice cold TFBI and 
incubated on ice for 40 minutes. The bacteria were then recovered by centrifugation, as above, 
re-suspended in 4ml TFBII, then incubated on ice for 4 minutes. Aliquots of 50µl were prepared, 
frozen on ethanol in dry ice and stored at -70°C until use.  
 
2.2.11.1.8. Transformation of competent bacteria 
Transformation refers to stable genetic change brought about by the uptake of exogenous DNA. 
Although able to take up DNA, competent bacteria must undergo further steps to optimise DNA 
entry. I used heat shock transformation to prepare this probe. Incubation on ice permits the 
plasmid to attach to the bacterial cell membrane, and the heat shock step allows efficient 
transportation of the plasmid into the bacteria. Incubation following heat shock promotes 
expression of resistance genes prior to antibiotic exposure. 
Materials 
LB (Appendix I) 
E. Coli XL1-B cells 
Products from ligation 
LB agar plate with ampicillin 
 
Methods 
Sterile technique was used throughout this procedure. An aliquot of frozen competent XL1-B 
bacteria was thawed on ice and 5μl ligation reaction added. This was left on ice for twenty 
minutes. The mixture was then placed in a 42°C water bath for forty seconds then returned to ice 
for two minutes. Two hundred microlitres of LB was added and the solution incubated at 37°C 
for thirty minutes. An ampicillin-supplemented agar plate was warmed and 100μl LB containing 
the bacteria was spread across the surface and incubated at 37°C overnight.  
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2.2.11.1.9. Small scale preparation of plasmid DNA 
Small scale culture allows several clones to be analysed simultaneously. The bacterial cell wall 
must first be disrupted to release intracellular contents using alkaline sodium dodecyl sulphate 
(SDS). Plasmid DNA is then separated from other components such as genomic DNA, RNA and 
protein by precipitation with NaAc and treatment with RNase. Digestion with EcoR1 and 
BamH1 allows clones containing the gene of interest to be identified. These are then selected for 
large scale amplification. 
 
Materials 
LB (Appendix I) 
Ampicillin (Sigma-Aldrich) 
Alkaline sodium dodecyl sulphate (SDS) (Appendix I) 
5M potassium acetate (KAc) (Appendix I) 
Glucose-Tris-EDTA (GTE) (Appendix I) 
Propan-2-ol (VWR) 
RNase A (GE Healthcare) (Appendix I) 
 
Methods 
Individual bacterial colonies were picked and inoculated in 2ml LB supplemented with 0.5mg/ml 
ampicillin. The reaction was left overnight at 37°C in a shaking incubator. The following 
morning 1.5ml of the reaction was centrifuged for three minutes at 12,300g and the pellet re-
suspended in 100µl GTE. Two hundred microlitres of alkaline SDS were added and the mixture 
incubated on ice for five minutes. One hundred and fifty microlitres of potassium acetate was 
added to the reaction which was then left on ice for a further five minutes and centrifuged at 
12,300g for five minutes; 350µl supernatant was removed. 
Phenol chloroform extraction was carried out and the DNA precipitated by adding 200µl propan-
2-ol. The reaction was left at room temperature for ten minutes and centrifuged for seven 
minutes at 12,300g. The pellet was re-suspended in 100µl GDW and ethanol precipitated. The 
reaction was centrifuged for seven minutes at 12,300g and 10µl GDW added to the pellet.  
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Restriction endonuclease digestion was performed to check which clones contained the correct 
plasmid insert. Two microlitres of purified DNA was digested with BamH1 and EcoR1 as 
described in section 2.2.11.1.4 with the addition of 0.5µg/µl RNase A. DNA was visualised by 
agarose gel electrophoresis as described in section 2.2.11.1.3. Clones containing the correct sized 
insert were selected for large scale purification. 
 
2.2.11.1.10. Large scale preparation of plasmid DNA 
Materials 
LB (Appendix I) 
Ampicillin (Sigma-Aldrich) 
GTE (Appendix I) 
Lysozyme (Sigma-Aldrich) 
Alkaline SDS (Appendix I) 
5M potassium acetate (Appendix I) 
Propan-2-ol (VWR) 
100x Tris-EDTA (TE) (Appendix I) 
 
Methods 
Using sterile technique, 50µl LB containing the clone of interest was added to 500ml warmed 
LB containing 0.5mg/ml ampicillin. The reaction was transferred to a ridged conical flask and 
left at 37°C overnight in a shaking incubator. 
The following morning the mixture was divided between two centrifuge tubes and centrifuged at 
3000g at 4°C for 8 minutes. The pellet was re-suspended in 12.5ml GTE supplemented with 
2mg/ml lysozyme and left at room temperature for five minutes. 25ml alkaline SDS was added 
to each centrifuge tube, mixed well and left on ice for five minutes then neutralised with 19ml 
5M potassium acetate. The reaction was incubated on ice for a further ten minutes, centrifuged at 
9000g at 4°C for fifteen minutes then filtered through nylon gauze into clean tubes, to which 
36ml room temperature propan-2-ol was added. Again tubes were incubated on ice for fifteen 
minutes and centrifuged for fifteen minutes at 9000g at 4°C. Supernatant was removed and the 
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pellet re-suspended in 5ml 1x TE. To remove any remaining RNA, 100µl 10mg/ml RNase A was 
added. The mixture was incubated at 37°C for thirty minutes. 
Phenol/chloroform extraction was performed, followed by precipitation with propan-2-ol and 5M 
NaAc. 
 
2.2.11.1.11. Caesium chloride gradient purification of plasmid DNA  
This technique was used to purify plasmid DNA from other DNA components. Ethidium 
bromide binds to closed circular plasmid DNA, linear nucleic DNA and nicked plasmid DNA to 
varying degrees. This results in complexes with different buoyancies which can be separated on 
a caesium chloride density gradient.  
Materials 
N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES) (Appendix I) 
Caesium chloride (CsCl2) 
CsCl2/isopropanol (Appendix I) 
Ethidium bromide (VWR) 
 
Methods 
The DNA obtained from large scale preparation of plasmid DNA was recovered by 
centrifugation at 24,000g at 4ºC for twenty minutes. The pellet was dissolved in 8.25ml TES, 
then 8.4g caesium chloride and 150µl ethidium bromide added.  
The reaction was transferred to two poly-alumina centrifuge tubes which were carefully 
balanced, overlayed with paraffin oil, crimped and ultra-centrifuged at 20°C and 185500g 
overnight. 
The following morning UV light was used to identify the DNA band in the caesium chloride 
gradient, which was removed using a hypodermic needle. Ethidium bromide was removed by 
repeatedly adding an equal volume of caesium chloride /isopropranol and removing the upper 
pink phase, until both the upper and lower phases were clear.  
Ethanol precipitation was performed and DNA concentration verified using a spectrophotometer. 
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2.2.11.1.12. Determination of DNA concentration by spectrophotometry 
DNA was diluted 1 in 100 in GDW and transferred to a cuvette. The absorbance was measured 
at 260nM and 280nM (UV-160 Spectrophotometer, Shimadzu, Kyoto, Japan). 
As 1 optical density for DNA is equal to 50µg DNA, the equation used to calculate the final 
quantity of DNA was as follows:  
DNA concentration (µg/ml) = (A260 x dilution factor) x 50 
The sample was then sent for sequence analysis at the MRC CSC Genomics Core Laboratory, 
Imperial College London. 
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2.2.11.2. The effect of changes in nutritional status on hypothalamic Pre-Cbln1 expression 
determined by in situ hybridization 
In situ hybridisation was carried out on fresh frozen sections. Cryostat-cut sections are more 
sensitive to detection as these sections are relatively thick and thus have greater mRNA signal. 
 
2.2.11.2.1. Preparation of slides for in situ hybridisation 
Materials 
4% formaldehyde (VWR) in 0.01M phosphate buffered saline (PBS) (Appendix I) 
0.01M PBS (Appendix I) 
100% acetic anhydride (VWR) 
0.1M Triethanolamine pH 8.0 (TEA) (Appendix I) 
70% ethanol in distilled water 
Chloroform (VWR) 
 
Methods 
Male Wistar rats were either fed ad libitum or fasted for 48 hours (n=4-6 per group). Rats were 
killed by decapitation and the brains removed, mounted on cork discs and snap frozen in 
isopentane and liquid nitrogen. Brain slices of 12µm thickness were cut on a cryostat at -25°C 
(Bright Instrument Company, Huntingdon, Cambridge, UK) and mounted onto polylysine coated 
slides (VWR).  
Slides were placed in a baked rack and fixed in 4% formaldehyde on ice for twenty minutes. 
Two five-minute washes in 0.01M PBS were then performed. Slides were acetylated in 0.25% 
(v/v) acetic anhydride in 0.1M TEA for ten minutes then rinsed twice for two minutes in 0.01M 
PBS. Slides were dehydrated in 70% ethanol in distilled water for three minutes, delipidated in 
100% chloroform for three minutes and left to air dry.  
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2.2.11.2.2. Production of a radio-labelled RNA probe for in situ hybridisation 
Materials 
5x RNA polymerase buffer (Promega) 
10x nucleotide mix: 10mM ATP, UTP and GTP (GE Healthcare) 
100mM dithiothreitol (DTT) 
Linearised template plasmid linearised by digestion with BamHI for anti-sense probe and 
EcoRI for sense probe 
RNase inhibitor (30U/µl) (Invitrogen) 
T3 RNA polymerase (20U/µl) (Promega) 
T7 RNA polymerase (20U/µl) (Promega) 
[35S] RA CTP (specific activity 1250Ci (46.2TBq)/mmol) (Perkin Elmer, Waltham, 
Massachusetts, USA) 
DNAse I (7.5U/µl) (GE Healthcare) 
DNAse buffer (Appendix I) 
5M ammonium acetate (Appendix I) 
 
Methods 
A transcription reaction was set up containing 200ng template DNA, 10mM DTT, 1x nucleotide 
mix, 1x polymerase buffer, 30U RNase inhibitor, 20U RNA polymerase (T3 for anti-sense strand 
and T7 for sense strand) and 3.75MBq [35S] CTPαS in a total volume of 20µl. This reaction was 
incubated at 37°C for two hours. Following incubation, 7.5U DNAseI and 3µl DNAse 10x buffer 
were added and the reaction was incubated at 37°C for a further fifteen minutes. The reaction 
was ethanol precipitated with 12µl 5M ammonium acetate and 80µl 100% cold ethanol at -20°C 
for at least ninety minutes. The mixture was then centrifuged for eight minutes, the supernatant 
discarded and the pellet re-suspended in 200µl GDW. 
Incorporation of the nucleotide into the riboprobe was determined by analysing 1µl of the 
reaction on a scintillation counter.  
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2.2.11.2.3. Hybridisation of radio-labelled probe to slides 
Materials 
Hybridisation buffer: 50% (v/v) deionised formamide 
                            600mM NaCl (Appendix I) 
                            80mM TRIS-HCl (pH 8) (Appendix I) 
                            4mM EDTA (Appendix I) 
                            0.1mg/ml yeast tRNA 
                            100mM DTT 
                             2% (w/v) dextran sulphate (Appendix I) 
 
20x saline sodium citrate (SSC) (Appendix I) 
1x RNAse buffer: 0.5M NaCl (Appendix I) 
                    10mM TRIS (pH 8) (Appendix I) 
                    1mM EDTA (Appendix I)                
10mg/ml RNAse A (Appendix I) 
1M DTT 
70% ethanol in distilled water 
Biomax film (Kodak, Hemel Hempstead, Hertfordshire, UK) 
 
Developer (Jet X-Ray, London, UK) 
 
Fixer (Jet X-Ray) 
 
Methods 
Enough 35S-labelled probe was added to the hybridisation buffer to give 1 million counts per 
slide. Seventy microlitres of probe-hybridisation mixture was pipetted onto a coverslip and the 
slide lowered onto the coverslip. The slides and coverslips were placed horizontally in a rack and 
hybridised at 60°C overnight. 
Slides were washed the following morning to remove excess probe/buffer mix. Slides were 
soaked in 4x SSC and the coverslips removed with gentle agitation. Slides were then subjected to 
four five-minute washes in 4x SSC.   
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Slides were incubated at 37˚C in 1x RNAse buffer containing 100µg/ml RNAse for thirty 
minutes. This was followed by two five minute washes in 10mM DTT/ 2x SSC, a ten minute 
wash in 10mM DTT/ 1x SSC and a ten minute wash in 10mM DTT/0.5x SSC at room 
temperature. Finally, slides were washed in 10mM DTT/0.1x SSC at 60˚C for thirty minutes then 
rinsed briefly in 10mM DTT/0.1x SSC at room temperature.  
Slides were then dehydrated in 70% ethanol and air dried.  After washing and dehydration the 
slides were exposed to Bio-Max film.  After three days’ exposure the film was developed. All 
slides were processed together to ensure uniform hybridization, washing, and development 
conditions. For each rat, three anatomically matched sections were analysed. Images were 
analysed densitometrically using ImageJ software (Wayne Rasband, National Institute of Health, 
USA http://rsb.info.nih.gov/nih-image/). Data is expressed as optical density normalised for 
background (arbitrary units). 
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2.2.12. The effect of ICV Cbln1 administration on plasma pituitary hormones and 
corticosterone in ad libitum fed rats 
Ad libitum fed male Wistar rats (n=8-10 per group per time point) were injected in the early light 
phase with saline or 10nmol Cbln1. Rats were killed by decapitation at either 10 or 40 minutes 
post injection. These time points were chosen because other hypothalamic neuropeptides which 
affect food intake have been shown to alter pituitary hormone release at 10 and 40 minutes post 
injection (Stanley et al., 1999; Kennedy et al., 2001; Smith et al., 2006c). Trunk blood was 
collected in plastic lithium heparin tubes containing 1000 kallikrein inactivator units of aprotinin 
(Nordic Pharma Ltd., Reading, UK) for analysis of TSH, LH, FSH and corticosterone, or in 
plastic EDTA tubes for ACTH analysis. Plasma was separated by centrifugation at 1600g and 
snap frozen in liquid nitrogen. Samples were stored at -20ºC until analysis by RIA for TSH, LH, 
FSH, ACTH and corticosterone (section 2.2.13). 
 
2.2.13. Plasma hormone RIAs 
2.2.13.1. TSH RIA 
The TSH assay was carried out in Kemteck buffer (Appendix I). Standards were serially diluted to 
construct a standard curve ranging from 0.05-25ng/ml. Sample volume was 100µl and samples were 
assayed in duplicate in a total volume of 400µl, containing antibody and 1200cpm/tube of iodinated 
TSH. Assays were incubated at 4°C for 72 hours. Free and antibody-bound TSH were separated 
using a goat anti-rabbit secondary antibody. 
 
2.2.13.2. LH RIA 
LH assays were carried out in Kemteck buffer (Appendix I). Standards were serially diluted to 
construct a standard curve ranging from 0.05-25ng/ml. Rabbit anti-LH antibody was donated by 
H.M Fraser (Medical Research Centre Reproductive Biology Unit, Edinburgh, UK) and used at a 
final dilution of 1:800,000. Sample volume was 25µl and samples were assayed in duplicate in a 
total volume of 400µl, containing antibody and 1200cpm/tube of iodinated LH. The assays were 
incubated at 4°C for 72 hours. Free and antibody-bound LH were separated using a goat anti-rabbit 
secondary antibody. 
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2.2.13.3. FSH RIA 
FSH assays were carried out in Kemteck buffer (Appendix I). Standards were serially diluted to 
construct a standard curve ranging from 0.05-25ng/ml. Sample volume was 150µl and samples were 
assayed in duplicate in a total volume of 400µl, containing antibody and 1200cpm/tube of iodinated 
FSH. Assays were incubated at 4°C for 72 hours. Free and antibody-bound FSH were separated 
using a goat anti-rabbit secondary antibody. 
 
2.2.13.4. ACTH RIA 
A solid phase immunoradiometric assay (IRMA) (Euro-Diagnostica, Huntingdon, Cambridge, 
UK) was used for determination of levels of ACTH in plasma. Two polyclonal antibodies were 
used, which recognize ACTH at two different binding sites. The first was a purified radio-
labelled (125I) sheep IgG recognizing the amino-terminal of ACTH, whereas the second antibody 
recognized and bound non-competitively to the C-terminal of the molecule. The second antibody 
was immobilized and coupled to sheep anti-rabbit antibody coating the polypropylene tubes. 
Both antibodies reacted with the ACTH molecule and the resulting complex bound to the tube 
wall. Following a short incubation, the remaining 125I labelled sheep anti-ACTH was decanted. 
The bound radioactivity in the tubes was proportional to the concentration of ACTH in the 
sample or standard. 
The calibrators, reference controls and 125I ACTH-antibody were supplied lysophilised and were 
reconstituted in GDW 30 minutes prior to use. Standard solutions, reference controls and 
samples were added in 200µl in duplicate followed by addition of 200µl 125I ACTH-antibody. 
The tubes were vortexed gently and incubated overnight at room temperature. All tubes, apart 
from the total counts tubes, were washed by addition of 2ml wash solution into each tube and 
then decanted. This step was then repeated. Each tube was counted for 60 seconds in a gamma 
counter. The mean cpm were calculated for standard, reference controls and samples and the 
mean cpm then plotted against the ACTH calibrators to construct a standard curve. The standard 
curve was used to interpolate the ACTH concentrations for the reference preparations and the 
unknown plasma samples. 
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2.2.13.5. Corticosterone RIA 
Corticosterone levels in plasma were determined by a commercial RIA kit (MP Biomedicals 
Inc., Illkirch, France). Calibrators, buffer and reference preparations were supplied in liquid 
form, ready to use. The assay was performed in a phosphosaline gelatine buffer (pH 7) 
containing rabbit gamma globulins in a total volume of 500µl. Samples were diluted 1:200 in 
buffer and diluted samples, calibrators and reference preparations were added at a volume of 
100µl to numbered tubes. Labelled 125I-corticosterone (200µl, 50,000cpm) was then added to all 
tubes followed by 200µl of specific corticosterone antibody. All tubes were vortexed and 
incubated at room temperature for 120 minutes. The free and bound fractions were then 
separated by addition of 500µl precipitant solution (goat anti-rabbit in TRIS buffer) followed by 
centrifugation at 1000g for 15 minutes. The pellet and supernatant were counted for 60 seconds 
in a gamma counter. Peptide concentrations in the samples were then calculated using a non-
linear plot and results calculated in terms of the standard preparations.  
 
2.2.14. Statistical analysis 
All data are presented as mean ± standard error of the mean (SEM), other than data from 
behavioural studies which are expressed as median and inter-quartile range. Food intake studies 
were analysed using a one-way analysis of variance (ANOVA) with Tukey’s post-hoc test 
(GraphPad Prism version 5 for Windows; GraphPad Software, San Diego, CA). Behavioural 
studies were analysed using the Kruskall-Wallis test (Systat, Evanston, IL) as data were non-
parametric. Hypothalamic explant data were analysed using a paired t-test between the basal and 
test period. Body weight and food intake from the chronic study was analysed using the 
generalized estimating equation (Stata 9, StataCorp LP, College Station, Texas). Hypothalamic 
Pre-Cbln1 expression data and plasma hormone data were analysed using an unpaired t-test. In 
all cases p values <0.05 were taken as significant.  
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2.3. Results 
2.3.1. The effect of ICV Cbln1 administration on food intake in fasted rats in the early light 
phase 
ICV administration of 30nmol Cbln1 significantly increased food intake between 1 and 2 hours 
post injection compared to saline injected controls (1-2 hour food intake (g): 0.45 ± 0.20 [saline], 
2.51 ± 0.64 [30nmol Cbln1], p<0.05 vs. saline, n=9 per group) (Figure 2.2).  
All doses of Cbln1 had no significant effect on food intake at any other time points.  
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Figure 2.2: The effect of ICV Cbln1 administration on food intake in 24-hour fasted rats in the 
early light phase. Male Wistar rats received an ICV injection of saline, 3, 10 or 30nmol Cbln1 in 
the early light phase. Food intake expressed as mean (g) ± SEM at (A) 0-1, (B) 1-2, (C) 2-4, (D) 4-
8, (E) 8-24 and (F) 0-24 hours post injection is shown (n=9 per group). *p<0.05 vs. saline. 
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2.3.2. The effect of ICV Cbln1 administration on food intake in ad libitum fed rats in the 
early light phase 
ICV administration of 10nmol and 30nmol Cbln1 to ad libitum fed rats significantly increased 
food intake in the first hour after injection when compared to saline injected controls (0-1 hour 
food intake (g): 0.37 ± 0.09 [saline], 1.41 ± 0.45 [10nmol Cbln1] p<0.05 vs. saline, 1.77 ± 0.41 
[30nmol Cbln1] p <0.05 vs. saline, n=9 per group) (Figure 2.3). 
Cumulative food intake was significantly increased in animals injected with 10 and 30nmol 
Cbln1 between 0 and 2, and 0 and 4 hours post-injection (0-2 hour food intake (g): 0.45 ± 0.11 
[saline], 2.31 ± 0.50 [10nmol Cbln1] p<0.01 vs. saline, 2.32 ± 0.55 [30nmol Cbln1] p <0.01 vs. 
saline; 0-4 hour food intake (g): 0.48 ± 0.11 [saline], 2.40 ± 0.49 [10nmol Cbln1] p<0.01 vs. 
saline, 2.75 ± 0.71 [30nmol Cbln1] p<0.01 vs. saline, n=9 per group) (Figure 2.4). 
All doses of Cbln1 had no significant effect on food intake at any other time points.  
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Figure 2.3: The effect of ICV Cbln1 administration on food intake in ad libitum fed rats in the 
early light phase. Male Wistar rats received an ICV injection of saline, 1, 3, 10 or 30nmol Cbln1 in 
the early light phase. Food intake expressed as mean (g) ± SEM at (A) 0-1, (B) 1-2, (C) 2-4, (D) 4-
8, (E) 8-24 and (F) 0-24 hours post injection is shown (n=9 per group). *p<0.05 vs. saline. 
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Figure 2.4: The effect of ICV Cbln1 administration on cumulative food intake in ad 
libitum fed rats in the early light phase. Ad libitum fed male Wistar rats received an ICV 
injection of saline, 1, 3, 10 or 30nmol Cbln1 in the early light phase. Food intake was 
measured at 1, 2, 4 and 8 hours post injection. Data is expressed as mean (g) ± SEM (n=9 per 
group). *p<0.05, **p<0.01 vs. saline. 
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2.3.3. The effect of ICV Cbln1 administration on behaviour in ad libitum fed rats in the 
early light phase 
ICV administration of 10 or 30nmol Cbln1 had no significant effect on behaviour compared to 
saline injected controls. ICV administration of NPS significantly increased burrowing (p<0.001) 
and locomotion activity (p<0.05) and reduced sleeping behaviour (p<0.001) compared to saline 
treated animals (Table 2.3).  
 
Behaviour Saline 10nmol Cbln1 30nmol Cbln1 10nmol NPS 
Feeding 
 
1.0 (0.0-3.8) 3.0 (0.0-5.0) 3.0 (0.0-6.0) 3.0 (0.0-6.0) 
Drinking 
 
0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 
Rearing 
 
7.0 (1.8-11.0) 3.0 (2.0-7.0) 7.0(3.0-10.0) 5.0(5.0-13.0) 
Locomotion 7.5 (2.0-8.8) 4.0 (3.0-5.5) 3.0 (2.0-4.0) 11.0 (8.0-13.0)* 
 
Grooming 
 
3.0 (2.3-6.0) 3.0 (2.0-8.5) 4.0 (3.0-6.0) 3.0 (0.0-5.0) 
Burrowing 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 3.0 (1.0-5.0)*** 
 
Head down 
 
6.0 (3.5-6.0) 4.0 (2.5-7.0) 3.0 (0.0-8.0) 3.0 (0.0-9.0) 
Sleep 12.0 (6.8-12.8) 18.0 (5.5-22.0) 12.0 (9.0-15.0) 0.0 (0.0-0.0)*** 
 
Pica  
 
0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 
 
 
 
 
 
Table 2.3: The effect of ICV Cbln1 administration on behaviour in ad libitum fed male Wistar 
rats during the early light phase. Behaviour was monitored for one hour post injection. Data is 
presented as median number of behaviours observed (inter-quartile range), n=10-12 per group; 
*p<0.05, ***p<0.001 vs. saline.  
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2.3.4. The effect of Cbln1 on neuropeptide release from hypothalamic explants 
Incubation of hypothalamic explants with 10, 100 and 1000nM Cbln1 significantly increased 
NPY release (NPY release (% basal): 100.00 ± 16.71 [basal], 253.31 ± 60.32 [10nM Cbln1] 
p<0.01; 100.00 ± 12.23 [basal], 169.76 ± 34.76 [100nM Cbln1] p<0.05; 100.00 ± 14.75 [basal], 
132.03 ± 19.02 [1000nM Cbln1] p<0.05, n= 9-12 slices per group) (Figure 2.5). 
Treatment of hypothalamic explants with Cbln1 had no effect of the release of AgRP, CART or 
α–MSH (Table 2.4).  
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Figure 2.5: The effect of Cbln1 treatment on NPY release from hypothalamic explants. 
Hypothalamic explants taken from male Wistar rats were treated with 10, 100 or 1000nM Cbln1. 
Data is presented as mean ± SEM as a percentage of basal release. Explants were treated with 
artificial CSF during the basal period (n=9-12 per group). *p<0.05, **p<0.01 vs. basal treatment. 
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 Dose of Cbln1 administered to hypothalamic explants 
 
10nM 
 
100nM 1000nM 
Peptide release  
(% basal) 
Basal Cbln1 Basal Cbln1 Basal Cbln1 
AgRP 100.00 ± 
13.27 
127.52 ± 
14.78 
100.00 ± 
10.26 
112.43 ± 
18.41 
100.00 ± 
10.29 
113.29 ± 
16.82 
CART 100.00 ± 
7.88 
132.59 ± 
15.71 
100.00 ± 
8.10 
126.33 ± 
12.10 
100.00 ± 
14.91 
113.64 ± 
11.56 
α-MSH 100.00 ± 
17.87 
134.67 ± 
15.69 
100.00 ± 
2.77 
94.02 ± 
8.04 
100.00 ± 
10.88 
116.12 ± 
9.86 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.4: The effect of Cbln1 treatment on the release of AgRP, CART and α-MSH release 
from hypothalamic explants. Hypothalamic explants taken from male Wistar rats were treated 
with 10, 100 or 1000nM Cbln1. Data is presented as mean ± SEM as a percentage of basal 
release. Explants were treated with artificial CSF during the basal period (n=9-12 per group).  
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2.3.5. The effect of ICV Cbln1 administration on food intake following pre-treatment with 
a Y1 receptor antagonist in the early light phase 
ICV administration of 10nmol Cbln1 significantly increased food intake compared to saline 
injected controls between 0 and 1 hours post-injection. BIBP 3226 at a dose of 60nmol had no 
significant effect on food intake. Administration of BIBP 3226 30 minutes prior to injection of 
10nmol Cbln1 partially attenuated the orexigenic effect of Cbln1 (0-1hr food intake (g): 0.46 ± 
0.14 [vehicle/saline]; 2.12 ± 0.59 [vehicle/Cbln1 10nmol] p<0.05 vs. vehicle/saline; 1.64 ± 0.60 
[BIBP 3226 60nmol/Cbln1 10nmol]; 0.33 ± 0.12 [BIBP 3226 60nmol/saline] n=10-12 per group) 
(Figure 2.6A). 
There was also a trend for an increase in 0-24 hour food intake induced by 10nmol Cbln1 which 
was attenuated by prior administration of BIBP 3226, although this did not reach statistical 
significance (Figure 2.6B). 
 
 
 
 
 
 
 
Figure 2.6: The effect of BIBP 3226 pre-treatment on Cbln1-induced food intake in ad libitum 
fed rats in the early light phase. Ad libitum fed male Wistar rats were injected ICV with vehicle or 
60nmol BIBP 3226 in the early light phase thirty minutes prior to ICV administration of saline or 
10nmol Cbln1. Food intake presented as mean ± SEM at (A) 0-1 and (B) 0-24 hours is shown 
(n=10-12 per group). *p<0.05 vs. vehicle/saline. 
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2.3.6. The effect of chronic ICV Cbln1 administration on food intake and body weight 
Chronic ICV injection of 10nmol Cbln1 twice daily for four days had no significant effect on 24-
hour food intake or body weight compared to saline treated animals (Table 2.5).  
 
 
 Day 1 Day 2 Day 3 Day 4 
Food 
intake 
Body 
weight 
Food 
intake 
Body 
weight 
Food 
intake 
Body 
weight 
Food 
intake 
Body 
weight 
Saline 20.2 ± 
1.8 
282.4 
± 8.2 
25.2 ± 
1.1 
291.7 
± 7.5 
23.7 ± 
2.5 
284.9 
± 9.1 
23.6 ± 
2.1 
286.3 
± 9.7 
Cbln1 
10nmol 
16.7 ± 
3.7 
286.7 
± 7.1 
20.9 ± 
2.5 
289.7 
± 7.8 
25.6 ± 
1.0 
292.7 
± 7.7 
27.7 ± 
1.3 
301.0 
± 7.9 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.5: The effect of chronic ICV Cbln1 administration on 24-hour food intake and 
body weight. Ad libitum fed male Wistar rats were administered ICV saline or 10nmol Cbln1 
twice daily, at the beginning of the light phase and just prior to the onset of the dark phase, for 
four days (n=8-10 per group). Data are expressed as mean ± SEM.  
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2.3.7. Production of a Pre-Cbln1 probe 
Rat whole brain tissue expressed Pre-Cbln1 as shown by RT-PCR. Although two bands were 
visible when compared to a 1Kb ladder, the band of interest of approximately 320 base pairs was 
confirmed and extracted by electroelution (Figure 2.7A). The second band represents another 
molecule found in the rat brain to which my primers also bound. By analysing the primer 
sequences and comparing the predicted PCR product sizes, I predict this band represents the rat 
olfactory receptor.    
Pre-Cbln1 was cloned into pBluescript plasmid using the restriction enzymes BamH1 and EcoR1 
(Figure 2.7B). Sequencing of plasmid DNA after large scale plasmid preparation confirmed 
generation of the correct probe. 
 
                                   
 
 
 
 
 
 
Figure 2.7: A) Pre-Cbln1 mRNA expression in rat brain as determined by reverse 
transcription-polymerase chain reaction (RT-PCR). L, 1-Kb ladder. The size of the expected 
PCR product for Pre-Cbln1 was 320 base pairs (shown by arrow). B) Pre-Cbln1 following large 
scale preparation of plasmid DNA in P.Bluescript and digestion with EcoR1 and BamHI 
restriction enzymes.  
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2.3.8. Expression of Pre-Cbln1 mRNA 
Using a radio-labelled Pre-Cbln1 anti-sense riboprobe, Pre-Cbln1 mRNA was detected in the 
VMN, thalamus, zona incerta, hippocampus and motor cortex (Figure 2.8A). No signal was 
observed when brain slices were hybridised with the corresponding Pre-Cbln1 sense probe 
(Figure 2.8B). 
 
 
 
 
 
 
 
 
Figure 2.8: Representative microphotographs showing in situ hybridisation using a (A) Pre-
Cbln1 anti-sense riboprobe and (B) Pre-Cbln1 sense riboprobe to confirm signal specificity. 
No non-specific binding was observed. Sections of 12μm thickness were taken approximately 
3.0mm caudal to bregma. Scale bars are equivalent to 1mm.  
B 
A 
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2.3.9. The effect of nutritional status on Pre-Cbln1 mRNA expression within the VMN 
Pre-Cbln1 mRNA expression in the VMN was measured by semi-quantitative in situ 
hybridisation. Pre-Cbln1 mRNA expression was significantly higher in rats fasted for 48 hours 
compared to ad libitum fed controls (Pre-Cbln1 mRNA expression (arbitrary units): 3.40 ± 0.09 
(fed) vs. 3.97 ± 0.19 (48-hour fasted) p<0.05, n=4-6 per group) (Figures 2.9 and 2.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3V 
VMN 
3V VMN 
Figure 2.9: Microphotographs of semi-quantitative in situ hybridisation for VMN Pre-
Cbln1 mRNA in (A) ad libitum fed and (B) 48-hour fasted male Wistar rats (12μm coronal 
sections, -3.0mm caudal to bregma). (C) Sections were compared to ‘The Rat Brain in 
Stereotaxic Coordinates (Paxinos and Watson, 2007). A coronal section at -3.0mm from bregma 
is shown. The VMN is outlined in red. Scale bars are equivalent to 1mm. Abbreviations: 3V, 
third cerebral ventricle; VMN, ventral medial nucleus of the hypothalamus.  
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Figure 2.10: Pre-Cbln1 mRNA expression as semi-quantified using Image J Software. Data 
is presented as mean ± SEM arbitrary units, *p < 0.05 vs. fed animals (n=4-6 per group).  
90 
 
2.3.10. The effect of ICV Cbln1 administration on plasma pituitary hormones and 
corticosterone in ad libitum fed rats  
2.3.10.1. Thyroid-stimulating hormone  
ICV administration of 10nmol Cbln1 significantly decreased plasma thyroid-stimulating 
hormone (TSH) levels at 10 minutes post-injection compared to saline-injected controls (plasma 
TSH (ng/ml): 5.36 ± 0.50 [saline], 3.77 ± 0.28 [Cbln1 10nmol] p<0.05, n=10-12 per group) 
(Figure 2.11). No differences were observed at 40 minutes post-injection. 
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Figure 2.11: The effect of ICV saline or 10nmol Cbln1 on plasma thyroid-stimulating 
hormone (TSH) levels in male Wistar rats. Plasma was collected at (A) 10 or (B) 40 minutes 
post-injection. Plasma TSH was measured by radioimmunoassay (n=8-10 per group per time point, 
*p<0.05 vs. saline). 
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B 
91 
 
2.3.10.2. Luteinizing hormone and follicle-stimulating hormone 
ICV injection of 10nmol Cbln1 had no effect on plasma luteinizing hormone (LH) levels at 10 
minutes post injection. However, at 40 minutes Cbln1 significantly increased circulating LH 
compared to saline controls (plasma LH (ng/ml): 0.86 ± 0.10 [saline], 1.32 ± 0.16 [Cbln1 
10nmol] p<0.05, n=10-12 per group) (Figure 2.12A and B). 
Similarly, although ICV 10nmol Cbln1 had no effect on circulating follicle-stimulating hormone 
(FSH) levels at 10 minutes post-injection, it induced a significant increase at 40 minutes 
compared to controls (plasma FSH (ng/ml): 8.92 ± 0.56 [saline]; 10.66 ± 0.59 [Cbln1 10nmol] 
p<0.05, n=10-12 per group) (Figure 2.12C and D). 
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Figure 2.12: The effect of ICV saline or 10nmol Cbln1 on plasma (A and B) luteinizing 
hormone (LH) and (C and D) follicle-stimulating hormone (FSH) levels in male Wistar 
rats. Plasma was collected at (A and C) 10 or (B and D) 40 minutes post-injection. Plasma LH 
and FSH were measured by radioimmunoassay (n=8-10 per group per time point, *p<0.05 vs. 
saline). 
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2.3.10.3. ACTH and corticosterone 
ICV administration of 10nmol Cbln1 had no effect on circulating ACTH or corticosterone at 
either 10 or 40 minutes post injection (Figure 2.13A and B).  
There was a non-significant reduction in circulating corticosterone 40 minutes post-injection in 
animals administered 10nmol Cbln1 ICV (plasma corticosterone 40 minutes (ng/ml): 121.40 ± 
29.51 [saline], 52.30 ± 14.74 [Cbln1 10nmol], n=10-12 per group) (Figure 2.13C and D). 
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Figure 2.13: The effect of ICV saline or 10nmol Cbln1 on plasma (A and B) 
adrenocorticotrophic hormone (ACTH) and (C and D) corticosterone levels in male Wistar 
rats. Plasma was collected at (A and C) 10 or (B and D) 40 minutes post-injection. Plasma ACTH 
and corticosterone were measured by radioimmunoassay (n=8-10 per group per time point). 
A B 
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2.4. Discussion  
I have identified a novel orexigenic role for the 16-amino acid peptide Cbln1, which may 
partially be mediated by hypothalamic NPY. When administered ICV to satiated rats in the early 
light phase, Cbln1 at doses of 10nmol and 30nmol induced a statistically significant increase in 
food intake which lasted up to 4 hours post injection. Although not statistically significant, there 
was also a trend towards an increase in food intake between 0 and 24 hours in animals 
administered 10 and 30nmol Cbln1. As rats are nocturnal, the light phase is not the usual feeding 
period and so stimulation of hunger circuits is more apparent in this experimental paradigm. The 
effect of Cbln1 on food intake was rapid, which indicates that the site of action for Cbln1 may be 
close to the third ventricle. However, the receptor for Cbln1 is unknown and so it is not possible 
to determine whether this assumption is correct. 
The orexigenic effect of Cbln1 was relatively weak compared to hypothalamic neuropeptides 
such as NPY and AgRP, which are able to stimulate food intake at doses as low as 0.5nmol and 
1nmol respectively (Levine and Morley, 1984; Rossi et al., 1998). Indeed, the effect of Cbln1 on 
food intake was much less potent when administered to fasted rats; 30nmol Cbln1 only elicited 
an increase in food intake between 1 and 2 hours post-injection. It is often difficult to observe the 
effect of an orexigenic peptide post-fasting because the drive to feed is extremely high in all 
animals and masks any additional stimulatory effects on feeding. 
Although Cbln1 had an acute effect on food intake, it did not affect 24-hour food intake or body 
weight when administered twice daily for four days. This is in contrast to NPY, which induced a 
dramatic increase in food intake and body weight gain when injected into the PVN three times 
daily for ten days (Stanley et al., 1986). It is therefore unlikely that Cbln1 plays a major role in 
long term maintenance of body weight and the development of obesity. However, other 
hypothalamic neuropeptides which acutely stimulate feeding, such as MCH, have no effect on 
body weight or 24-hour food intake when administered ICV twice daily for several days (Rossi 
et al., 1997).  
Mice lacking Pre-Cbln1 have not been reported to have any alterations in food intake or body 
weight compared to their wild type littermates (Hirai et al., 2005). However, these mice had 
grossly impaired motor function which may have masked any changes in energy homeostasis. 
Additionally, transgenic models can be complicated by developmental compensation, as 
demonstrated by the NPY knock-out mouse which unexpectedly has a normal body weight and 
food intake (Erickson et al., 1996). It would be interesting to reduce endogenous hypothalamic 
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Cbln1 levels using an antibody or anti-sense RNA, to determine whether Cbln1 has a 
physiological role in the control of energy homeostasis. Additionally, if the receptor by which 
Cbln1 mediates its effects on feeding could be isolated, an antagonist could be administered to 
further investigate the role of Cbln1 in appetite regulation.  
When studying food intake it is important to determine the effect of an administered substance 
on behaviour, as non-specific effects of the substance may alter feeding. For example, adverse 
effects such as nausea and pain may reduce food intake. An increase in grooming behaviour is 
often associated with activation of stress pathways (Dunn et al., 1987). Alternatively, stimulation 
of arousal pathways, demonstrated by an increase in locomotor activity, may increase food 
intake (Ida et al., 1999; Hagan et al., 1999). ICV administration of both 10 and 30nmol Cbln1 
had no effect on behaviour compared to saline controls. This suggests that the orexigenic effect 
of Cbln1 is not secondary to non-specific behavioural changes and may therefore be due to 
activation of hypothalamic pathways involved in the control of energy homeostasis.  
An ex vivo hypothalamic explant system was used to investigate whether Cbln1 acts via known 
hypothalamic regulators of energy homeostasis to increase food intake. Incubation of 
hypothalamic slices in 10, 100 and 1000nM Cbln1 induced a significant increase in NPY release. 
As incubation in 10nM Cbln1 induced the largest response, Cbln1 may have a threshold, rather 
than a dose-response, effect on NPY release. Alternatively, receptor desensitization may occur at 
high doses of Cbln1, leading to a blunted response.  
Cbln1 had no effect on the release of AgRP, α-MSH or CART release from hypothalamic 
explants. This is surprising, as NPY is co-localised with AgRP within the Arc, and NPY/AgRP 
neurones inhibit adjacent POMC/CART neurones via release of GABA. I would therefore expect 
Cbln1 to increase AgRP release and reduce α–MSH or CART release from hypothalamic 
explants. However, there are numerous NPY-expressing neurones within the hypothalamus, and 
not all express AgRP (Broberger et al., 1998). Additionally, only a sub-population inhibit 
neighbouring anorectic neurones (Cowley et al., 2001). Orexigenic substances have previously 
been reported to increase NPY release from hypothalamic explants but have no effect on AgRP 
(Seth et al., 2003).  
Within the hypothalamus, Cbln1 is primarily located within the VMN (Segal et al., 2005). 
Although the primary output of the VMN is anorexigenic, excitatory projections from the VMN 
exist which terminate on NPY neurones in the Arc (Sternson et al., 2005). Cbln1 may therefore 
be expressed by these neurones and mediate its effects on food intake via arcuate NPY.  
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I hypothesised that Cbln1 may act upstream of NPY to stimulate feeding. To test this in vivo, I 
administered an NPY Y1 receptor antagonist, BIBP 3226, 30 minutes prior to administration of 
Cbln1. BIBP 3226 is a non-peptide antagonist at the Y1 receptor and has been shown to 
attenuate the effect of NPY on feeding, but have no effect when administered alone at the dose 
used in this study (O'Shea et al., 1997).  
Pre-administration of BIBP 3226 partially attenuated the orexigenic effect of Cbln1 between 0 
and 1 hours post-injection; this trend was also observed between 0 and 24 hours, suggesting 
Cbln1 may act upstream of the Y1 receptor. However, as blockade of NPY Y1 receptors did not 
completely abolish the orexigenic effect of Cbln1 acutely, it is likely to act through additional 
mechanisms to stimulate feeding.  
Brain-derived neurotrophic factor (BDNF), a neurotrophin essential for brain development, is 
highly expressed within the VMN (Xu et al., 2003). BDNF is involved in energy homeostasis 
and is thought to act downstream of the melanocortin system to reduce food intake (Xu et al., 
2003). Cbln1 may therefore inhibit local BDNF production to stimulate feeding. Dopamine and 
serotonin are also expressed within the VMN and have been implicated in the control of food 
intake (Davidowa et al., 2002; Hikiji et al., 2004). Cbln1 may modulate the release or activity of 
these neurotransmitters to influence energy homeostasis.  
I chose to use semi-quantitative in situ hybridisation to determine the effect of nutritional status 
on Pre-Cbln1 mRNA expression because this technique allows changes within specific 
hypothalamic nuclei to be detected. Within the VMN, the primary hypothalamic location of Pre-
Cbln1, mRNA expression was significantly higher in rats fasted for 48 hours compared to ad 
libitum fed controls. This suggests that Pre-Cbln1 expression is regulated by nutritional status. 
Many other endogenous hypothalamic neuropeptides important in the control of energy 
homeostasis are regulated by energy status. Fasting increases NPY mRNA expression within the 
Arc (White and Kershaw, 1990) which is thought to be mediated by a reduction in circulating 
leptin levels (Schwartz et al., 1998). It would be interesting to investigate if Pre-Cbln1 
expression is also negatively regulated by leptin, as the leptin receptor is abundantly expressed 
within the VMN (Elmquist et al., 1998b) and peripheral leptin administration has been shown to 
induce Fos-like immuno-reactivity, an indirect marker of neuronal activation, in this nucleus 
(Elmquist et al., 1997).  
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As peptide and mRNA levels are often poorly correlated (Gygi et al., 1999) it would be 
interesting to perform punch biopsies of the VMN and extract and quantity Cbln1 peptide, to 
determine whether Cbln1 protein expression is also altered by acute food restriction.  
The hypothalamo-pituitary-thyroid axis plays a vital role in the control of energy expenditure. 
TRH, produced in the PVN, acts at the anterior pituitary gland to stimulate the release of TSH 
into the circulation. TSH binds to receptors on the thyroid gland to stimulate the synthesis and 
release of the thyroid hormones, T3 and T4. Thyroid hormones increase basal metabolic rate and 
oxygen consumption and hence stimulate energy expenditure (Yen, 2001). 
ICV Cbln1 administration significantly lowered circulating TSH levels at 10 minutes post-
injection. It is possible that Cbln1 may mediate this effect via hypothalamic NPY. NPY- 
expressing neurones within the Arc terminate on TRH neurones in the PVN (Toni et al., 1990) 
and administration of NPY has been shown to lower circulating TSH, T3 and T4 levels and 
suppress hypothalamic pro-TRH mRNA expression (Fekete et al., 2001). Cbln1 may therefore 
act via NPY to induce a state of hypothyroidism, potentially mediated by TRH, to reduce energy 
expenditure and promote weight gain.  
Starvation suppresses the HPT axis as an adaptive response to conserve energy. A reduction in 
circulating leptin during fasting increases hypothalamic NPY/AgRP and reduces POMC/CART 
signalling, causing a reduction in TRH expression (Sarkar and Lechan, 2003). As hypothalamic 
Pre-Cbln1 mRNA expression was up-regulated by a 48-hour fast, this further supports the 
hypothesis that Cbln1 is an endogenous factor which stimulates feeding and lowers energy 
expenditure to promote a state of positive energy balance. 
Although ICV administration of Cbln1 significantly increased circulating LH and FSH 40 
minutes post-injection, these results must be treated with caution as levels of both LH and FSH 
dropped between 10 and 40 minutes in saline injected animals. This experiment requires 
repeating and it would be interesting to perform a dose-response study to confirm the effect of 
Cbln1 on the reproductive axis.   
However, many hypothalamic neuropeptides involved in the control of energy homeostasis also 
influence reproductive function. For example, NPY and galanin both increase feeding and 
paradoxically stimulate the HPG axis in gonadally intact animals (Sahu et al., 1987; Kyrkouli et 
al., 1986; Levine and Morley, 1984).  If my results regarding the effect of Cbln1 on LH and FSH 
were to be confirmed, they may further support the hypothesis that Cbln1 acts upstream of NPY, 
as ICV NPY administration also increases circulating LH levels (Kalra and Crowley, 1984). 
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NPY is hypothesised to act at hypothalamic GnRH neurones to aid the pre-ovulatory GnRH 
surge (Bauer-Dantoin et al., 1991).  It would be interesting to investigate whether Cbln1 also 
increases GnRH release from hypothalamic explants ex vivo. 
Peripheral Cbln1 administration has been demonstrated to increase circulating corticosterone 
independently of ACTH release in rats (Hochol et al., 2001). I therefore investigated the effect of 
ICV Cbln1 on circulating ACTH and corticosterone. ICV Cbln1 administration had no effect on 
plasma levels of ACTH or corticosterone. This suggests that Cbln1 does not act at the PVN to 
stimulate CRH release and supports the hypothesis that Cbln1 exerts its effects at the adrenal 
gland via an autocrine or paracrine mechanism, which may be dependent on catecholamine 
release (Mazzocchi et al., 1999; Hochol et al., 2001). Interestingly, 10nmol Cbln1 lowered 
circulating corticosterone at 40 minutes post-injection, although this did not reach significance.  
In conclusion, I have shown that Cbln1 acutely stimulates food intake when administered ICV to 
male rats. Additionally, ICV Cbln1 administration lowered circulating TSH, suggesting it may 
reduce energy expenditure and promote a state of positive energy balance. It is possible that 
Cbln1 exerts its effects on feeding and the HPT axis via hypothalamic NPY. Similarly to other 
orexigenic neuropeptides, hypothalamic Pre-Cbln1 mRNA expression was increased following a 
48 hour fast, suggesting it may be regulated by leptin and hence have an endogenous role in the 
control of energy homeostasis. 
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Chapter 3: Investigating the role of 
VTA melanocortin signalling in the 
regulation of food intake 
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3.1. Introduction 
3.1.1. Homeostatic and non-homeostatic control of food intake 
Hypothalamic circuits involved in the homeostatic regulation of food intake and energy 
expenditure are effective in defending an organism against starvation, but are relatively 
ineffective at limiting food intake in an environment in which there is an excess of readily 
available, palatable, energy dense food (Berthoud, 2006). Homeostatic circuits can thus be easily 
over-powered by non-homeostatic signals such as the palatability and rewarding value of food. 
Such non-homeostatic cues are processed by cortico-limbic structures, including the ventral 
tegmental area (VTA) and nucleus accumbens (NAc). Projections from limbic areas to the 
hypothalamus may permit reward signals to over-ride homeostatic circuits, and hence promote 
food intake even in the fed state (Berthoud, 2006). Conversely, hypothalamic neurones project to 
reward centres and may modulate reward- and motivation-based food intake. 
 
3.1.2. Anatomy of the mesocorticolimbic pathway 
The mesocorticolimbic pathway is composed of dopamine neurones which project primarily 
from the VTA to the ventral striatum (which includes the NAc and olfactory tubercle), and to 
other limbic structures including the amygdala, hippocampus, and pre-frontal cortex. 
This pathway is important in mediating the rewarding and reinforcing effects of stimuli including 
natural rewards, such as food and social contact, and drugs of abuse. It also modulates goal-
directed and motivational behaviour in response to such stimuli. 
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3.1.2.1. The VTA 
The VTA is located in the ventral midbrain between the caudal hypothalamus and brainstem. It 
is termed an area, rather than a nucleus, due to its heterogeneous structure and the lack of clear 
borders distinguishing it from the neighbouring substantia nigra (Ikemoto, 2007). 
The rodent VTA can be sub-divided into four zones: the paranigral nucleus (PN), the 
parabrachial pigmented area (PBP), the parafasciculus retroflexus area and the ventral tegmental 
tail (VTT) (Halliday and Tork, 1986; Ikemoto, 2007). The PN and PBP, which make up the 
middle two-thirds of the VTA, are rich in dopamine-expressing cells and stain heavily for 
tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. In contrast, the 
parafasciculus retroflexus area and VTT contain only a low number of dopamine-expressing 
neurones (Ikemoto, 2007). 
Dopamine neurones comprise approximately 60-70% of the VTA; most of the remaining 30-
40% of neurones are GABAergic (Swanson, 1982; Olson and Nestler, 2007). Additionally, a 
small number of VTA neurones are glutamatergic (Lavin et al., 2005). The majority of VTA 
GABAergic neurones are local interneurones, which are interspersed with, and terminate on, 
dopamine-expressing neurones (Bayer and Pickel, 1991; Olson and Nestler, 2007). These 
interneurones tonically inhibit the activity of VTA dopamine neurones (Matthews and German, 
1984; David et al., 1997). A small number of VTA GABAergic neurones project to limbic areas 
including the pre-frontal cortex and NAc (Carr and Sesack, 2000; Van Bockstaele and Pickel, 
1995). 
The VTA sends efferent fibres to forebrain areas including the ventral striatum, amygdala, pre-
frontal and insular cortices, septal region, hypothalamus and thalamus (Swanson, 1982) (Figure 
3.1). The VTA also projects through the midbrain to the periaqueductal grey, the parabrachial 
nucleus, the locus coeruleus and the raphe nuclei (Swanson, 1982). 
The VTA receives afferent inputs from many of the limbic areas to which it projects, including 
the NAc (Nauta et al., 1978) and pre-frontal cortex (Leonard, 1969). It also receives projections 
from hypothalamic nuclei including the VMN and the LH (Saper et al., 1979), and from 
brainstem regions including the tegmental pedunculopontine nucleus (TPP), an area which 
mediates dopamine-independent aspects of reward, and the laterodorsal tegmental nucleus 
(Oakman et al., 1995) (Figure 3.1). 
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3.1.2.2. The nucleus accumbens 
The NAc lies in the anterior and ventral striatum and has two subdivisions; the core and the 
shell. The shell lies medial and ventral to the core and is thought to be particularly important in 
mediating reward (Di Chiara, 2002). The NAc is primarily composed of GABAergic neurones 
which project widely to other limbic and non-limbic structures, but also contains GABAergic 
interneurones and cholinergic neuronal cell bodies (Meredith, 1999). 
In addition to receiving afferent projections from the VTA, the NAc receives glutamatergic 
inputs from regions including the hippocampus, amygdala and prefrontal cortex (O'Donnell and 
Grace, 1995) (Figure 3.1). The NAc sends efferent fibres to numerous structures including the 
ventral pallidum, substantia nigra, VTA, preoptic region, and thalamus (Nauta et al., 1978). The 
shell, but not the core, of the NAc also has reciprocal projections with the LH (Heimer et al., 
1991) and this connection is thought to be important in integrating homeostatic and hedonistic 
control of food intake (Stratford and Kelley, 1999). 
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3.1.3. Dopamine signalling 
The amino acid tyrosine is the initial substrate in dopamine biosynthesis. Tyrosine is taken up by 
dopamine neurones, and is converted to levodopa (L-DOPA) by the cytosolic enzyme tyrosine 
hydroxylase (TH). L-DOPA is then converted to dopamine by aromatic amino acid 
decarboxylase (AAAD), also known as dopa decarboxylase. Dopamine is transported from the 
cytoplasm into storage vesicles, which fuse with the neuronal membrane and release dopamine 
into the synapse in response to a pre-synaptic action potential (Elsworth and Roth, 1997) (Figure 
3.2). 
Tonic dopamine release is maintained by slow, irregular firing of dopamine neurones (Overton 
and Clark, 1997). Midbrain dopamine neurones fire action potentials in bursts in response to 
sensory stimuli, including those associated with reward. This results in large quantities of 
dopamine being released into target areas such as the NAc (Overton and Clark, 1997; Gonon, 
1988). 
Dopamine receptors are G-protein coupled receptors. There are at least five types of dopamine 
receptors in the CNS, which can be subdivided according to whether they increase (D1-like) or 
decrease (D2-like) adenylate cyclase activity (Kebabian, 1978; Seeman and Van Tol, 1994) 
(Figure 3.2). The D2 receptor gene is alternatively spliced to generate two isoforms; a long form 
(D2L), which is located post-synaptically, and a short form (D2S), which is a pre-synaptic 
autoreceptor (Usiello et al., 2000).  
D2 receptors play a critical role in reward and reinforcement. Peripheral pre-treatment with a D2 
receptor agonist enhances the reinforcing effects of cocaine in rats (Caine et al., 2000), and mice 
lacking the D2 receptor show reduced sensitivity to the rewarding properties of morphine 
(Maldonado et al., 1997) and cocaine (Welter et al., 2007). 
The dopamine transporter (DAT), located on dopamine nerve terminals, pumps extracellular 
dopamine back into the neuron and hence switches off the dopamine signal at the synapse 
(Figure 3.2). Dopamine is then recycled or degraded by the enzymes monoamine oxidase (MAO) 
or catechol-O-methyltransferase (COMT), which are located within dopamine neurones, and in 
neighbouring glial cells and astrocytes. 
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Figure 3.2: The dopamine synapse. Tyrosine (Tyr) is converted to L-DOPA by tyrosine 
hydroxylase (TH), and then to dopamine (DA) by aromatic amino acid decarboxylase (AAAD). 
Dopamine is packaged into vesicles which fuse with the neuronal membrane upon stimulation by 
an action potential. Dopamine binds to and activates D1-like (D1) and D2-like (D2) receptors, 
which stimulate or inhibit adenylate cyclase activity respectively. Dopamine is cleared from the 
synaptic cleft by the dopamine transporter; this transporter is inactivated by cocaine.  
Abbreviations: ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate. Adapted 
from (Kreek et al., 2002). 
(D2) 
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3.1.4. The role of the VTA in motivation, reward and addiction 
The VTA, NAc and related limbic structures are critical in mediating the rewarding and 
motivational properties of natural rewards and addictive drugs. It should be noted that ‘wanting’ 
and ‘liking’ a stimulus are considered to be separate components of reward (Berridge, 1996). 
The mesocorticolimbic dopamine pathway primarily mediates the ‘wanting’, or incentive 
salience, of a reward, but not necessarily the ‘liking’ (Berridge, 1996; Pecina et al., 2003). This 
is hypothesised to be primarily controlled by opioid circuits and endocannabinoids (Pecina and 
Berridge, 2000; Mahler et al., 2007). 
Drugs of abuse and naturally rewarding behaviours stimulate the firing of VTA dopamine 
neurones and increase extracellular dopamine levels within the NAc (Ljungberg et al., 1992; 
Pettit and Justice, Jr., 1989; Di Chiara and Imperato, 1988). Amphetamines and cocaine increase 
dopamine levels directly by increasing dopamine release and inhibiting dopamine re-uptake, 
respectively (Bradberry and Roth, 1989; Ritz et al., 1987; Hurd et al., 1992). In contrast, opiates 
increase NAc dopamine levels indirectly by inhibiting GABAergic interneurones and hence 
disinhibiting VTA dopamine neurones (Bergevin et al., 2002). Lesioning the VTA dramatically 
reduces motivational behaviour in rodents (Ungerstedt, 1971). Additionally, destruction  of the 
NAc prevents cocaine self-administration (Roberts et al., 1980), and inhibits the rewarding 
effects of opiates, in rats (Kelsey et al., 1989). 
Reward is linked to a reduction in NAc output. Administration of morphine (Hakan and 
Henriksen, 1989) or cocaine (Peoples and West, 1996) decreases neuronal activity in the NAc. 
The major output of the NAc is GABAergic and thus inhibitory. Rewarding stimuli decrease 
NAc firing and therefore disinhibit downstream structures, such as the ventral pallidum. In 
support of this theory, a sucrose reward increases the activity of ventral pallidal neurones in rats 
(Tindell et al., 2004). 
Drug addiction is a highly complex process that is not fully understood. Repetitive stimulation of 
reward circuits induced by chronic drug use induces neuroadaptations within the mesolimbic 
dopamine pathway. Addicted subjects have decreased dopamine function, and are less sensitive 
to non-drug related stimuli including natural reinforcers. However, dopamine transmission in 
response to the addicted drug is increased, which is postulated to cause drug craving (Volkow et 
al., 2004; Nestler, 2005). It is possible that excessive stimulation of reward circuits by over-
consumption of palatable food may induce similar adaptations, and play a role in the 
development of obesity. 
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3.1.5. The role of mesolimbic dopamine in the control of food intake 
Midbrain dopamine neurones have long been implicated in the control of food intake. Feeding is 
a naturally rewarding behaviour, and, similarly to administration of drugs of abuse, is associated 
with an increase in extracellular dopamine levels within the NAc (Hernandez and Hoebel, 1988). 
Peripheral administration of a dopamine receptor antagonist attenuates lever-pressing behaviour 
for a food reward in fasted rats (Phillips and Nikaido, 1975) and blocks feeding induced by 
electrical stimulation of the LH (Wise et al., 1978). Additionally, dopamine depletion within the 
midbrain induced by the neurotoxin 6-hydroxydopamine (6-OHDA) induces hypophagia and 
hypodipsia in mice (Ungerstedt, 1971). However, the role of dopamine in general motivation and 
movement must be considered when evaluating this model. 
A hypophagic, lean phenotype is also observed in mice unable to synthesise dopamine 
specifically within neurones due to TH inactivation. L-DOPA administration restores feeding 
and growth in these animals (Zhou and Palmiter, 1995). Conversely, mice with increased 
synaptic dopamine due to deletion of the DAT gene are hyperphagic, hyperdipsic and show 
increased behavioural motivation to obtain a sweet reward compared to wild type littermates 
(Pecina et al., 2003). 
In humans, positron emission tomography (PET) scanning has demonstrated that obese 
individuals have significantly lower striatal D2 receptor availability compared to non-obese 
controls, and that D2 receptor availability is inversely correlated with body mass index (BMI) in 
obese subjects (Wang et al., 2001). A similar reduction in D2 receptors has also been identified 
in cocaine (Volkow et al., 1993) and opiate (Wang et al., 1997a) addicts, suggesting that drug 
addiction and over-eating may either be caused by, or exert, similar changes in the mesolimbic 
dopamine system. 
Two hypotheses have been suggested to explain these findings. D2 receptors may be down-
regulated following over-stimulation induced by excessive feeding or drug-taking. Alternatively, 
subjects with lower striatal D2 receptor availability may be more susceptible to addictive 
behaviour, including over-eating (Wang et al., 2001). Recent work has demonstrated that 
overconsumption of palatable food decreases the responsiveness of brain reward circuits and 
reduces striatal D2 receptor density in rats (Johnson and Kenny, 2010). Additionally, D2 
receptor availability increases in female subjects following weight loss induced by Roux-en-Y 
gastric bypass surgery (Steele et al., 2010). The evidence therefore favours the hypothesis that 
reduced dopamine receptor density is a consequence, rather than a cause, of obesity. 
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3.1.6. Changes in nutritional status alter the mesolimbic dopamine system 
Caloric deficit is generally thought to increase reward-related behaviour, and the evolutionary 
advantage of the rewarding value of food increasing during periods of food deprivation is clear. 
Conditioned place preference (CPP) is a technique used to determine reward-induced learning. 
Rats form a CPP to food more effectively when food restricted than when fed (Swerdlow et al., 
1983). This effect can be abolished by peripheral pre-treatment with a dopamine receptor 
antagonist (Spyraki et al., 1982). Unsurprisingly, rats will also work harder for food when food-
deprived (Figlewicz et al., 2006). Food restriction increases drug self-administration (Carroll et 
al., 1979; Carroll and Meisch, 1981; Bell et al., 1997) and drug-induced locomotion (Campbell 
and Fibiger, 1971), suggesting functional overlap in CNS circuits which control food intake and 
drug reward. 
Chronic food restriction increases TH and DAT mRNA and protein levels in the rat VTA 
(Lindblom et al., 2006), and has been reported to reduce basal extracellular dopamine levels in 
the NAc (Pothos et al., 1995). It has been proposed that in states of negative energy balance, 
dopamine synthesis and re-uptake increases, resulting in an accumulation of pre-synaptic 
dopamine and low extracellular levels. This leads to sensitization of post-synaptic dopamine 
receptors (Carr et al., 2003) and enables higher than usual quantities of dopamine to be released 
upon stimulation, leading to initiation of reward-seeking behaviour (Pothos et al., 1998; 
Lindblom et al., 2006). 
It is currently unclear which energy homeostasis-regulating factors influence the dopamine 
reward system. However, recent evidence suggests that peripheral hormones may be involved. 
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3.1.7. The role of peripheral hormones involved in energy homeostasis in the VTA 
Recent work has suggested that peripheral hormones including leptin, insulin, and ghrelin signal 
not only to the hypothalamus and brainstem, but also to limbic structures involved in reward, to 
modulate food intake. 
 
3.1.7.1. Leptin 
A large body of evidence suggests that midbrain dopamine neurones are direct targets for leptin. 
Approximately 60% of VTA dopamine neurones express both ObRb and signal transducer and 
activator of transcription 3 (STAT3), an intracellular signalling molecule which is 
phosphorylated (pSTAT3) upon leptin binding to its receptor (Hommel et al., 2006; Fulton et al., 
2006). Peripheral and intra-VTA leptin administration increases VTA pSTAT3 protein 
expression, suggesting that leptin signals directly to VTA neurones (Hommel et al., 2006; Fulton 
et al., 2006). Similarly to food-restricted animals, leptin deficient ob/ob mice have impaired 
dopamine release within the NAc compared to wild-type controls (Fulton et al., 2006). 
It has been suggested that leptin may both modulate reward-seeking behaviour and influence 
feeding by acting directly on VTA dopamine neurones. Leptin administration into the VTA 
decreases food intake in rats, and peripheral leptin treatment reduces dopamine cell firing within 
the VTA (Hommel et al., 2006). Mice lacking the leptin receptor specifically within the VTA 
consume more sucrose and palatable high fat food than wild-type controls (Hommel et al., 2006). 
Peripheral leptin administration reverses CPP in food deprived rats (Figlewicz et al., 2001), and 
ICV leptin treatment reduces lever pressing behaviour to obtain a sucrose reward (Figlewicz et 
al., 2006). Leptin may therefore inhibit the firing of VTA dopamine neurones to decrease food 
intake and blunt the rewarding properties of food. 
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3.1.7.2. Insulin 
Similarly to leptin, insulin is hypothesised to reduce the rewarding properties of food. Insulin 
receptors are expressed on dopamine neurones within the VTA (Figlewicz et al., 2003), 
suggesting insulin may have a direct action on reward circuits.  ICV administration of insulin 
abolishes the CPP associated with a food reward in fed rats (Figlewicz et al., 2004), and, like 
leptin administration, reduces lever-pressing behaviour to obtain sucrose (Figlewicz et al., 2006). 
Central administration of insulin attenuates consumption of palatable food induced by ICV 
injection of an opioid receptor agonist (Sipols et al., 2002), and enhances the action of a D2 
receptor antagonist to attenuate sucrose ingestion (Sipols et al., 2000). 
Electrical stimulation of certain areas of the brain, including the LH, is thought to artificially 
activate reward circuitry and hence has reinforcing and rewarding properties. Rats will actively 
seek out, and perform tasks in order to receive, electrical stimulation of the LH (Margules and 
Olds, 1962). Lateral hypothalamic self-stimulation (LHSS) is therefore a useful technique to 
assess the responsiveness of brain reward systems. The threshold for LHSS is lowered in insulin-
deficient diabetic and food-restricted rats, implying there is an increase in sensitivity to reward 
when circulating insulin and/or leptin levels are low (Carr et al., 2000). This threshold increases 
to baseline levels following central insulin (Carr et al., 2000) or leptin (Fulton et al., 2000) 
administration. 
 
3.1.7.3. Ghrelin 
The orexigenic hormone ghrelin is also hypothesised to target the mesolimbic dopamine system. 
Ghrelin increases the firing rate of VTA dopamine neurones, and increases dopamine turnover in 
the NAc (Abizaid et al., 2006). Injection of ghrelin directly into the VTA stimulates feeding 
(Naleid et al., 2005; Abizaid et al., 2006). Additionally, administration of a ghrelin receptor 
antagonist into the VTA blocks feeding induced by peripheral ghrelin injection and by fasting 
(Abizaid et al., 2006). This suggests ghrelin may enhance reward signals and therefore have 
opposing actions to leptin and insulin. 
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3.1.8. The role of hypothalamic neuropeptides involved in energy homeostasis in the VTA 
Hypothalamic neuropeptides involved the control of energy homeostasis may also influence food 
intake by modulating reward pathways. 
 
3.1.8.1. Orexins 
Orexin neurones located within the LH project heavily to the VTA, where they terminate in close 
proximity to TH-expressing neurones (Fadel and Deutch, 2002; Marcus et al., 2001). Orexin 1 
and 2 receptor immunoreactivity is colocalised with TH within the VTA (Narita et al., 2006). 
Orexin A increases calcium influx in isolated VTA dopamine neurones (Uramura et al., 2001), 
and both orexin A and B increase the firing frequency of VTA dopamine neurones (Korotkova et 
al., 2003). Additionally, intra-VTA administration of either orexin A and B increases dopamine 
levels within the NAc (Narita et al., 2006). 
Orexin signalling is involved in mediating the rewarding effects of morphine. Morphine 
administration fails to increase extracellular dopamine in the NAc, and does not induce 
formation of a CPP, in mice lacking the prepro-orexin gene (Narita et al., 2006). The orexins 
also have a role in mediating reward-based food intake. Administration of a µ-opioid receptor 
agonist into the NAc stimulates consumption of a palatable high-fat diet in rats (Zhang et al., 
1998). Pre-administration of an orexin 1 receptor antagonist into the VTA inhibits this 
orexigenic effect (Zheng et al., 2007). This suggests that orexin signalling from the LH to the 
VTA may regulate activation of the mesolimbic dopamine system by opioid receptors, and thus 
influence both food intake and responsiveness to morphine. 
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3.1.8.2. NPY 
NPY immunoreactive neuronal cell bodies and axons are widely distributed throughout the 
mammalian brain, and the NAc is one of the areas within the CNS in which NPY 
immunoreactivity is highest (de Quidt and Emson, 1986). Administration of NPY into the NAc 
induces a CPP in rats, which can be prevented by pre-administration of a dopamine receptor 
antagonist (Josselyn and Beninger, 1993). This suggests that NPY signalling within the NAc 
may have rewarding and reinforcing properties, and this effect may be mediated by dopamine. 
Additionally, ICV administration of NPY increases heroin self-administration, and re-establishes 
extinguished heroin-seeking behaviour, in rats (Maric et al., 2008). NPY may also have a role in 
mediating the rewarding effect of food, as central administration of a Y1 receptor antagonist 
inhibits high fat feeding induced by injection of a µ-opioid receptor agonist into the NAc (Zheng 
et al., 2010). 
 
3.1.8.3. The melanocortin system 
POMC and AgRP immunoreactive fibres project widely to numerous sites within the CNS, 
including the VTA and NAc shell (Bagnol et al., 1999). The MC4R (Mountjoy et al., 1994) and 
MC3R (Roselli-Rehfuss et al., 1993) are expressed within the VTA and NAc. 
There is evidence to suggest that the melanocortin system may have a role in mediating reward-
related behaviours, although studies investigating drug reward have produced conflicting results. 
ICV injection of α-MSH has been shown to antagonise the addictive properties of opiates in 
mice (Contreras and Takemori, 1984). However, a more recent study reported that infusion of a 
melanocortin receptor antagonist into the NAc blocked the reinforcing effects of cocaine (Hsu et 
al., 2005). 
It has also been suggested that the melanocortin system may interact with reward pathways to 
influence feeding. Mice lacking the MC4R are hyperphagic and show increased motivation to 
obtain food compared to wild-type controls (Vaughan et al., 2006). Additionally, animals will 
work harder to obtain a high-fat reward, but not sucrose, following ICV administration of AgRP, 
suggesting that AgRP may specifically increase the rewarding value of high-fat foods (Tracy et 
al., 2008). 
Fos protein is coded for by the immediate early gene c-fos, and is used as an indirect marker of 
neuronal activation. ICV administration of AgRP induces fos-like immunoreactivity in midbrain 
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dopamine neurones (Davis et al., 2010), the NAc shell, and the lateral hypothalamus (Hagan et 
al., 2001). Additionally, ICV AgRP administration increases dopamine turnover within the 
forebrain (Davis et al., 2010). This suggests that AgRP may influence mesolimbic dopamine 
pathways and activate areas involved in reward, whilst stimulating food intake. However, little is 
known about the role of melanocortin signalling within the VTA in the control of food intake, 
and whether melanocortins directly influence VTA neurones to regulate food intake. 
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3.1.9. Hypothesis 
Administration of melanocortin receptor agonists and antagonists directly into the VTA will 
influence feeding behaviour. 
 
3.1.10. Aims 
I aim to investigate the role of the VTA melanocortin system in the control of food intake. In 
order to do this I will determine: 
- The effect of intra-VTA administration of NDP-MSH, AgRP and a selective MC4R 
antagonist on food intake in male Wistar rats. 
- The effect of intra-VTA NDP-MSH administration on behaviour in male Wistar rats. 
- Possible mechanisms by which the VTA melanocortin system may influence food intake. 
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3.2. Methods 
3.2.1. Materials 
AgRP (86-132) was supplied by The Peptide Institute (Osaka, Japan). Cis-(Z)-Flupenthixol 
dihydrochloride, a dopamine receptor antagonist, and bicuculline methiodide, a GABAA receptor 
antagonist, were supplied by Sigma-Aldrich. All other peptides used were supplied by Bachem. 
 
3.2.2. Animals 
Adult male Wistar rats (Charles River) were maintained in individual cages as described in 
section 2.2.2. 
 
3.2.3. Verification of intra-VTA cannula placement  
3.2.3.1. Ink injections 
Prior to intra-VTA cannulation, suitable stereotactic coordinates were identified using ‘The Rat 
Brain in Stereotactic Co-ordinates’ (Paxinos and Watson, 2007) and verified by injection of 1µl 
10% dilution of India ink in water. 
Male Wistar rats (n=6) were terminally anaesthetised with intraperitoneal 200mg/kg 
Pentobarbitone (Animalcare Ltd., Dunnington, Yorkshire, UK). Rats were positioned on a 
stereotactic frame (David Kopf Instruments, supplied by Clark Electromedical Instruments) with 
the incisor bar 3mm below the interaural line. A 1.5cm longitudinal incision was made in the 
scalp. A hole was drilled using a stereotactically mounted electric drill (Department of Medical 
Engineering, Imperial College London, UK). A 26-gauge cannula (Plastics One Inc.) was 
directed to the dopamine-rich PBP nucleus of the VTA and therefore implanted 6mm posterior to 
the bregma, 0.5mm lateral from the midline and 8.5mm below the surface of the skull. Each 
animal was injected unilaterally with ink via a 33-gauge steel injector (Plastics One Inc.) inserted 
into, and projecting 1mm beyond the tip of, the guide cannula. 
Following injection, animals were removed from the frame and brains were rapidly dissected. 
Brains were fixed in a 4% formaldehyde solution (Appendix I) at 4ºC overnight, then dehydrated 
in a 30% sucrose solution at room temperature for five days.  
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Brains were snap frozen in isopentane, and 30µm coronal slices taken using a sled microtome 
(Bright Instrument Company). Sections containing ink were stored in antifreeze (Appendix I) at -
20ºC. Slices were mounted onto polylysine coated slides (VWR) then counter-stained using 
cresyl violet (Section 3.2.3.2).  
 
3.2.3.2 Cresyl violet staining of ink injected rat brains 
Materials 
Acetic acid (VWR) 
Ethanol (VWR) 
Cresyl violet stain (Appendix I) 
Xylene (VWR) 
DPX (Thermo Fisher Scientific, Epsom, Surrey, UK) 
 
 
Method 
Once mounted onto slides, brain sections containing India ink were allowed to dry for at least 
four hours. Slides were fixed in a solution of 5% acetic acid in 100% ethanol, and then stained in 
cresyl violet for 15 minutes. Slides were washed twice in GDW, dehydrated in 70% ethanol and 
delipidated in xylene overnight. The following morning, slides were mounted with DPX and 
coverslips. Animals with ink more than 0.2mm outside the VTA when viewed under the 
microscope (Nikon, Eclipse 50i) were classed as outliers. 
 
3.2.4. VTA cannulation and injection 
Cannulation surgery was carried out as described in section 2.2.3 except that for VTA 
cannulation, a 26-gauge stainless steel cannula (Plastics One Inc.) and different cannulation co-
ordinates were used (see section 3.2.3).  
 
Peptides or vehicle were administered to conscious, freely moving rats in a volume of 1μl via a 
33-gauge stainless steel injector placed into, and projecting 1mm below, the tip of the cannula. 
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3.2.5. The effect of intra-VTA NDP-MSH administration on food intake in ad libitum fed 
rats in the early dark phase 
Nle4, D-Phe7-α-MSH (NDP-MSH) is a potent, degradation resistant, synthetic analogue of α-
MSH (Sawyer et al., 1980).  Ad libitum fed rats were randomised into groups by body weight 
and injected into the VTA with either saline or 0.1, 0.3 or 1nmol NDP-MSH (n=7 per group) in 
the early dark phase (19:30-20:30). Following injection, rats were returned to their home cage 
with a pre-determined amount of food and free access to water. Food was re-weighed at 1, 2, 4, 8 
and 24 hours post-injection. Body weight was measured at 24 hours post-injection.  
 
3.2.6. The effect of intra-VTA administration of lower doses of NDP-MSH on food intake in 
ad libitum fed rats in the early dark phase 
The doses of NDP-MSH administered in study 3.2.5 elicited a profound reduction in food intake. 
I therefore repeated the study using ten-fold lower doses, to determine the minimum effective 
dose of intra-VTA NDP-MSH. 
Ad libitum fed rats were randomised into groups by body weight and injected into the VTA with 
either saline or 0.01, 0.03 or 0.1nmol NDP-MSH (n=7 per group) in the early dark phase. 
Following injection, rats were returned to their home cage with a pre-determined amount of food 
and free access to water. Food was re-weighed at 1, 2, 4, 8 and 24 hours post-injection. Body 
weight was measured at 24 hours post-injection. 
 
3.2.7. The effect of intra-VTA NDP-MSH administration on food intake in fasted rats in the 
early light phase 
The effect of intra-VTA NDP-MSH administration on fasting-induced re-feeding was studied to 
investigate whether the responsiveness of the VTA to melanocortins is altered by changes in 
nutritional status. 
Overnight-fasted rats were randomised into groups by body weight and injected into the VTA 
with either saline or 0.03, 0.1 or 1nmol NDP-MSH (n=7 per group) in the early light phase. 
Following injection, rats were returned to their home cage with a pre-determined amount of food 
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and free access to water. Food was re-weighed at 1, 2, 4, 8 and 24 hours post-injection. Body 
weight was measured at 24 hours post-injection. 
 
3.2.8. The effect of intra-VTA NDP-MSH administration on behaviour in ad libitum fed 
rats in the early dark phase 
Behaviour was monitored following intra-VTA administration of NDP-MSH to determine 
whether the effects on food intake were secondary to behavioural changes. 
Ad libitum fed rats were injected into the VTA with saline or 0.03nmol NDP-MSH (n=8 per 
group) in the early dark phase and returned to their home cages. This dose of NDP-MSH was 
chosen because it was the lowest to significantly reduce food intake in study 3.2.6.  
Behaviour was continuously monitored for thirty minutes by two observers blinded to the 
experimental treatment using methods adapted from Fray et al (Fray et al., 1980; Scott et al., 
2005). Each rat was observed for fifteen seconds every five minutes. Each fifteen second period 
was sub-divided into three five second periods and the behaviour of the rat was noted in each 
time period. Behaviour was classified into the following categories: feeding, drinking, rearing, 
locomotion, grooming, burrowing, head down, sleeping and pica. 
 
3.2.9. The effect of intra-VTA NDP-MSH administration on food intake following intra-
peritoneal pre-treatment with a GABAA receptor antagonist in the early dark phase 
I hypothesised that the inhibitory effect of intra-VTA NDP-MSH administration on food intake 
may be mediated by stimulation of endogenous VTA GABAergic neurones, which tonically 
inhibit dopamine neurones. It has been suggested that this inhibition is mediated by GABAA 
receptors (Sugita et al., 1992). I therefore used the GABAA receptor antagonist bicuculline to 
determine whether the anorexigenic effect of intra-VTA NDP-MSH can be attenuated by 
GABAA receptor antagonism. Bicuculline methiodide is a stable, water-soluble form of 
bicuculline.  
Ad libitum fed rats were randomised by body weight and injected intra-peritoneally (IP) with 
either saline or 3mg/kg bicuculline methiodide fifteen minutes prior to onset of the dark phase. 
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This dose of bicuculline methiodide was chosen because it has previously been shown to not 
affect food intake in rats (Zarrindast et al., 1989).  
Fifteen minutes later, rats were injected into the VTA with either saline or 0.03nmol NDP-MSH 
(n=6-7 per group). This dose of NDP was chosen because it was the lowest to significantly 
reduce food intake in study 3.2.6.  
Following injection, rats were returned to their home cage with a pre-determined amount of food 
and free access to water. Food was re-weighed at 1, 2, 4, 8 and 24 hours post-injection. Body 
weight was measured at 24 hours post-injection. 
 
3.2.10. The effect of intra-VTA AgRP administration on food intake in ad libitum fed rats 
in the early light phase 
Ad libitum fed rats were randomised into groups by body weight and injected into the VTA with 
either saline or 0.1, 0.3 or 1nmol AgRP (n=9-11 per group) in the early light phase. Following 
injection, rats were returned to their home cage with a pre-determined amount of food and free 
access to water. Food was re-weighed at 1, 2, 4, 8 and 24 hours post-injection. Body weight was 
measured at 24 hours post-injection. 
 
3.2.11. The effect of intra-VTA AgRP administration on food intake following intra-
peritoneal pre-treatment with a dopamine receptor antagonist in the early light phase 
In order to determine whether VTA dopamine neurones mediate the orexigenic effect of intra-
VTA AgRP administration, I treated rats with a non-specific dopamine receptor antagonist prior 
to intra-VTA AgRP administration. 
Ad libitum fed rats were randomised by body weight and injected IP with either saline or 
0.15mg/kg Cis-(Z)-Flupenthixol dihydrochloride, a non-specific dopamine receptor antagonist, 
in the early light phase. This dose has previously been shown not to induce motor impairments in 
rats (Cousins et al., 1994). Fifteen minutes later, rats were injected into the VTA with either 
saline or 0.3nmol AgRP (n=10 per group). This dose of AgRP was chosen because it robustly 
increased food intake in study 3.2.10.  
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Following injection, rats were returned to their home cage with a pre-determined amount of food 
and free access to water. Food was re-weighed at 1, 2, 4, 8 and 24 hours post-injection. Body 
weight was measured at 24 hours post-injection. 
 
3.2.12. The effect of intra-VTA administration of JKC 363, an MC4R antagonist, on food 
intake in ad libitum fed rats in the early light phase 
Ad libitum fed rats were randomised into groups by body weight and injected into the VTA with 
either saline or 0.1, 0.3 or 1nmol JKC 363 (n=9 per group) in the early light phase. Following 
injection, rats were returned to their home cage with a pre-determined amount of food and free 
access to water. Food was re-weighed at 1, 2, 4, 8 and 24 hours post-injection. Body weight was 
measured at 24 hours post-injection. 
 
3.2.13. The effect of intra-VTA JKC 363 administration on food intake following intra-
peritoneal pre-treatment with a dopamine receptor antagonist in the early light phase 
I treated rats with a dopamine receptor antagonist prior to intra-VTA JKC 363 administration to 
determine whether VTA dopamine neurones act downstream of the MC4R to stimulate food 
intake. 
Ad libitum fed rats were randomised by body weight and injected IP with either saline or 
0.15mg/kg Cis-(Z)-Flupenthixol dihydrochloride in the early light phase. Fifteen minutes later, 
rats were injected into the VTA with either saline or 1nmol JKC 363 (n=7-8 per group). This 
dose of JKC 363 was chosen because it significantly increased 0-1 hour food intake in study 
3.2.12.  
Following injection, rats were returned to their home cage with a pre-determined amount of food 
and free access to water. Food was re-weighed at 1, 2, 4, 8 and 24 hours post-injection. Body 
weight was measured at 24 hours post-injection. 
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3.2.14. Statistics 
All data are presented as mean ± standard error of the mean (SEM), other than data from 
behavioural studies which are expressed as median and inter-quartile range. Food intake studies 
were analysed using a one-way analysis of variance (ANOVA) with Tukey’s post-hoc test 
(GraphPad Prism version 5 for Windows; GraphPad Software, San Diego, CA). Behavioural 
studies were analysed using the Kruskall-Wallis test (Systat, Evanston, IL) as data were non-
parametric. In all cases p values <0.05 were taken as significant.  
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3.3. Results 
3.3.1. Verification of intra-VTA cannula placement  
Prior to intra-VTA cannulation, correct coordinates were confirmed with ink injections. Ink was 
observed unilaterally in the PBP of the VTA in 83% of animals (n=6). A representative 
photograph is shown in Figure 3.3A.  
 
 
            
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Confirmation of the parabrachial pigmented nucleus (PBP) coordinates using ink 
injections. Rats were injected unilaterally with India ink (coordinates 6mm posterior to the bregma, 
0.5mm lateral from the midline and 9.5mm below the surface of the skull). Brain sections were 
stained with cresyl violet (A), and compared to ‘The Rat Brain in Stereotaxic Coordinates’ (Paxinos 
and Watson, 2007) (B). A coronal section at -6mm from bregma is shown. Scale bar is equivalent to 
1mm. Abbreviations: IF, interfascicular nucleus; IPC, interpeduncular nucleus, caudal part; IPL, 
interpeduncular nucleus, lateral part; IPR, interpeduncular nucleus, rostral part; PIF, 
parainterfascicular nucleus of the VTA; PN, paranigral nucleus of the VTA; vtgx, VTA 
decussation. 
A B 
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3.3.2. The effect of intra-VTA NDP-MSH administration on food intake in ad libitum fed 
rats in the early dark phase 
Intra-VTA administration of 0.1, 0.3 and 1.0nmol NDP-MSH to ad libitum fed rats in the early 
dark phase significantly reduced food intake in the first hour after injection when compared to 
saline injected controls (0-1 hour food intake (g): 2.29 ± 0.34 [saline]; 0.41 ± 0.15 [0.1nmol 
NDP-MSH] p<0.001 vs. saline; 0.38 ± 0.07 [0.3nmol NDP-MSH] p<0.001 vs. saline; 0.17 ± 
0.02 [1nmol NDP-MSH] p<0.001 vs. saline, n=7 per group) (Figure 3.4A). This reduction was 
maintained at 1-2 hours post-injection (1-2 hour food intake (g) 2.79 ± 0.25 [saline]; 1.03 ± 0.35 
[0.1nmol NDP-MSH] p<0.01 vs. saline; 0.43 ± 0.13 [0.3nmol NDP-MSH] p<0.001 vs. saline; 
0.78 ± 0.34 [1nmol NDP-MSH] p<0.001 vs. saline, n=7 per group) (Figure 3.4B). 
All doses of NDP-MSH also induced a significant reduction in food intake between 2 and 4 
hours post injection (2-4 hour food intake (g) 4.63 ± 0.65 [saline]; 0.92 ± 0.34 [0.1nmol NDP-
MSH] p<0.001 vs. saline; 0.76 ± 0.27 [0.3nmol NDP-MSH] p<0.001 vs. saline; 1.96 ± 0.65 
[1nmol NDP-MSH] p<0.01 vs. saline, n=7 per group) (Figure 3.4C). 
All doses of NDP-MSH had no significant effect on food intake at any other time points.  
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Figure 3.4: The effect of intra-VTA NDP-MSH administration on food intake in ad libitum fed 
rats in the early dark phase. Male Wistar rats received an intra-VTA injection of saline, 0.1, 0.3 
or 1.0nmol NDP-MSH in the early dark phase. Food intake expressed as mean (g) ± SEM at (A) 0-
1, (B) 1-2, (C) 2-4, (D) 4-8, (E) 8-24 and (F) 0-24 hours post injection is shown (n=7 per group). 
**p<0.01, ***p<0.001 vs. saline. 
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3.3.3. The effect of intra-VTA administration of lower doses of NDP-MSH on food intake in 
ad libitum fed rats in the early dark phase 
Intra-VTA administration of 0.03 and 0.1nmol NDP-MSH to ad libitum fed rats in the early dark 
phase significantly reduced food intake 0-1 hours post-injection compared to saline injected 
controls (0-1 hour food intake (g): 2.16 ± 0.23 [saline]; 0.93 ± 0.42 [0.03nmol NDP-MSH] 
p<0.05 vs. saline; 0.51 ± 0.21 [0.1nmol NDP-MSH] p<0.01 vs. saline, n=7 per group) (Figure 
3.5A).  
These doses of NDP-MSH also significantly reduced food intake 2-4 hours post-injection (2-4 
hour food intake (g): 4.02 ± 0.47 [saline]; 1.46 ± 0.80 [0.03nmol NDP-MSH] p<0.05 vs. saline; 
1.28 ± 0.84 [0.1nmol NDP-MSH] p<0.05 vs. saline, n=7 per group) (Figure 3.5C).  
Additionally, intra-VTA administration of 0.03nmol NDP-MSH significantly reduced food 
intake between 4 and 8, and 0 and 24 hours post-injection (4-8 hour food intake (g): 8.22 ± 0.76 
[saline] vs. 3.38 ± 1.24 [0.03nmol NDP-MSH] p<0.01 (Figure 3.5D); 0-24 hour food intake (g): 
27.41 ± 0.81 [saline] vs. 18.24 ± 2.71 [0.03nmol NDP-MSH] p<0.01, n=7 per group (Figure 
3.5F)).  
All doses of NDP-MSH had no significant effect on food intake at any other time points.  
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Figure 3.5: The effect of intra-VTA NDP-MSH administration on food intake in ad libitum fed 
rats in the early dark phase. Male Wistar rats received an intra-VTA injection of saline, 0.01, 0.03 
or 0.1nmol NDP-MSH in the early dark phase. Food intake expressed as mean (g) ± SEM at (A) 0-
1, (B) 1-2, (C) 2-4, (D) 4-8, (E) 8-24 and (F) 0-24 hours post injection is shown (n=7 per group). 
*p<0.05, **p<0.01 vs. saline. 
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3.3.4. The effect of intra-VTA NDP-MSH administration on food intake in fasted rats in the 
early light phase 
Intra-VTA administration of 0.03, 0.1 and 1nmol NDP-MSH to overnight fasted rats in the early 
light phase significantly reduced food intake between 2 and 4 hours post-injection (2-4 hour food 
intake (g): 3.80 ± 1.06 [saline]; 1.19 ± 0.47 [0.03nmol NDP-MSH] p<0.05 vs. saline; 0.62 ± 0.51 
[0.1nmol NDP-MSH] p<0.05 vs. saline; 0.80 ± 0.43  [1nmol NDP-MSH] p<0.05 vs. saline, n=7 
per group) (Figure 3.6C). 
All doses of NDP-MSH had no significant effect on food intake at any other time points.  
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Figure 3.6: The effect of intra-VTA NDP-MSH administration on food intake in fasted rats in 
the early light phase. Male Wistar rats received an intra-VTA injection of saline, 0.03, 0.1 or 
1nmol NDP-MSH in the early dark phase. Food intake expressed as mean (g) ± SEM at (A) 0-1, (B) 
1-2, (C) 2-4, (D) 4-8, (E) 8-24 and (F) 0-24 hours post injection is shown (n=7 per group). *p<0.05 
vs. saline. 
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3.3.5. The effect of intra-VTA NDP-MSH administration on behaviour in ad libitum fed 
rats in the early dark phase 
Intra-VTA administration of 0.03nmol NDP-MSH to ad libitum fed male Wistar rats in the early 
dark phase significantly reduced head down behaviour compared to saline injected controls 
(p<0.05, n=8 per group) (Table 3.1). 
 
Behaviour Saline 0.03nmol NDP-MSH 
Feeding 
 
3.0 (1.5-3.5) 1.0 (0.5-4.5) 
Drinking 
 
0.0 (0.0-2.5) 0.0 (0.0-1.5) 
Rearing 
 
4.0 (3.5-5.5) 3.5 (2.0-5.5) 
Locomotion 
 
2.5 (2.0-3.0) 2.5 (1.5-3.5) 
Grooming 
 
4.5 (3.5-6.5) 6.5 (5.0-10.0) 
Burrowing 
 
0.0 (0.0-0.0) 0.0 (0.0-0.0) 
Head down 
 
2.5 (1.0-3.0) 1.0 (0.5-1.0)* 
Sleep 
 
0.0 (0.0-0.0) 0.0 (0.0-0.0) 
Pica 
 
0.0 (0.0-0.0) 0.0 (0.0-0.0) 
 
 
 
 
 
Table 3.1: The effect of intra-VTA NDP-MSH administration on behaviour in ad libitum fed 
rats during the early dark phase. Behaviour was monitored for thirty minutes post-injection. 
Data is presented as median number of behaviours observed (inter-quartile range), n=8 per group; 
*p<0.05 vs. saline.  
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3.3.6. The effect of intra-VTA NDP-MSH administration on food intake following intra-
peritoneal pre-treatment with a GABAA receptor antagonist in the early dark phase 
Intra-VTA administration of 0.03nmol NDP-MSH significantly reduced food intake between 0 
and 2 hours post-injection in ad libitum fed rats compared to saline injected controls. IP 
administration of 3mg/kg bicuculline-methiodide had no significant effect on food intake. 
Administration of 3mg/kg bicuculline-methiodide fifteen minutes prior to injection of 0.03nmol 
NDP-MSH partially attenuated the anorexigenic effect of NDP-MSH (0-2hr food intake (g): 4.23 
± 0.56 [saline/saline]; 4.05 ± 0.37 [bicuculline/saline]; 1.92 ± 0.62 [saline/NDP-MSH 0.03nmol] 
p<0.05 vs. saline/saline; 3.27 ± 0.64 [bicuculline/NDP-MSH 0.03nmol] n=6-7 per group) (Figure 
3.7). 
No significant differences in food intake were observed between groups at any other time points. 
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Figure 3.7: The effect of intra-VTA NDP-MSH administration on food intake following intra-
peritoneal pre-treatment with a GABAA receptor antagonist in the early dark phase.  Ad 
libitum fed male Wistar rats were injected IP with saline or 3mg/kg bicuculline methiodide in the 
early dark phase fifteen minutes prior to intra-VTA administration of saline or 0.03nmol NDP-
MSH. Food intake, presented as mean ± SEM, at 0-2 hours post injection is shown (n=6-7 per 
group). *p<0.05 vs. saline/saline. 
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3.3.7. The effect of intra-VTA AgRP administration on food intake and body weight in ad 
libitum fed rats in the early light phase 
Administration of 1nmol AgRP intra-VTA to ad libitum fed rats in the early light phase 
significantly increased food intake between 1 and 2 hours post-injection (1-2 hour food intake 
(g): 0.89 ± 0.30 [saline] vs. 2.81 ± 0.65 [1nmol AgRP] p<0.05, n=9-11 per group) (Figure 3.8B). 
All doses of AgRP significantly increased food intake between 4 and 8 hours following intra-
VTA injection (4-8 hour food intake (g): 0.71 ± 0.35 [saline]; 2.55 ± 0.34 [0.1nmol AgRP] 
p<0.05 vs. saline; 3.17 ± 0.60 [0.3nmol AgRP] p<0.01 vs. saline; 3.06 ± 0.78 [1nmol AgRP] 
p<0.05 vs. saline, n=9-11 per group) (Figure 3.8D). 
Cumulative food intake was significantly increased between 0 and 2 hours following intra-VTA 
administration of 1nmol AgRP (0-2 hour food intake (g): 2.03 ± 0.50 [saline] vs. 4.94 ± 1.21 
[1nmol AgRP] p<0.05, n=9-11 per group) (Figure 3.9). Intra-VTA injection of 0.1 and 1nmol 
significantly increased cumulative food intake between 0 and 4 hours compared to saline 
controls (0-4 hour food intake (g): 2.89 ± 0.62 [saline]; 5.25 ± 0.62 [0.1nmol AgRP] p<0.05 vs. 
saline; 6.28 ± 0.99 [1nmol AgRP] p<0.01 vs. saline, n=9-11 per group) (Figure 3.9). 
Additionally, all doses of AgRP induced a significant rise in food intake between 0 and 8 hours 
after injection (0-8 hour food intake (g): 3.60 ± 0.89 [saline]; 7.81 ± 0.62 [0.1nmol AgRP] 
p<0.001 vs. saline; 7.03 ± 1.42 [0.3nmol AgRP] p<0.01 vs. saline; 9.34 ± 0.68 [1nmol AgRP] 
p<0.001 vs. saline, n=9-11 per group) (Figure 3.9). The highest dose of AgRP administered, 
1nmol, also significantly increased 0-24 hour food intake (0-24 hour food intake (g): 26.61 ± 
2.93 [saline] vs. 38.05 ± 1.45 [1nmol AgRP] p<0.01, n=9-11 per group) (Figure 3.8F). 
There was a dose-dependent increase in body weight change at 24 hours following intra-VTA 
AgRP administration (0-24 hour body weight change (g): -9.9 ± 3.2 [saline]; 3.5 ± 2.6 [0.1nmol 
AgRP] p<0.01 vs. saline; 5.2 ± 2.3 [0.3nmol AgRP] p<0.001 vs. saline; 9.3 ± 1.7 [1nmol AgRP] 
p<0.001 vs. saline, n=9-11 per group) (Figure 3.10). 
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Figure 3.8: The effect of intra-VTA AgRP administration on food intake in ad libitum fed rats 
in the early light phase. Male Wistar rats received an intra-VTA injection of saline, 0.1, 0.3 or 
1nmol AgRP in the early light phase. Food intake expressed as mean (g) ± SEM at (A) 0-1, (B) 1-2, 
(C) 2-4, (D) 4-8, (E) 8-24 and (F) 0-24 hours post injection is shown (n=9-11 per group). *p<0.05, 
**p<0.01 vs. saline. 
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Figure 3.10: The effect of intra-VTA AgRP administration on 24-hour body weight change in ad 
libitum fed rats in the early light phase. Male Wistar rats received an intra-VTA injection of saline, 0.1, 
0.3 or 1nmol AgRP in the early light phase. Body weight change expressed as mean (g) ± SEM at 24 hours 
post injection is shown (n=9-11 per group). **p<0.01, ***p<0.001 vs. saline. 
 
Figure 3.9: The effect of intra-VTA AgRP administration on cumulative food intake in ad libitum 
fed rats in the early light phase. Male Wistar rats received an intra-VTA injection of saline, 0.1, 0.3 or 
1nmol AgRP in the early light phase. Food intake expressed as mean (g) ± SEM at 0, 1, 2, 4 and 8 hours 
post injection is shown (n=9-11 per group). *p<0.05, **p<0.01, ***p<0.001 vs. saline.  
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3.3.8. The effect of intra-VTA AgRP administration on food intake following intra-
peritoneal pre-treatment with a dopamine receptor antagonist in the early light phase 
Intra-VTA administration of 0.3nmol AgRP significantly increased food intake between 4 and 8 
hours post-injection in ad libitum fed rats compared to saline injected controls. Administration of 
0.15mg/kg dopamine receptor antagonist fifteen minutes prior to injection of 0.3nmol AgRP 
attenuated the orexigenic effect of AgRP (4-8hr food intake (g): 1.36 ± 0.40 [saline/saline]; 1.40 
± 0.34 [dopamine receptor antagonist /saline]; 4.33 ± 0.76 [saline/AgRP 0.3nmol] p<0.01 vs. 
saline/saline and dopamine receptor antagonist/saline; 3.10 ± 0.48 [dopamine receptor 
antagonist/AgRP 0.3nmol] n=10 per group) (Figure 3.11).  
A similar trend was observed in cumulative food intake between 0 and 8 hours post-injection. 
Intra-VTA administration of 0.3nmol AgRP significantly increased food intake compared to 
saline injected controls, and this effect was partly attenuated by pre-administration of 0.15mg/kg 
dopamine receptor antagonist (0-8hr food intake (g): 4.25 ± 0.42 [saline/saline]; 3.61 ± 0.72 
[dopamine receptor antagonist/saline]; 9.06 ± 0.10 [saline/AgRP 0.3nmol] p<0.01 vs. 
saline/saline, p<0.001 vs. dopamine receptor antagonist/saline; 7.20 ± 1.23 [dopamine receptor 
antagonist/AgRP 0.3nmol] n=10 per group) (data not shown).  
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Figure 3.11: The effect of pre-treatment with a dopamine receptor antagonist on AgRP-
induced food intake in ad libitum fed rats in the early light phase. Ad libitum fed male Wistar 
rats were injected IP with saline or 0.15mg/kg dopamine receptor antagonist in the early light phase 
fifteen minutes prior to intra-VTA administration of saline or 0.3nmol AgRP. Food intake, 
presented as mean ± SEM, at 4-8 hours post-injection is shown (n=10 per group). **p<0.01 vs. 
saline/saline and dopamine receptor antagonist/saline. 
136 
 
3.3.9. The effect of intra-VTA administration of JKC 363, an MC4R antagonist, on food 
intake in ad libitum fed rats in the early light phase 
Intra-VTA administration of 0.3 and 1nmol JKC 363 significantly increased food intake in a 
dose-dependent manner in the first hour following injection compared to saline controls (0-1 
hour food intake (g): 1.42 ± 0.28 [saline]; 3.03 ± 0.62 [0.3nmol JKC] p<0.05 vs. saline; 3.09 ± 
0.33 [1nmol JKC] p<0.05 vs. saline, n=9 per group) (Figure 3.12A).  
JKC 363 administered at the lowest dose of 0.1nmol significantly increased food intake between 
4 and 8 hours (4-8 hour food intake (g): 1.01 ± 0.21 [saline]; 2.67 ± 0.35 [0.1nmol JKC] p<0.05 
vs. saline, n=9 per group) (Figure 3.12D).  
Additionally, cumulative food intake was significantly increased between 0 and 2, and 0 and 4 
hours following injection of 1nmol JKC 363 (0-2 hour food intake (g): 2.17 ± 0.57 [saline]; 4.58 
± 0.56 [1nmol JKC] p<0.05 vs. saline; 0-4 hour food intake (g): 2.89 ± 0.65 [saline]; 5.83 ± 0.81 
[1nmol JKC] p<0.05 vs. saline, n=9 per group) (Figure 3.13). All doses of JKC 363 significantly 
increased food intake between 0 and 8 hours post-injection (0-8 hour food intake (g): 3.90 ± 0.52 
[saline]; 7.00 ± 0.76 [0.1nmol JKC] p<0.05 vs. saline; 7.16 ± 0.58 [0.3nmol JKC] p<0.05 vs. 
saline; 8.14 ± 1.12 [1nmol JKC] p<0.01 vs. saline, n=9 per group) (Figure 3.13).  
All doses of JKC 363 had no significant effect on food intake at any other time points.  
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Figure 3.12: The effect of intra-VTA JKC 363 administration on food intake in ad libitum fed 
rats in the early light phase. Male Wistar rats received an intra-VTA injection of saline, 0.1, 0.3 or 
1nmol JKC 363 in the early light phase. Food intake expressed as mean (g) ± SEM at (A) 0-1, (B) 
1-2, (C) 2-4, (D) 4-8, (E) 8-24 and (F) 0-24 hours post injection is shown (n=9 per group). *p<0.05 
vs. saline. 
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Figure 3.13: The effect of intra-VTA JKC 363 administration on cumulative food intake in 
ad libitum fed rats in the early light phase. Male Wistar rats received an intra-VTA injection of 
saline, 0.1, 0.3 or 1nmol JKC 363 in the early light phase. Food intake expressed as mean (g) ± 
SEM at 0, 1, 2, 4 and 8 hours post injection is shown (n=9 per group). *p<0.05, **p<0.01 vs. 
saline.  
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3.3.10. The effect of intra-VTA JKC 363 administration on food intake following intra-
peritoneal pre-treatment with a dopamine receptor antagonist in the early light phase 
Intra-VTA administration of 1nmol JKC 363 significantly increased food intake between 1 and 2 
hours post-injection in ad libitum fed rats compared to saline injected controls. Administration of 
0.15mg/kg dopamine receptor antagonist fifteen minutes prior to injection of 1nmol JKC 363 
significantly attenuated the orexigenic effect of JKC 363 (1-2hr food intake (g): 0.93 ± 0.25 
[saline/saline]; 0.64 ± 0.24 [dopamine receptor antagonist/saline]; 3.09 ± 0.35 [saline/JKC 
1nmol] p<0.001 vs. saline/saline, dopamine receptor antagonist/saline and dopamine receptor 
antagonist/JKC; 0.81 ± 0.43 [dopamine receptor antagonist/JKC 1nmol] n=7-8 per group) 
(Figure 3.14A).  
JKC 363 also significantly increased food intake between 2 and 4 hours post-injection, and this 
effect was partly attenuated by pre-treatment with a dopamine receptor antagonist (2-4hr food 
intake (g): 0.23 ± 0.18 [saline/saline]; 0.43 ± 0.23 [dopamine receptor antagonist/saline]; 2.02 ± 
0.88 [saline/JKC 1nmol] p<0.05 vs. saline/saline; 0.53 ± 0.29 [dopamine receptor 
antagonist/JKC 1nmol] n=7-8 per group) (Figure 3.14B).  
Cumulative food intake was significantly increased following administration of JKC 363 
between 0 and 2, 0 and 4, and 0 and 8 hours compared to saline injected controls. This effect was 
significantly attenuated by pre-treatment with a dopamine receptor antagonist (0-2hr food intake 
(g): 2.04 ± 0.47 [saline/saline]; 1.98 ± 0.45 [dopamine receptor antagonist/saline]; 5.65 ± 0.62 
[saline/JKC 1nmol] p<0.01 vs. saline/saline and dopamine receptor antagonist/saline, p<0.05 vs. 
dopamine receptor antagonist/JKC; 2.74 ± 1.03 [dopamine receptor antagonist/JKC 1nmol]; 0-
4hr food intake (g): 2.33 ± 0.54 [saline/saline]; 2.41 ± 0.52 [dopamine receptor 
antagonist/saline]; 7.67 ± 1.47 [saline/JKC 1nmol] p<0.01 vs. saline/saline and dopamine 
receptor antagonist/JKC, p<0.05 vs. dopamine receptor antagonist/saline; 3.71 ± 1.07 [dopamine 
receptor antagonist/JKC 1nmol]; 0-8hr food intake (g): 3.87 ± 0.87 [saline/saline]; 4.10 ± 0.94 
[dopamine receptor antagonist/saline]; 9.49 ± 1.15 [saline/JKC 1nmol] p<0.01 vs. saline/saline 
and dopamine receptor antagonist/saline, p<0.05 vs. dopamine receptor antagonist/JKC; 5.27 ± 
0.75 [dopamine receptor antagonist/JKC 1nmol], n=7-8 per group) (data not shown).  
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Figure 3.14: The effect of pre-treatment with a dopamine receptor antagonist on JKC 363-induced 
food intake in ad libitum fed rats in the early light phase. Ad libitum fed male Wistar rats were 
injected IP with saline or 0.15mg/kg dopamine receptor antagonist in the early light phase fifteen minutes 
prior to intra-VTA administration of saline or 1nmol JKC 363. Food intake, presented as mean ± SEM, at 
(A) 0-1, (B) 1-2 and (C) 2-4 hours post-injection is shown (n=7-8 per group). *p<0.05 and ***p<0.001.  
A 
B 
C 
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3.4. Discussion 
The VTA is part of the mesolimbic dopamine system, and is important in mediating the 
rewarding aspects of numerous substances, including food. The melanocortin system is 
classically thought to act within the hypothalamus to regulate energy homeostasis. However, 
melanocortin-expressing neurones extend to extra-hypothalamic regions including the VTA, and 
may influence dopamine reward pathways to modulate food intake.  
The VTA contains POMC and AgRP immunoreactive fibres (Bagnol et al., 1999), and both the 
MC4R (Mountjoy et al., 1994) and MC3R (Roselli-Rehfuss et al., 1993) are expressed within the 
VTA. Although there is evidence to suggest that the melanocortin system may influence the 
rewarding properties of drugs of abuse (Contreras and Takemori, 1984; Hsu et al., 2005), few 
studies have focused on the effects of melanocortin receptor signalling within the VTA on 
feeding. My results suggest the presence of an endogenous melanocortin tone within the VTA 
which reduces food intake.  
Intra-VTA administration of NDP-MSH (0.03, 0.1, 0.3 and 1.0nmol) significantly reduced food 
intake for up to 4 hours post-injection when administered to ad libitum fed rats in the early dark 
phase. The reduction in food intake was almost immediate, and the highest dose administered 
(1.0nmol) reduced food intake to approximately 10% of that of saline-injected controls in the 
first hour post-injection.  
In contrast, injection of NDP-MSH to fasted rats in the early light phase had a delayed effect on 
food intake, which was significant only between 2 and 4 hours. No difference in food intake was 
observed at any other time points after injection compared to saline controls. It is interesting to 
compare the effect of NDP-MSH on food intake when administered into the VTA and the 
hypothalamus. When injected into discrete hypothalamic nuclei, including the PVN and DMN, 
0.1nmol NDP-MSH significantly reduced food intake to approximately 50% of controls between 
0 and 1 hours in fasted rats (Kim et al., 2000a). The same dose of NDP-MSH had no effect when 
injected into the VTA under similar fasted conditions. However, when administered to ad libitum 
fed rats, 0.1nmol NDP-MSH reduced food intake to approximately 20% of controls in the first 
hour after injection. This suggests that the VTA may be more sensitive to the anorectic effect of 
NDP-MSH than the hypothalamus, but only under free-feeding conditions. In the fasted state, 
homeostatic signals acting upon and within the hypothalamus may override signals from reward 
pathways to ensure that feeding behaviour is maintained.  
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The effect of intra-VTA NDP-MSH administration on behaviour was investigated to determine 
whether changes in food intake were secondary to changes in behaviour. NDP-MSH (0.03nmol) 
significantly reduced head-down behaviour in the first thirty minutes following injection 
compared to controls, suggesting an increase in activity and wakefulness. Intra-VTA 
administration of α-MSH has previously been reported to induce grooming behaviour in rats 
(Klusa et al., 1998). However, I did not observe any differences in grooming between groups. 
This may be because I used a much lower dose than previous studies (0.03nmol compared to 
3nmol).   
It is interesting that NDP-MSH reduced both head-down behaviour and food intake.  Other 
neuropeptides reported to increase wakefulness, such as the orexins, stimulate feeding when 
administered ICV (Ida et al., 1999). It is unlikely that NDP-MSH reduced food intake secondary 
to nausea or malaise, as these symptoms are associated with an increase in head-down and 
hunching behaviour in rodents (Holmes et al., 2009). In addition, blockade of melanocortin 
receptor signalling by intra-VTA AgRP administration increased food intake, which suggests the 
presence of an endogenous melanocortin agonist tone in the VTA, and that the effects of NDP-
MSH administration on food intake are due to the activation of a physiological circuit. 
Within the VTA, GABAergic interneurones tonically inhibit the activity of dopamine neurones, 
mainly via GABAA receptors (Matthews and German, 1984; Sugita et al., 1992). As an increase 
in dopamine transmission within the mesolimbic pathway is associated with feeding (Hernandez 
and Hoebel, 1988), it is likely that intra-VTA NDP-MSH exerts its anorexigenic effects either 
via direct inhibition of dopamine neurones, or via stimulation of GABAergic neurones and hence 
indirect inhibition of dopamine neuronal activity. In order to determine if GABAergic neurones 
signal downstream of melanocortin receptors in the VTA, I administered the GABAA receptor 
antagonist bicuculline prior to intra-VTA injection of NDP-MSH. 
Bicuculline partly attenuated the effect of NDP-MSH on feeding, although food intake was not 
completely restored to that observed in control animals. This suggests that GABA signalling may 
be important in mediating the anorectic effect of intra-VTA NDP-MSH. However, it is likely 
that other pathways also contribute. In addition to dopamine neurones and GABAergic 
interneurones, the VTA contains GABAergic and glutamatergic neuronal cell bodies which 
project to the NAc and pre-frontal cortex (Van Bockstaele and Pickel, 1995; Carr and Sesack, 
2000; Lavin et al., 2005). These may also have a role in mediating the effects of intra-VTA 
NDP-MSH on food intake.  
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AgRP (0.1, 0.3 and 1.0nmol) administered into the VTA elicited a potent increase in food intake 
which was significant between 4 and 8, and 0 and 8 hours following injection. Additionally, the 
highest dose (1.0nmol) significantly increased food intake between 1 and 2, and 0 and 24 hours. 
AgRP is documented to have a delayed, but long-lasting effect on food intake. When 
administered into the PVN, AgRP significantly increased food intake at 4 hours, and this effect 
was maintained at 24 hours post-injection (Kim et al., 2000a). This time-course is similar to that 
observed in my studies. This delayed yet long-lasting effect may be due to the structure of 
AgRP. AgRP is very stable within the brain, and its structure has been suggested to render it 
relatively resistant to degradation by peptidases (Kastin et al., 2000; Lu et al., 2001). It has also 
been shown that the AgRP molecule is prone to aggregation, which may slow its diffusion time 
to its target sites, resulting in a delayed onset of action (Kastin et al., 2000; Kim et al., 2002). 
Alternatively, AgRP may alter the properties of target neurones, or activate downstream circuits 
(Hagan et al., 2001), to elicit its long-lasting orexigenic effects.  
Intra-VTA administration of AgRP at all doses also significantly increased body weight at 24 
hours post-injection compared to controls. This is likely due to an increase in water intake in 
AgRP-injected animals. Administration of AgRP into the third ventricle has previously been 
reported to increase water intake in proportion to food intake (Clegg et al., 2003).  
I hypothesised that dopamine neurones may mediate the effects of intra-VTA AgRP 
administration on food intake. ICV administration of AgRP has been reported to increase Fos 
expression in midbrain dopamine neurones, and increase dopamine turnover in the forebrain 
(Davis et al., 2010). Feeding is associated with an increase in dopamine release in the NAc 
(Hernandez and Hoebel, 1988). 
In order to investigate this I administered a dopamine receptor antagonist prior to intra-VTA 
injection of AgRP. Dopamine receptor antagonists have been reported to induce motor 
impairments, which may have a secondary effect on food intake. However, care was taken to 
select a dose of dopamine receptor antagonist which has previously been shown not to affect 
motor function (Cousins et al., 1994).  
Pre-administration of a dopamine receptor antagonist partially attenuated the orexigenic effect of 
intra-VTA AgRP, suggesting that AgRP may partly increase food intake by activating VTA 
dopamine neurones. As the orexigenic effect of AgRP was not completely suppressed, the dose 
of antagonist administered may not have been sufficient to induce complete receptor antagonism. 
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Alternatively, other pathways may mediate the effect of AgRP on food intake, as discussed 
previously. 
AgRP is an antagonist at both the MC3R and the MC4R. In order to determine which 
melanocortin receptor mediates the effect of intra-VTA AgRP on feeding, I administered JKC 
363, a selective MC4R antagonist, into the VTA. The two highest doses of JKC 363 
administered (0.3 and 1nmol) significantly increased food intake in the first hour post injection, 
and the lowest dose (0.1nmol) significantly increased food intake between 4 and 8 hours. This 
time course of action is different to that of AgRP, which had no acute effect. A similar 
discrepancy between the time course of AgRP and JKC 363 has been reported when both 
compounds were injected into the third ventricle (Kim et al., 2002). It is possible that the delayed 
action of AgRP is due to MC4R-independent pathways, or may reflect pharmacokinetic 
differences between the two compounds. It would be interesting to administer a selective MC3R 
antagonist intra-VTA and compare the effect on feeding to that of JKC 363. However, selective 
MC3R antagonists are difficult to obtain; most have some effects at the MC4R. 
The increase in feeding induced by JKC 363 was completely abolished by pre-treatment with a 
dopamine receptor antagonist. This is in contrast to AgRP, where pre-treatment with a dopamine 
receptor antagonist only partially attenuated the orexigenic effect of AgRP. This suggests that 
dopamine neurones may predominantly mediate the effects of MC4R signalling, whereas the 
MC3R may act via alternative pathways, as discussed above.  
My results tentatively suggest that melanocortin signalling within the VTA may stimulate 
GABAergic neurones, causing suppression of dopamine neuronal firing. Antagonism of 
melanocortin receptor signalling by AgRP may disinhibit dopamine neurones, leading to 
increased neuronal firing, increased dopamine release within the NAc and increased food intake. 
More work is required to elucidate the mechanisms by which the VTA melanocortin system 
influences food intake. Co-localisation studies are necessary to determine whether the MC3R 
and MC4R are located on GABAergic and/or dopamine neurones in the VTA. It would be 
interesting to examine the effect of intra-VTA NDP-MSH and AgRP administration on 
dopamine release within the NAc using microdialysis, and the effect of AgRP on dopamine 
neuronal cell firing using electrophysiological techniques. Additionally, I would like to examine 
the pattern of fos-like immunoreactivity in response to intra-VTA AgRP administration. If 
staining was observed in areas downstream of the VTA, for example the NAc and pre-frontal 
145 
 
cortex, it would suggest that reward pathways are involved in mediating the orexigenic effect of 
AgRP.   
It would also be interesting to determine the effect of intra-VTA NDP-MSH and AgRP 
administration on reward-related behaviours, for example sucrose self-administration and CPP. 
ICV administration of AgRP has been shown to enhance a CPP for high fat diet in rats (Davis et 
al., 2010), and increase motivational behaviour to obtain a high-fat reward (Tracy et al., 2008). 
However, no studies have focused on the effect of AgRP or NDP-MSH administration directly 
into the VTA or NAc on food reward.  
In summary, my results suggest that melanocortin signalling within the VTA may play a 
physiological role in the regulation of food intake in rats.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
 
Chapter 4: Investigating the role of 
arcuate kisspeptin signalling in the 
control of reproduction 
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4.1. Introduction 
4.1.1. The hypothalamo-pituitary-gonadal axis 
Fertility and energy homeostasis are intimately linked, and the hypothalamus plays a key role in 
integrating metabolic signals to ensure body fat reserves are sufficient to support reproduction. 
Conversely, gonadal steroid hormones have been shown to influence food intake and body 
weight (Bull et al., 1974; Asarian and Geary, 2006; Terao et al., 2004).  
Fertility in mammals is maintained by the hypothalamo-pituitary-gonadal (HPG) axis. GnRH is 
released in a pulsatile pattern from the hypothalamus into the pituitary portal circulation, and 
stimulates the pulsatile release of LH and FSH from gonadotrophs in the anterior pituitary gland. 
LH and FSH circulate peripherally to stimulate the gonads, and ultimately control gonadal 
steroidogenesis and gametogenesis. Gonadal steroid feedback to the pituitary and hypothalamus 
ensures this system is tightly controlled. Recently, kisspeptin has been identified as an upstream 
regulator of GnRH, which is postulated to mediate the feedback of sex steroids and other signals 
onto GnRH neurones (d'Anglemont de Tassigny and Colledge, 2010). 
 
4.1.2. The female reproductive cycle  
4.1.2.1. The human menstrual cycle 
Reproductive capacity in female mammals is maintained by repetitive cycles of follicle 
maturation and ovulation. In humans, the menstrual cycle is approximately 28 days long. During 
the follicular phase of the cycle, ovarian follicles develop and their surrounding cells secrete 
oestrogen in response to stimulation by LH and FSH. Oestrogen exerts negative feedback at the 
hypothalamus and pituitary gland, which suppresses FSH and LH release. By the late follicular 
phase, a single dominant follicle is selected and the remaining follicles undergo atresia.  
At this point in the cycle, oestrogen switches from a negative to a positive feedback effect at the 
hypothalamus and pituitary gland. This causes an increase in GnRH and LH pulse frequency, 
ultimately leading to a surge in LH release which is responsible for inducing final maturation of 
the follicle, and ovulation. Ovulation generally occurs on day 14 of the cycle.  
In the post-ovulatory luteal phase, the corpus luteum secretes progesterone and oestrogen, which 
exert negative feedback on LH and FSH release. The corpus luteum degenerates as 
gonadotrophin levels fall, leading to a reduction in sex steroid production and shedding of the 
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endometrial lining. Gonadotrophin levels then begin to rise, stimulating the development of the 
next follicle (Laycock J and Wise P, 1996). 
 
4.1.2.2. The rodent oestrous cycle 
In rats, the reproductive cycle is known as the oestrous cycle. This cycle is much shorter than the 
menstrual cycle in humans, lasting on average for four days. It can be divided into four stages: 
proestrous, oestrous, metestrous (or diestrous 1) and diestrous (or diestrous 2) (Mandl, 1951).  
Hormonal changes in the rat oestrous cycle are similar to those that occur in humans. Figure 4.1 
demonstrates levels of oestrogen, progesterone, LH and FSH in each stage of the rat and human 
reproductive cycle. The LH surge occurs in the afternoon of proestrous, which induces the final 
stages of ovarian follicular maturation. High circulating oestrogen levels at the time of the LH 
surge induce sexual receptivity in rodents (Nequin and Schwartz, 1971), and ovulation follows 
the LH surge by 10 to 12 hours. Progesterone levels begin to increase during proestrous, and 
peak around the time of ovulation. Unlike humans, a fully functioning corpus luteum does not 
develop unless mating occurs during oestrous. Vaginocervical stimulation induces prolactin 
release, which maintains the corpus luteum and prolongs diestrous. If mating is fertile, the 
fertilised ovum implants into the endometrium. However, if mating does not result in a fertilised 
ovum, the female enters a state of pseudopregnancy which can last for up to 10 days before 
normal cycles resume.  
149 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Fluctuations in circulating levels of oestrogen, progesterone, LH and FSH 
throughout the female (A) rat and (B) human reproductive cycle. Grey shaded areas in (A) 
represent the dark phase (approximately 7pm-7am). Abbreviations: LH, luteinizing hormone; FSH, 
follicle-stimulating hormone. Adapted from (Staley and Scharfman, 2005). 
A B 
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4.1.3. Kisspeptin  
The kisspeptins are coded for by the KiSS-1 gene and belong to the RF-amide family of peptides 
(Ohtaki et al., 2001; Muir et al., 2001; Kotani et al., 2001). The RF-amide peptide family are so 
named due to the arginine-phenylalanine-amide residues present at the carboxyl terminus. In 
humans, the initial translation product of KiSS-1 is a 145 amino acid peptide which is cleaved to 
produce a 54-amino acid protein named kisspeptin-54 (Ohtaki et al., 2001; Muir et al., 2001; 
Kotani et al., 2001).  Shorter peptides of 14, 13 and 10 amino acids have also been identified, 
which may be degradation products of kisspeptin-54 (Kotani et al., 2001; Bilban et al., 2004). 
All four peptides (kisspeptin-54, -14, -13 and -10) share a common carboxyl terminal, which is 
essential for receptor binding and activation (Kotani et al., 2001) (Figure 4.2). 
 
 
 
 
Figure 4.2: Products of the human KiSS-1 gene. Translation of the KiSS-1 gene produces a 
145-amino acid propeptide, which is cleaved to generate kisspeptin-54. Shorter peptides 
(kisspeptin-14, -13 and -10) have also been identified, which all share a C terminus with 
kisspeptin-54. From (Popa et al., 2008). 
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In rats and mice, kisspeptin is a 52-amino acid peptide which shares approximately 46% 
sequence homology with human kisspeptin-54 (Terao et al., 2004). This diversity is mainly due 
to differences in the amino terminal of the peptide; the carboxyl terminal decapeptide is highly 
conserved between species (Stafford et al., 2002; Terao et al., 2004) (Figure 4.3).  
 
 
 
 
 
 
 
 
 
Kisspeptin is the endogenous ligand of the G-protein coupled receptor GPR54 (Ohtaki et al., 
2001; Muir et al., 2001; Kotani et al., 2001). GPR54 shares weak sequence homology with the 
galanin receptor, but does not bind either galanin or galanin-like peptide (Lee et al., 1999; Ohtaki 
et al., 2001). Kisspeptin-54, -14, -13 and -10 all bind to GPR54 with equal affinity and efficacy 
in vitro (Kotani et al., 2001). 
 
4.1.4. Kisspeptin and GPR54 localisation 
In humans, KiSS-1 mRNA is abundantly expressed in the placenta and brain, and is also 
expressed in the ovary, testis, pancreas, and small intestine (Muir et al., 2001; Ohtaki et al., 
2001; Kotani et al., 2001). Within the human CNS, kisspeptin immunoreactive cell bodies are 
predominantly located in the infundibular nucleus of the hypothalamus, the equivalent of the 
rodent Arc (Hrabovszky et al., 2010). GPR54 mRNA is expressed at high levels within the 
placenta, pituitary gland and brain, specifically in the amygdala, nucleus accumbens, 
hypothalamus and hippocampus (Muir et al., 2001).  
Human: 112    Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe   121 
Mouse:  110     Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Tyr   119 
Rat:       110     Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Tyr     119 
Figure 4.3: Alignment of the human, mouse and rat amino acid sequences corresponding 
to human kisspeptin 45-54 (kisspeptin-10). Abbreviations: Arg, arginine; Asn, asparagine; 
Gly, glycine; Leu, leucine; Phe, phenylalanine; Ser, serine; Trp, tryptophan; Tyr, tyrosine. 
From (Terao et al., 2004).  
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Distribution of KiSS-1 and GPR54 in rodents is similar to that observed in humans (Lee et al., 
1999; Brailoiu et al., 2005). Within the rodent CNS, two major populations of kisspeptin 
immunoreactive cell bodies have been identified in the hypothalamus: in the Arc, and in the 
rostral periventricular region of the third ventricle, which includes the anteroventral 
perviventricular nucleus (AVPV) (Clarkson and Herbison, 2006; Clarkson et al., 2009). The 
expression of KiSS-1 within the AVPV, but not the Arc, is sexually differentiated; females have 
up to 25 times more kisspeptin-expressing neuronal cell bodies in this area than males 
(Kauffman et al., 2007). Kisspeptin immunoreactive fibres are located within the medial preoptic 
area (MPOA), PVN, Arc, and in extra-hypothalamic areas including the amygdala, brainstem 
and thalamus (Brailoiu et al., 2005; Clarkson et al., 2009).   
 
4.1.5. Kisspeptin and GPR54 are vital regulators of reproduction 
A major role for the kisspeptin/GPR54 system in the control of reproduction was identified when 
it was noted that patients with homozygous mutations in the gene encoding GPR54 suffered 
from hypogonadotropic hypogonadism, defined as impaired pubertal development and 
reproductive function due to defective pituitary LH and FSH secretion (Seminara et al., 2003; de 
Roux N. et al., 2003). These patients have abnormally low levels of circulating gonadotrophins 
and sex steroids, and do not demonstrate normal sexual maturation. Mice lacking GPR54 show a 
similar phenotype (Seminara et al., 2003). Both humans and mice with defective GPR54 
signalling respond to treatment with GnRH by increasing circulating gonadotrophin levels 
(Seminara et al., 2003). KiSS-1 knockout mice are also infertile, but are not as severely affected 
as  GPR54 knockouts (d'Anglemont de Tassigny et al., 2007; Lapatto et al., 2007). 
Central and peripheral administration of kisspeptin markedly increases circulating levels of LH 
and FSH in numerous species, including humans (Irwig et al., 2004; Matsui et al., 2004; 
Thompson et al., 2004; Messager et al., 2005; Dhillo et al., 2005). The mechanism by which 
kisspeptin stimulates the HPG axis is GnRH-dependent. ICV kisspeptin administration increases 
cerebrospinal fluid levels of GnRH in female sheep (Messager et al., 2005), and the rise in 
circulating LH induced by kisspeptin administration is attenuated by pre-treatment with a GnRH 
antagonist in rats (Irwig et al., 2004). Approximately 77% of GnRH neurones express GPR54 
mRNA, and kisspeptin is able to directly depolarize and increase firing rates of GnRH neurones 
(Pielecka-Fortuna et al., 2008). Additionally, ICV injection of kisspeptin induces Fos expression, 
a marker of neuronal activation, in GnRH neurones (Irwig et al., 2004). Kisspeptin neuronal 
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fibres terminate in close proximity to GnRH neuronal cell bodies and dendrites, particularly 
those located in the pre-optic area (Clarkson and Herbison, 2006). 
 
4.1.6. Kisspeptin neurones relay gonadal steroid feedback to GnRH neurones 
Feedback from gonadal steroids to hypothalamic GnRH neurones is crucial in maintaining HPG 
axis activity. In males, testosterone reduces GnRH and LH pulse frequency (Jackson et al., 
1991). In females, oestrogen and progesterone negatively regulate the HPG axis at most stages of 
the oestrous cycle, except immediately prior to the LH surge and ovulation, when they exert 
positive feedback (Laycock J and Wise P, 1996). As GnRH neurones do not express receptors 
for gonadal steroids, an intermediary factor must relay these feedback signals (Shivers et al., 
1983). The majority of hypothalamic kisspeptin neurones express receptors for oestrogen and 
testosterone, (Smith et al., 2005b), and project to areas where GnRH neurones reside (Brailoiu et 
al., 2005; Clarkson et al., 2009). This suggests that kisspeptin neurones may relay sex steroid 
signals from the gonads to GnRH neurones. 
 
4.1.6.1. The arcuate nucleus 
Kisspeptin neurones in the Arc may relay negative feedback signals to GnRH neurones. KiSS-1 
mRNA expression within the Arc increases following castration or ovariectomy, and decreases 
following gender-appropriate sex steroid replacement (Smith et al., 2005b; Smith et al., 2005a). 
In female rats, KiSS-1 mRNA expression in the Arc reaches a peak during diestrous, when 
circulating oestrogen levels are low, and falls dramatically during the oestrogen surge (Smith et 
al., 2006b). This suggests that high circulating levels of gonadal steroids may negatively regulate 
Arc kisspeptin expression, and thus indirectly reduce GnRH, LH and FSH release.  
Additionally, female mice lacking GPR54 do not exhibit a compensatory rise in circulating LH 
following ovariectomy (Dungan et al., 2007). Similarly, castrated male mice do not exhibit a rise 
in circulating LH if administered a kisspeptin antagonist following castration (Roseweir et al., 
2009). This suggests that kisspeptin/GPR54 signalling is required for negative feedback 
regulation of GnRH and gonadotrophins (Figure 4.4). 
In several species, kisspeptin neurones in the Arc co-express the neuropeptides neurokinin B 
(NKB) and dynorphin (Goodman et al., 2007; Navarro et al., 2009; Hrabovszky et al., 2010). 
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These neurones form autosynaptic contacts with one another, in addition to projecting to GnRH 
neurones, and it has been suggested that the autosynaptic action of kisspeptin, NKB and 
dynorphin drives the pulsatile secretion of kisspeptin and hence of  GnRH release (Navarro et al., 
2009). 
 
4.1.6.2. The AVPV 
It has been suggested that in female rodents, AVPV kisspeptin neurones are involved in the 
generation of the pre-ovulatory GnRH/LH surge. Administration of an anti-kisspeptin antibody 
into the pre-optic area of rats blocks the pre-ovulatory LH surge (Kinoshita et al., 2005), as does 
ICV infusion of a kisspeptin receptor antagonist (Pineda et al., 2010). These findings suggest that 
signalling from AVPV kisspeptin neurones to GnRH neurones mediates the positive feedback 
effects of oestrogen, and hence generates the pre-ovulatory GnRH/LH surge (Figure 4.4).  
In contrast to the Arc, kisspeptin expression in the AVPV is positively regulated by gonadal 
steroids. In female mice, kisspeptin expression in the AVPV decreases following ovariectomy, 
and rises after oestradiol replacement (Smith et al., 2005a). Similarly, testosterone positively 
regulates KiSS-1 expression in the AVPV of male mice (Smith et al., 2005b). The number of 
KiSS-1-expressing cells in the AVPV peaks on the afternoon of proestrous in rats, and reaches a 
nadir at diestrous (Smith et al., 2006b). The majority of AVPV kisspeptin neurones express Fos 
on the afternoon of proestrous, suggesting that transcriptional activation occurs (Smith et al., 
2006b). These data suggest that AVPV kisspeptin neurones mediate the positive feedback effects 
of sex steroids on the HPG axis. 
It should be noted that these observations regarding the role of AVPV kisspeptin neurones are 
limited to rodents, as female sheep and primates (including humans) do not have a population of 
kisspeptin neurones equivalent to the AVPV. In these species, kisspeptin neurones in the Arc are 
hypothesised to relay both the negative and positive feedback effects of gonadal steroids to 
GnRH neurones, perhaps via discrete neuronal populations (Estrada et al., 2006).  
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In summary, it is assumed that kisspeptin neurones in the Arc provide a tonic, stimulatory drive 
to GnRH neurones. When circulating levels of sex steroids decline, Arc KiSS-1 expression 
increases, leading to an increase in GnRH and gonadotrophin secretion. This in turns facilitates a 
rise in circulating gonadal steroids. In contrast, in rodents it is hypothesised that kisspeptin 
neurones in the AVPV mediate the ‘surge’ mode of GnRH and LH release. However, conclusive 
evidence to support these assumptions is lacking. Although studies have investigated the acute 
effects of administration of anti-kisspeptin antibodies (Kinoshita et al., 2005) or a kisspeptin 
receptor antagonist  (Li et al., 2009) into specific areas of the brain, the long-term effects of 
reducing kisspeptin expression in either the Arc or AVPV have not been investigated. One 
possible method to investigate the role of kisspeptin signalling within these discrete nuclei over 
long time periods is to use gene knockdown.  
 
4.1.7. Gene transfer methods 
Gene transfer allows modulation of gene expression either in vitro or in vivo. When administered 
in vivo, spatial and temporal control of gene expression can be achieved, and problems 
associated with transgenic models or chronic injection of a receptor agonist or antagonist can be 
avoided. 
Gene vectors may be non-viral or viral.  Injection of naked plasmid DNA is the simplest form of 
non-viral transfection. Although simple to produce and non-immunogenic, naked plasmid DNA 
is only expressed transiently and at a relatively low level in vivo (Yovandich et al., 1995). 
Plasmid DNA can be combined with cationic lipids or polymers to enhance cellular uptake and 
improve stability (Davis, 2002; Gardlik et al., 2005).    
Viruses have developed specialised mechanisms to permit effective transport of DNA into cells, 
and hence are useful gene vectors. Viral vectors have been developed from numerous viruses 
including retrovirus, adenovirus, lentivirus and adeno-associated virus (AAV). The viral vector 
used in the work described in this chapter was AAV. 
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4.1.8. Adeno-associated virus 
Adeno-associated viruses (AAVs) are single-stranded, non-enveloped DNA viruses which 
belong to the Parvoviridae family. The AAV genome consists of two inverted terminal repeats 
(ITRs) located at the 5’ and 3’ ends, and two large open reading frames which contain rep 
(replication) and cap (capsid) genes. The rep gene encodes four Rep proteins, which are essential 
for viral DNA replication and transcriptional control, and the cap gene encodes three capsid 
proteins. AAV is a dependovirus, as it requires a helper virus such as adenovirus to permit 
replication and infection. Although a number of AAV serotypes have been identified, AAV 
serotype 2 (AAV2) is the most widely used as a gene vector (Lu, 2004). AAV2 enters target cells 
by binding to the heparin sulphate proteoglycan cell surface receptor (Summerford and 
Samulski, 1998).  
Recombinant AAV (rAAV) is a modified form of AAV. It is a good choice of gene vector 
because it is non-pathogenic and does not induce an inflammatory response when administered 
to animals (Chamberlin et al., 1998). Recombinant AAV2 is an ideal vector for gene transfer to 
neurones within the CNS because it is selectively taken up by neurones, and not by astrocytes or 
microglia (Bartlett et al., 1998). Additionally, transgene expression following rAAV 
administration is long-lasting, and has been reported to persist for at least 15 months (Xu et al., 
2001).   
In rAAV vectors, all viral DNA except the ITRs is removed and replaced with the gene of 
interest. Host cells are then co-transfected in vitro with this packaging plasmid and a helper 
plasmid (containing AAV rep and cap genes and several adenovirus helper genes), in order to 
produce rAAV particles (Grimm et al., 1998). The rAAV vector also contains the early 
cytomegalovirus (CMV) promoter, a constitutively active promoter in mammalian cells, and 
woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), which increases 
transgene expression (Loeb et al., 1999).  
There are disadvantages to using rAAV as a viral vector. The genome of AAV is small, and 
hence it is not possible to efficiently incorporate transgenes larger than 4.9kb (Dong et al., 1996). 
Additionally, following administration of the vector, transgene expression is delayed because 
single stranded viral DNA must be converted to double stranded DNA (Ferrari et al., 1996).  
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4.1.9. Antisense RNA 
Antisense RNA is a transcript which is complementary to an endogenous protein-coding mRNA 
sequence. Binding of antisense and sense RNA strands by Watson and Crick base-pairing 
prevents translation of the mRNA sequence, and hence reduces protein expression.  Antisense 
RNA is a naturally occurring mechanism present in prokaryotic and eukaryotic cells to regulate 
gene expression (Werner and Sayer, 2009).  
The precise mechanism by which antisense RNA reduces gene expression is not known, 
although the most widely accepted theory is that formation of double-stranded RNA induces 
RNA editing. Double-stranded RNA duplexes are targets for adenosine deaminases, or ADARs. 
These enzymes convert adenosine residues (A) to inosines (I). In long RNA duplexes, numerous 
A to I conversions cause the double-stranded RNA duplex to become unstable and partially 
unwind (Bass and Weintraub, 1988). The modified RNA then becomes trapped in the nucleus, 
and cannot associate with translation machinery in the cytoplasm (Kumar and Carmichael, 
1997).  If a smaller number of A to I modifications take place on a shorter RNA duplex, point 
mutations are introduced into the transcript which results in translation of a non-functioning 
protein (Kumar and Carmichael, 1998).  
In this work I used a rAAV2 vector expressing kisspeptin antisense cDNA (rAAV-Kisspeptin-
AS) as a tool to investigate the effects of kisspeptin down-regulation in the rat Arc. A schematic 
diagram of the vector used in this work is shown in Figure 4.5. The same vector containing 
enhanced green fluorescent protein (EGFP) instead of kisspeptin antisense was used as a control 
in this study. Green fluorescent protein was originally isolated from the jellyfish Aequorea 
Victoria, and is commonly used as a reporter gene. The enhanced variant has been modified to 
improve expression in mammalian cells (Zhang et al., 1996).  
Although kisspeptin signalling is important in both males and females, I used female rats in this 
work, because vaginal smearing is a relatively non-disruptive method of assessing reproductive 
function.  
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4.1.10. Hypothesis 
Reducing kisspeptin expression using rAAV-Kisspeptin-AS within the Arc will disrupt 
reproductive function in adult female rats. 
 
4.1.11. Aims 
In order to investigate the effect of reducing kisspeptin expression within the Arc on 
reproductive function I will: 
- Verify that the rAAV-Kisspeptin-AS transgene is expressed in vivo.  
- Determine the effect of intra-Arc rAAV-Kisspeptin-AS administration on oestrous 
cyclicity, reproductive hormones, food intake and body weight in female Wistar rats. 
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4.2. Methods 
4.2.1. Production of rAAV-EGFP and rAAV-Kisspeptin-AS 
The production of rAAV-Kisspeptin-AS and rAAV-EGFP was carried out by Dr James Gardiner 
(Division of Diabetes, Endocrinology and Metabolism, Imperial College London). The two 
plasmid system was used (Grimm et al., 1998). Briefly, host cells were co-transfected with the 
rAAV plasmid and a helper plasmid. As there was no homology between the two plasmids, they 
were unable to recombine to form wild-type virus. This resulted in the production of rAAV 
particles, which were released from the host cells by freeze-thawing, and subsequently purified.  
Prior to the work described in this thesis, the kisspeptin-AS plasmid was tested in vitro to ensure 
that the construct was able to reduce kisspeptin release. Kisspeptin secretion from RIN 1056a 
cells was significantly reduced following transfection with rAAV-Kisspeptin-AS.  
 
4.2.2. Animals 
Female Wistar rats (specific pathogen free; Charles River) weighing 220-250g were maintained 
as described in section 2.2.2. 
All animal procedures undertaken were approved by the British Home Office Animals 
(Scientific Procedures) Act 1986 (Project License 70/6377). 
 
4.2.3. Confirmation of Arc coordinates with ink injections 
Prior to administration of rAAV-Kisspeptin-AS, suitable stereotactic coordinates were identified 
using ‘The Rat Brain in Stereotactic Co-ordinates’ (Paxinos and Watson, 2007). Stereotactic 
coordinates calculated were as follows: 3.3mm posterior to the bregma, 0.5mm lateral from the 
midline and 10.5mm below the surface of the skull. These coordinates were verified by injection 
of 1µl 10% dilution of India ink and water.  
Female Wistar rats (n=5) were terminally anaesthetised with intraperitoneal administration of 
200mg/kg Pentobarbitone (Animalcare Ltd.). Ink injections were carried out as described in 
section 3.2.3.1.  
Following dissection and slicing of the brains, slices were mounted onto polylysine coated slides 
(VWR) then counter-stained using cresyl violet.  
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4.2.4. Cresyl violet staining of ink injected rat brains 
Cresyl violet staining was carried out as described in section 3.2.3.2.  
 
4.2.5. Recombinant adeno-associated virus intra-nuclear administration to verify transgene 
expression  
Prior to carrying out the main experiment I first verified that the rAAV encoding Kisspeptin-AS 
would result in transgene expression in vivo. Female Wistar rats (n=5) were anaesthetised with 
2L/minute oxygen and 4% inhaled isoflurane (Abbott Laboratories Ltd). Animals were placed in 
the induction chamber until they lost the pedal reflex. Once anaesthetised, animals were 
administered intra-peritoneal prophylactic antibiotics (amoxycillin (37.5mg/kg) and 
flucloxacillin (37.5mg/kg)) to prevent post-operative infection. Rats were positioned on a 
stereotactic frame (David Kopf Instruments, supplied by Clark Electromedical Instruments) with 
the incisor bar 3mm below the interaural line. The head was cleaned with 10% w/v 
povidone/iodine solution (Ecolabs Ltd) and a 1.5cm longitudinal incision made in the scalp. Two 
holes were drilled using a stereotactically mounted electric drill (Department of Medical 
Engineering, Imperial College London, UK), using stereotactic coordinates described in section 
4.2.3. Each animal was injected bilaterally into the Arc with 1µl rAAV-Kisspeptin-AS at a titre 
of 1.33 x 1015 genome particles per microlitre. The cannula and injector were maintained in situ 
for five minutes after injection to minimize backflow. The incision was sutured using 6.0 proline 
thread. Animals were administered subcutaneous buprenorphine (45mg/kg, Schering-Plough 
Corp.) for post-operative analgesia and rehydrated with 0.9% sodium chloride (5ml/rat). 
Three weeks post injection, animals were culled and in situ hybridization performed to confirm 
expression of rAAV-Kisspeptin-AS.  
 
4.2.6. Confirmation of transgene expression by in situ hybridisation 
In situ hybridisation (ISH) was performed to confirm expression of the rAAV-Kisspeptin-AS 
construct using a 35S radiolabelled probe specific for WPRE. WPRE is part of the rAAV 
construct and aids transgene expression (Loeb et al., 1999). As WPRE is not naturally expressed 
in mammalian tissues, a probe complementary to WPRE will only bind to tissue where the 
transgene is expressed.  
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Preparation of slides, production of a radiolabelled RNA probe and hybridisation of the probe to 
slides was carried out as described in section 2.2.11.2 (n=5). The 35S antisense and sense WPRE 
riboprobes were labelled using pBluescript-WPRE as a template, which contains a 308bp 
fragment of WPRE. The template plasmid was linearised by digestion with ApaI for the anti-
sense probe and SpeI for the sense probe. 
 
4.2.7. Oestrous cycle stage determination 
The rat oestrous cycle lasts on average for four days, and is characterised by four stages: 
proestrous, oestrous, metestrous and diestrous (Mandl 1951). Vaginal smear cytology can be 
used to determine each phase of the oestrous cycle. Proestrous is characterised by a 
predominance of round, nucleated epithelial cells. A smear taken at oestrous consists of 
irregular, anucleated cornified cells. Metestrous is characterised by an equal proportion of 
epithelial cells, cornified cells and leukocytes, and at diestrous the smear predominantly contains 
leukocytes (Mandl, 1951; Marcondes et al., 2002). Figure 4.6 shows representative vaginal 
smears taken at different stages of the rat oestrous cycle. 
As the aim of my study was to determine the effect of knockdown of Arc kisspeptin expression 
on the oestrous cycle, it was important to determine that the animals used in my study exhibited 
normal cycles prior to rAAV administration. It has previously been reported that up to 25% of 
female rats do not exhibit regular oestrous cycles (Mandl, 1951). Prior to injection of rAAV-
Kisspeptin-AS or rAAV-EGFP as described in section 4.2.8, oestrous cyclicity was monitored 
for 10 days. Only rats exhibiting regular oestrous cycles were included in the study (29 out of 40 
rats).  
Vaginal cytology of each of the rats was monitored by once-daily vaginal lavage, which was 
performed between 9am and 11am. Vaginal secretions were collected using a 1ml syringe filled 
with 100µl sterile water, by gently inserting the tip of the syringe into the rat vagina. The 
procedure was performed as gently as possible to eliminate the risk of the rats becoming 
pseudopregnant (Steuer et al., 1987). One drop of vaginal fluid from each rat was placed on a 
glass slide. Unstained fluid was observed under a light microscope (Jencons-PLS, Forest Row, 
East Sussex, UK) at 10x and 20x magnification. Cells were identified as described above, and 
the proportion of the cells observed was used to determine the stage of the oestrous cycle 
(Mandl, 1951).  
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Cycles were analysed using previously described methods. Cycles were classified as regular, 
extended or abnormal. A regular cycle lasted between 3 and 5 days, with either 1 or 2 days of 
oestrous, or 2 or 3 days of diestrous. An extended cycle contained either 3 or 4 days of oestrous, 
or 4 or 5 days of diestrous. An abnormal cycle contained more than 4 consecutive days of 
oestrous, or more than 6 days of diestrous (Goldman et al., 2007). 
A second, more stringent analysis was also performed to detect subtler changes between groups. 
A ‘complete’ cycle was classified as one in which three stages of the oestrous cycle were 
observed in the correct order.  
Finally,  cycle length was determined by the number of days between each occurrence of 
oestrous (Goldman et al., 2007).  
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Figure 4.6: Photomicrographs of unstained vaginal smears from female rats in (A) proestrous, 
(B) oestrous, (C) metestrous, and (D) diestrous. Smears were viewed under a light microscope at 
20x magnification. Examples of nucleated cells (N), cornified cells (C) and leukocytes (L) are 
labelled. The proportion of the three types of cells was used to determine oestrous cycle stage.  
L
166 
 
4.2.8. Recombinant adeno-associated virus intra-nuclear administration 
Female Wistar rats (200-240g) were randomised into groups by both body weight and pre-
surgery cycle length, and administered either rAAV-EGFP (titre 5 x 1012 genome particles per 
microlitre) (n=14) or rAAV-Kisspeptin-AS (n=15) bilaterally into the Arc using methods 
described in section 4.2.5.  
After a four day recovery period, vaginal cytology was monitored daily for 100 days to 
determine the length and regularity of each individual animal’s oestrous cycle. Smears were 
taken between 9am and 11am daily. Body weight and food intake were measured every other 
day for 100 days. 
 
4.2.9. Tissue and plasma collection 
The study ended on day 100 post-injection. Rats were culled in the diestrous phase of the 
oestrous cycle, as this is when basal LH levels are less variable and hence differences between 
groups may have been easier to detect. 
Rats were killed by decapitation. Plasma was collected in plastic lithium heparin tubes 
containing 1000 kallikrein inactivator units of aprotinin (Nordic Pharma Ltd.). Plasma was 
separated by centrifugation at 1600g and snap frozen in liquid nitrogen. Samples were stored at -
20ºC until analysis for LH and oestradiol. LH was measured by RIA (see section 2.2.13). 
Oestradiol was measured using a mouse/rat oestradiol enzyme-linked immunosorbent assay 
(ELISA) kit (Calbiotech, Spring Valley, California, USA). 
Brains were rapidly removed, cut to the level of the hypothalamus, snap frozen in isopentane and 
stored at -80ºC until quantification of kisspeptin levels in the Arc.  
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4.2.10. Statistics 
All data are presented as mean ± standard error of the mean (SEM). Oestrous cyclicity data and 
plasma hormone data were analysed using an unpaired t-test (GraphPad Prism version 5 for 
Windows; GraphPad Software, San Diego, CA). Percentage time spent in each stage of the 
oestrous cycle was analysed using the Mann-Whitney U test (Systat, Evanston, IL) as data were 
non-parametric. Body weight and food intake data were analysed using the generalized 
estimating equation (Stata 9, StataCorp LP, College Station, Texas). Three outliers were 
removed from data analysis due to being more than two standard deviations away from mean 
body weight and/or food intake measurements. In all cases p values <0.05 were taken as 
significant.  
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4.3. Results 
 
4.3.1. Confirmation of Arc coordinates with ink injections 
Prior to rAAV administration, correct coordinates were confirmed with ink injections. Ink was 
observed unilaterally in the Arc in 80% of animals (n=5). A representative photograph is shown 
in Figure 4.7A, and the corresponding diagram of the rat brain (Paxinos and Watson, 2007) is 
shown in Figure 4.7B. 
 
 
                  
 
 
 
 
 
 
Figure 4.7: Confirmation of arcuate nucleus coordinates with ink injections. Female Wistar rats 
were injected unilaterally with India ink (coordinates 3.3mm posterior to the bregma, 0.5mm lateral 
from the midline and 10.5mm below the surface of the skull). Brain sections were stained with cresyl 
violet (A), and compared to ‘The Rat Brain in Stereotaxic Coordinates’ (Paxinos and Watson, 2007) 
(B). A coronal section -3.4mm from bregma is shown. Scale bars are equivalent to 1mm. 
Abbreviations: 3V, third ventricle; A11, dopamine cells; ArcLP, arcuate nucleus, lateroposterior part; 
ArcMP, arcuate nucleus, medial posterior part; DMC, dorsomedial nucleus, compact part; DMD, 
dorsomedial nucleus, dorsal part; DMV, dorsomedial nucleus, ventral part; InfS, infundibular stem; Pe, 
periventricular hypothalamic nucleus; PH, posterior hypothalamic nucleus.  
A B 
Arc LP 
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4.3.2. Verification of transgene expression  
Rats were killed three weeks post-injection (n=5) and ISH was performed to confirm transgene 
expression, using a radiolabelled probe complementary to WPRE. 
All brains demonstrated transgene expression in the Arc. An image from a representative brain is 
shown in Figure 4.8A. No non-specific binding was observed when ISH was performed using a 
WPRE sense radiolabelled probe (Figure 4.8B). 
 
 
 
 
 
 
A 
B 
Figure 4.8: Representative microphotographs showing in situ hybridisation using (A) a 
woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) anti-sense riboprobe 
and (B) a WPRE sense riboprobe to confirm signal specificity in an animal injected bilaterally 
intra-Arc with rAAV-Kisspeptin-AS. Arrows show riboprobe binding.  No non-specific binding was 
observed. Sections of 12μm thickness were taken approximately 3.3mm caudal to bregma. Scale bars 
are equivalent to 5mm.  
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4.3.3. The effect of intra-Arc rAAV-Kisspeptin-AS administration on oestrous cyclicity 
Animals administered intra-Arc rAAV-Kisspeptin-AS had significantly fewer ‘regular’ cycles 
between day 4 and day 100 post-injection compared to EGFP controls (number of ‘regular’ 
cycles: 17.12 ± 0.46 [rAAV-EGFP] vs 15.00 ± 0.87 [rAAV-Kisspeptin-AS] p<0.05, n=12-14 per 
group). There was also a trend for animals administered rAAV-Kisspeptin-AS to have more 
‘extended’ and ‘abnormal’ cycles than controls, although this did not reach significance (Table 
4.1). 
A more stringent cycle analysis was performed to detect subtler changes in oestrous cyclicity 
between groups. Animals administered intra-Arc rAAV-Kisspeptin-AS had significantly fewer 
‘complete’ cycles than animals administered rAAV-EGFP between days 4 and 100 post-injection 
(number of complete cycles: 10.00 ± 0.63 [rAAV-EGFP] vs 6.50 ± 0.82 [rAAV-Kisspeptin-AS] 
p<0.01, n=12-14 per group) (Table 4.1 and Figure 4.9A).  
Animals injected with rAAV-Kisspeptin-AS had significantly longer cycles than controls, as 
demonstrated by an increased number of days between each occurrence of oestrous (average 
number of days per cycle: 3.84 ± 0.10 [rAAV-EGFP] vs 4.30 ± 0.11 [rAAV-Kisspeptin-AS] 
p<0.01, n=12-14 per group) (Table 4.1 and Figure 4.9B). 
No significant differences between groups were observed in the percentage time spent in 
proestrous, oestrous, metestrous or diestrous (Figure 4.10).  
 
 
 
 
 
 
 
 
171 
 
 
 
Intra-Arc 
treatment 
Regular cycles 
 
Extended cycles Abnormal cycles Complete cycles Average number of days per 
cycle 
rAAV-EGFP 17.12 ± 0.46 
 
0.58 ± 0.29  0.00 ± 0.00  10.00 ± 0.63 3.84 ± 0.10 
rAAV-
Kisspeptin-AS 
15.00 ± 0.87* 
 
1.38 ± 0.33 0.23 ± 0.17 6.50 ± 0.82** 4.30 ± 0.11** 
 
 
 
 
Table 4.1: The effect of intra-Arc rAAV-EGFP or rAAV-Kisspeptin-AS administration on oestrous cyclicity in adult female Wistar 
rats. Vaginal cytology was analysed daily from day 4 to day 100 post-injection to determine oestrous cycle stage. The number of regular, 
extended and abnormal cycles was calculated. A regular cycle was one lasting between 3 and 5 days, with either 1 or 2 days of oestrous or 2 or 
3 days of diestrous. An extended cycle contained either 3 or 4 days of oestrous, or 4 or 5 days of diestrous. An abnormal cycle contained more 
than 4 consecutive days of oestrous, or more than 6 days of diestrous (Goldman et al., 2007). Additionally, a complete cycle was counted as 
one in which 3 out of 4 cycle stages were observed in the correct order. Cycle length was calculated as the average number of days between 
each occurrence of oestrous (Goldman et al., 2007). Data is presented as mean ± SEM. *p<0.05, **p<0.01 vs. rAAV-EGFP group, n= 12-14 
per group.  
172 
 
 
EGFP Kisspeptin-AS
0
2
4
6
8
10
12
**
Treatment
N
um
be
r 
of
 c
om
pl
et
e 
cy
cl
es
 
EGFP Kisspeptin-AS
0
2
4
6
**
Treatment
N
um
be
r 
of
 d
ay
s 
pe
r 
cy
cl
e
 
 
 
 
 
 
 
A 
B 
Figure 4.9: The effect of intra-Arc rAAV-Kisspeptin-AS administration on oestrous cyclicity in 
adult female Wistar rats. Vaginal cytology was analysed daily from day 4 to day 100 post-injection 
to determine oestrous cycle stage. Number of complete cycles (A) and average number of days per 
cycle (B) were calculated. Data is presented as mean ± SEM. **p<0.01 vs. rAAV-EGFP group, n= 12-
14 per group.  
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Figure 4.10: The effect of intra-Arc rAAV-Kisspeptin-AS administration on percentage time 
spent in each stage of the oestrous cycle in adult female Wistar rats. Vaginal cytology was 
analysed daily from day 4 to day 100 post-injection to determine oestrous cycle stage. Percentage 
time spent in proestrous, oestrous, metestrous and diestrous in animals administered (A) rAAV-
EGFP or (B) rAAV-Kisspeptin-AS was calculated. N= 12-14 per group.  
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4.3.4. The effect of intra-Arc rAAV-Kisspeptin-AS administration on plasma LH  and 
oestradiol 
No statistically significant differences in plasma LH (Figure 4.11A) or oestradiol (Figure 4.11B) 
were observed between animals administered rAAV-EGFP or rAAV-Kisspeptin-AS.   
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Figure 4.11: Plasma (A) luteinizing hormone (LH) and (B) oestradiol levels in female Wistar rats 
administered intra-Arc rAAV-EGFP or rAAV-Kisspeptin-AS. Animals were killed in diestrous 
between day 100 and day 105 post-injection. Plasma LH was measured by radioimmunoassay, and 
oestradiol by enzyme-linked immunosorbent assay. Data is presented as mean ± SEM, n=12-14 per 
group.  
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4.3.5. The effect of intra-Arc rAAV-Kisspeptin-AS administration on body weight and food 
intake 
There was no difference in body weight between the rAAV-EGFP and rAAV-Kisspeptin-AS 
groups at the onset of the study. The body weights of both groups remained similar until the 
termination of the study on day 100 post-injection (Figure 4.12A). 
Similarly, there was no difference in food intake between groups at any time point throughout 
the experiment (Figure 4.12B).   
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Figure 4.12: (A) Body weight and (B) cumulative food intake following bilateral intra-Arc 
injection of rAAV-EGFP or rAAV-Kisspeptin-AS to adult female Wistar rats. Body weight 
and food intake were measured every other day from day 4 to day 100 post-injection of rAAV-
EGFP (green line) or rAAV-Kisspeptin-AS (pink line). Data is presented as mean ± SEM, n= 12-
14 per group.  
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4.4. Discussion 
In the work described in this chapter I have investigated the effects of rAAV-mediated 
expression of kisspeptin antisense RNA in the Arc of adult female rats on oestrous cyclicity, 
plasma levels of gonadotrophins and oestradiol, food intake and body weight. 
In the rodent hypothalamus, kisspeptin neuronal cell bodies are predominantly located in the Arc 
and the AVPV (Clarkson and Herbison, 2006). Kisspeptin neurones in the Arc are hypothesised 
to regulate the tonic, pulsatile release of GnRH, and mediate the negative feedback effects of 
gonadal steroids on GnRH release (Smith et al., 2005a; Li et al., 2009). Conversely, kisspeptin 
neurones within the AVPV are thought to have a role in generating the preovulatory LH surge in 
females, and relay the positive feedback effect of oestrogen to GnRH neurones (Smith et al., 
2005a; Kinoshita et al., 2005).  
No studies have investigated the long-term effects of kisspeptin down-regulation in adult animals 
on the reproductive axis. Knockout models are extremely useful, but can be complicated by 
developmental compensation. Repeated injections of a kisspeptin antagonist or anti-kisspeptin 
antibodies avoid this problem, but are stressful for the animal, which may confound results. 
Recombinant AAV circumvents these problems and is a useful tool for investigating the long-
term effects of transgene expression. The rAAV construct can be administered to adult animals, 
and rAAV-mediated transgene expression has been reported to be stable for up to 15 months in 
the rat CNS (Xu et al., 2001). Although the exact mechanism by which antisense RNA reduces 
protein expression is unknown, it is thought that antisense RNA binds to endogenous sense 
RNA, and hence forms a double-stranded RNA duplex. This duplex is then subjected to 
modification by ADAR enzymes, which convert approximately 50% of adenosine residues to 
inosines (Bass and Weintraub, 1988). The RNA duplex then becomes unstable and is retained in 
the nucleus, unable to be translated (Kumar and Carmichael, 1997). The newly formed 
mismatched RNA is also extremely susceptible to degradation by ribonucleases (Nishikura, 
1992). 
Vaginal lavage was performed daily to determine the cycle stage of each animal. Lavage was 
performed at a similar time each day to minimise variability and ensure consistency. Cycles were 
classified as regular, extended, or abnormal, as previously described (Goldman et al., 2007). A 
more stringent classification was also used to detect smaller changes between treatment groups; a 
‘complete’ oestrous cycle was defined as one in which 3 out of 4 stages were observed in the 
correct order. Cycle length was calculated as the number of days between one oestrous and the 
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next. These methods have been previously used to evaluate the oestrous cycle in rodents 
(Goldman et al., 2007; Risvanli et al., 2010). 
Intra-Arc administration of rAAV-Kisspeptin-AS to adult female rats significantly reduced the 
number of both regular and complete oestrous cycles over a 100-day period, and significantly 
increased the length of each cycle. This suggests that rAAV-Kisspeptin-AS administration 
lengthened each cycle sufficiently to result in a reduced number of total overall cycles. There 
was also a tendency for animals administered rAAV-Kisspeptin-AS to have more extended and 
abnormal cycles than controls, although this effect did not reach statistical significance. The 
percentage time spent in each stage of the cycle was calculated to determine whether rAAV-
Kisspeptin-AS induced a tendency to remain in one stage of the cycle. However, no statistically 
significant differences were observed between groups. 
Pulsatile GnRH release is crucial for normal functioning of the HPG axis. It has long been 
thought that the GnRH pulse generator resides in the Arc, as surgically isolating this nucleus in 
female rats induces persistent oestrous, but maintains pulsatile LH release (Blake and Sawyer, 
1974). The exact mechanisms underlying the GnRH pulse generator are unknown. Numerous 
neurotransmitters, including NPY and glutamate, are known to regulate GnRH release (Crowley 
and Kalra, 1987; Bourguignon et al., 1989). Additionally, GnRH neurones possess intrinsic 
pulsatile firing properties (Wetsel et al., 1992). It has recently been suggested that Arc kisspeptin 
neurones may also regulate GnRH, and hence LH, pulsatility. Kisspeptin is released in a pulsatile 
fashion, and kisspeptin pulses closely match release of GnRH into the median eminence (Keen et 
al., 2008). In the goat, LH pulses closely follow multi-unit electrical activity volleys in the 
posterior Arc, where kisspeptin neurones reside (Ohkura et al., 2009). Additionally, intra-Arc 
administration of a kisspeptin antagonist to female rats prolongs LH pulse interval, resulting in 
fewer overall LH pulses measured over 8 hours (Li et al., 2009). This is presumed to be due to 
reduced stimulatory input to GnRH neurones. Administration of the same antagonist to the 
MPOA had no effect on LH pulse amplitude or frequency (Li et al., 2009).    
It is therefore possible that intra-Arc administration of kisspeptin antisense reduced GnRH, and 
hence LH, pulse frequency, resulting in lengthened oestrous cycles. I was not able to measure the 
effect of intra-Arc rAAV-Kisspeptin-AS administration on LH pulsatility in this study; repeated 
blood sampling is stressful for rats and thus would likely disrupt oestrous cyclicity. However, it 
would be interesting to investigate this in the future. It is interesting to note that my results are in 
accord with previous work in which destruction of the Arc in female mice resulted in 
lengthening of oestrous cycles (May et al., 1989). At the time, the authors did not know which 
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neuronal population was responsible for this phenotype, but their findings may have reflected a 
reduction in Arc kisspeptin signalling.     
Arcuate kisspeptin neurones are also thought to relay the negative feedback effects of gonadal 
steroids onto GnRH neurones (Smith et al., 2005a; Smith et al., 2005b). It would be interesting to 
investigate whether kisspeptin knockdown disrupts this process by, for example, determining 
whether oestradiol replacement is able to suppress high circulating LH levels induced by 
ovariectomy in female rats administered intra-Arc rAAV-Kisspeptin-AS.  
My results suggest that intra-Arc administration of rAAV-Kisspeptin-AS increases the length of 
the oestrous cycle in adult female rats, but does not severely disrupt reproductive function. There 
are several reasons why this may not be. Firstly, the antisense construct may not have reduced 
kisspeptin expression sufficiently to have a marked phenotypic effect. Antisense RNA 
expression is unable to reduce protein levels by 100%, and so residual kisspeptin signalling may 
have been adequate to ensure that reproductive cycles continued. Previous published work from 
our laboratory has demonstrated that rAAV-NPY-AS administration into the Arc reduces 
hypothalamic NPY peptide content by over 50% at day fifteen post-injection (Gardiner et al., 
2005). Although I have demonstrated transgene expression in vivo using in situ hybridisation, at 
the time of writing this thesis I have not yet been able to confirm that the rAAV-Kisspeptin-AS 
construct reduced arcuate levels of kisspeptin protein in vivo. There is currently no 
radioimmunoassay to quantify rat kisspeptin available, and I am currently in the process of 
establishing such an assay. Once this assay has been optimised, I plan to take punch biopsies of 
the arcuate nuclei of animals used in this study, and to compare levels of kisspeptin protein in 
rAAV-Kisspeptin-AS and rAAV-EGFP animals. At present it is therefore not possible to firmly 
conclude that the results obtained are due to a reduction in kisspeptin expression.  
Secondly, it is possible that signalling by neuropeptides other than kisspeptin to GnRH neurones 
were sufficient to compensate for the reduction in kisspeptin, to ensure reproductive capacity 
was maintained. GnRH neurones receive stimulatory afferent inputs from numerous 
neurotransmitters including glutamate, NPY, galanin and vasoactive intestinal peptide 
(Bourguignon et al., 1989; Crowley and Kalra, 1987; Lopez and Negro-Vilar, 1990; Samson et 
al., 1981). Additionally, Arc kisspeptin neurones co-express dynorphin and NKB in several 
species (Goodman et al., 2007; Navarro et al., 2009). Administration of an NKB agonist 
increases plasma LH in female rats, and an autoregulatory circuit comprising kisspeptin, NKB 
and dynorphin signalling has been proposed to play an important role in generating pulsatile 
GnRH secretion (Navarro et al., 2011). The hypothesis that NKB signalling is an important 
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regulator of the HPG axis is supported by the finding that in humans, mutations of the genes 
encoding NKB or its receptor result in hypogonadotrophic hypogonadism (Topaloglu et al., 
2009; Young et al., 2010). If Arc kisspeptin expression is reduced, NKB signalling may 
compensate to ensure reproductive capacity is maintained. However, such compensatory 
signalling is obviously insufficient to maintain fertility when either kisspeptin or GPR54 are 
completely absent, as KiSS-1 (d'Anglemont de Tassigny et al., 2007) and GPR54 (Seminara et 
al., 2003) knockout mice do not progress through puberty and are infertile.  
Rats were culled in diestrous as this is when basal levels of LH and FSH are less variable, and 
hence small differences between groups may have been easier to detect. However, there were no 
differences in plasma LH between groups. This is perhaps not surprising, as LH secretion 
follows a pulsatile pattern, with peaks occurring every 20 to 40 minutes in the rat (Dierschke et 
al., 1970; Blake and Sawyer, 1974). It is therefore difficult to obtain true baseline measurements. 
Additionally, it has recently been demonstrated that ICV administration of a kisspeptin 
antagonist does not affect basal LH levels in male and female rats; only the pre-ovulatory LH 
surge was attenuated by antagonist administration in females (Roseweir et al., 2009; Pineda et 
al., 2010). It is likely that this represents blockade of kisspeptin neurones originating in the 
AVPV, not the Arc, as AVPV kisspeptin neurones become activated immediately prior to the LH 
surge (Smith et al., 2006b).  Although plasma oestradiol levels were lower in animals 
administered rAAV-Kisspeptin-AS compared to EGFP controls, this effect did not reach 
statistical significance. It is perhaps unlikely that we would detect a significant change, as mice 
lacking a functional KiSS-1 gene do not have significantly lower plasma oestradiol levels 
compared to wild-type controls (d'Anglemont de Tassigny et al., 2007).  
Expression of kisspeptin antisense RNA had no effect on food intake or body weight over a 100-
day period. This confirms that the differences in oestrous cyclicity observed were not due to 
differences in energy status. Fertility is dependent on adequate body fat  reserves. In rats, food 
deprivation and body weight loss suppress circulating LH and sex steroid levels and prevent 
normal reproductive function (Badger et al., 1985; Castellano et al., 2005; Terry et al., 2005; 
Glass et al., 1976). Kisspeptin has been hypothesised to mediate the permissive effects of leptin 
on the HPG axis, as Arc kisspeptin neurones co-express ObRb mRNA, and leptin-deficient ob/ob 
mice have significantly lower hypothalamic KiSS-1 mRNA levels than wild type controls (Smith 
et al., 2006a). It is therefore reassuring that there were no differences in body weight or food 
intake between groups, which may have confounded my results. Conversely, kisspeptin neurones 
have recently been shown to directly stimulate anorexigenic POMC neurones, and so 
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administration of kisspeptin antisense RNA might have been postulated to modulate energy 
homeostasis (Fu and van den Pol, 2010). However, no differences between groups were 
observed.  
To continue with this work I would like to administer rAAV-Kisspeptin-AS to the AVPV of 
adult female rats, and monitor oestrous cyclicity to determine whether reproductive function is 
impaired. It would be particularly interesting to determine the effect of AVPV kisspeptin 
knockdown on the pre-ovulatory LH surge.  
Kisspeptin signalling has a crucial role in the initiation of puberty. Humans and mice lacking 
GPR54 do not progress through puberty (de Roux N. et al., 2003; Seminara et al., 2003), and 
chronic ICV administration of kisspeptin to immature female rats advances pubertal onset 
(Navarro et al., 2004). Kisspeptin expression increases at the onset of puberty in both sexes, 
particularly in the AVPV, as does the number of appositions between kisspeptin immunoreactive 
fibres and GnRH neurones (Clarkson and Herbison, 2006). It would therefore be interesting to 
determine whether kisspeptin antisense administration to pre-pubertal male and female rats 
delays puberty.   
In conclusion, my work has demonstrated that intra-Arc administration of kisspeptin antisense to 
adult female rats resulted in significantly fewer oestrous cycles over a 100 day period, and 
increased the average length of each cycle, compared to controls. No significant differences in 
plasma LH or oestradiol were observed. Although this work has begun to investigate the long-
term effects of Arc kisspeptin knockdown on reproduction, more work is required to further 
characterise the importance of kisspeptin signalling in both the Arc and AVPV.      
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Chapter 5: General discussion 
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5.1. Introduction 
The hypothalamus has a crucial role in maintaining energy homeostasis and reproduction. 
Nutrients, gut hormones and metabolic factors such as leptin signal to the hypothalamus, where 
appropriate downstream circuits are activated to modulate food intake and energy expenditure. 
Energy homeostasis and fertility are intimately linked, as fat reserves must be adequate to permit 
pubertal onset and normal functioning of the HPG axis, which is regulated by the hypothalamus.  
The CNS reward system also has an important role in the control of feeding. It is hypothesised 
that dominance of hedonic signals over homeostatic signals may be a major contributing factor 
to the current obesity epidemic, particularly in an environment where palatable, high-fat food is 
readily available. However, the reward pathways involved in the regulation of feeding are not 
well characterised. 
This thesis has described work investigating the role of the hypothalamus in food intake and 
reproduction, and the role of the reward system in food intake. 
 
5.2. Investigating the role of Cerebellin 1 in the regulation of energy homeostasis and 
neuroendocrine function 
Cerebellin 1 (Cbln1) is a 16-amino acid peptide derived from the precursor Pre-Cbln1 (Yiangou 
et al., 1989; Urade et al., 1991). Cbln1 was originally isolated from the cerebellum, and it is 
thought to have a role in cerebellar development and motor coordination (Slemmon et al., 1984; 
Hirai et al., 2005). Cbln1 is also highly expressed in the hypothalamus, particularly in the VMN 
(Burnet et al., 1988; Miura et al., 2006). My studies focused on the effect of Cbln1 on food 
intake and neuroendocrine function.  
My work suggests that Cbln1 is a novel orexigenic peptide. ICV administration of Cbln1 
significantly increased food intake in both fasted and ad libitum fed rats, although the effect was 
more pronounced in fed animals. Hypothalamic explants treated with Cbln1 had significantly 
increased NPY release, suggesting that Cbln1 may mediate its orexigenic effect via NPY. 
However, pre-treatment with an NPY Y1 receptor antagonist did not significantly attenuate the 
effect of Cbln1 on feeding in vivo, suggesting that signalling by this receptor is not necessary for 
the orexigenic effect of Cbln1, and that additional pathways are likely to be involved. It would 
be interesting to block other orexigenic hypothalamic neuropeptide pathways using, for example, 
antagonists or antibodies to the orexins and MCH, and determine the effect on Cbln1-induced 
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feeding. Alternatively, Cbln1 may reduce expression of the anorectic neuropeptide BDNF, which 
is, like Cbln1, highly expressed in the VMN (Xu et al., 2003).  
I demonstrated that Pre-Cbln1 mRNA expression within the VMN altered following changes in 
nutritional status. This implies that Cbln1 may have a physiological role in the control of food 
intake. It would be interesting to measure levels of hypothalamic Pre-Cbln1 mRNA in lean and 
obese rodents; differences in expression may indicate a possible role for Cbln1 in the 
development of obesity.   
ICV Cbln1 administration significantly reduced circulating levels of TSH. This suggests that in 
addition to increasing food intake, Cbln1 may reduce energy expenditure. Other orexigenic 
neuropeptides, for example NPY and AgRP, have also been shown to reduce energy expenditure 
(Fekete et al., 2001; Kim et al., 2000b). NPY decreases energy expenditure by reducing activity 
of the thyroid axis, and by reducing sympathetic outflow to brown adipose tissue (BAT), a major 
site of adaptive thermogenesis in rodents (Fekete et al., 2001; Egawa et al., 1991). It would be 
interesting to determine whether central administration of Cbln1 also affects the activity of BAT 
by, for example, quantifying UCP-1 expression.  
It would be interesting to determine which hypothalamic pathways are activated following Cbln1 
administration. I would like to localise and quantify expression of Fos, a marker of neuronal 
activation, in specific hypothalamic nuclei following central injection of Cbln1. It would also be 
interesting to perform dual staining for Fos and NPY following Cbln1 administration. If co-
localisation was observed, it would confirm that NPY neurones are stimulated by Cbln1. 
Investigating whether Cbln1 is able to increase food intake in NPY knockout animals would 
determine whether Cbln1 is dependent on NPY for its orexigenic effect.  
The receptor through which Cbln1 exerts its orexigenic effect is unknown, and therefore cannot 
be targeted by an antagonist. To determine whether a reduction in hypothalamic Cbln1 signalling 
affects food intake, it would be possible to administer an anti-Cbln1 antibody ICV. If anti-Cbln1 
administration reduced food intake, it would provide strong evidence that Cbln1 has a 
physiological role in the control of energy intake. Administering Pre-Cbln1 anti-sense DNA via 
a suitable vector, such as rAAV, into the VMN of rats and monitoring their food intake and body 
weight would also help to determine the physiological role of Cbln1. Knockdown of Cbln1 
expression would be expected to cause a reduction in food intake and body weight gain if Cbln1 
has a physiological orexigenic role.  
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5.3. Investigating the role of VTA melanocortin signalling in the regulation of food intake 
Cortico-limbic structures involved in cognition, emotion and reward play an important role in the 
control of feeding. The VTA, which predominantly contains dopamine neurones and GABAergic 
inter-neurones, is an important component of the CNS motivational circuitry and has a major 
role in mediating the rewarding and reinforcing properties of palatable food (Kenny, 2011).  
Recently, it has been suggested that hypothalamic neuropeptides may have a role in the hedonic 
control of feeding, in addition to their role in maintaining energy homeostasis (Davis et al., 2010; 
Zheng et al., 2007). My studies focused on the effect of melanocortin administration into the 
VTA on food intake. I found that intra-VTA administration of NDP-MSH potently reduced food 
intake when administered to ad libitum fed rats, even at extremely low doses. However, NDP-
MSH had no significant early effect on food intake when administered to fasted rats. This 
suggests that the effect of VTA melanocortin signalling on food intake may vary with nutritional 
status; in times of caloric deficit, homeostatic signals may override hedonic signals to promote 
food intake and protect body fat reserves. The anorectic effect of intra-VTA NDP-MSH 
administration was attenuated by pre-administration of a GABAA receptor antagonist, suggesting 
that NDP-MSH may act via GABAergic interneurones in the VTA to reduce food intake. 
Intra-VTA administration of AgRP increased food intake and body weight in ad libitum fed rats. 
This effect was attenuated by pre-treatment with a dopamine receptor antagonist. Similarly, 
injection of an MC4R antagonist stimulated feeding, and this effect was completely abolished by 
pre-treatment with a dopamine receptor antagonist. From these results it is possible to construct a 
hypothetical model of how melanocortin signalling in the VTA may influence feeding. 
Activation of melanocortin receptors within the VTA may stimulate GABAergic neurones, 
causing suppression of dopamine neuronal firing. Antagonism of melanocortin receptor 
signalling by AgRP may disinhibit dopamine neurones, leading to increased neuronal firing, 
increased dopamine release and increased food intake. 
However, further work is required to support this hypothesis. Although the MC3R and MC4R 
have been found in the VTA (Mountjoy et al., 1994; Roselli-Rehfuss et al., 1993), co-localisation 
studies are necessary to determine whether melanocortin receptors are located on GABAergic 
and/or dopamine neurones. I would also like to determine whether intra-VTA administration of 
AgRP increases dopamine turnover in the NAc and pre-frontal cortex.  
The finding that blocking MC4R signalling in the VTA increases food intake suggests that there 
is an endogenous melanocortin tone acting in the VTA. Mice lacking a functional MC4R gene 
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are obese and hyperphagic (Huszar et al., 1997). It is possible to purchase mice with a loxp-
flanked transcriptional blocking sequence that prevents normal transcription and translation of 
the endogenous MC4R gene. The blocking sequence can be removed by injecting the enzyme 
Cre-recombinase. It would be interesting to investigate whether re-expression of the MC4R 
specifically within the VTA of these mice could partially reverse their obese, hyperphagic 
phenotype. This would help determine the importance of endogenous MC4R signalling in the 
VTA in the modulation of energy homeostasis.  
In contrast to hypothalamic pathways, relatively little is known about the role of the reward 
system in feeding. There has been much interest recently in the role of the reward system in the 
development of obesity. It has been suggested that both hypo- and hyper-sensitivity to reward 
may predispose to obesity. An increase in the responsiveness of reward circuitries may lead to 
overeating and weight gain (Gautier et al., 2000). Conversely, ‘reward deficiency’ has been 
suggested to result in overconsumption of palatable food, to compensate for hypo-functioning of 
the reward circuitry. Reward deficiency may be caused by genetic factors; patients with a 
polymorphism downstream of the D2R gene have reduced D2R expression in the striatum, and 
are more likely to become obese (Stice et al., 2008).  Additionally, studies in humans and rodents 
have suggested that over-consumption of palatable food and weight gain reduce D2R availability 
in the striatum and hence reduce responsiveness to reward (Colantuoni et al., 2001; Johnson and 
Kenny, 2010; Stice et al., 2010). Interestingly, the functional changes observed in the 
mesolimbic dopamine pathway in obese patients are similar to those observed in drug addicts, 
suggesting that there is overlap in the pathways controlling hedonic food intake and drug abuse 
(Wang et al., 1997a).  
Although the reward system may be an attractive therapeutic target for treating obesity, care 
must be taken when manipulating this pathway. Rimonabant, a cannabinoid receptor antagonist, 
was previously prescribed as an effective weight loss agent. However, it was withdrawn from 
clinical practice in 2008. Its side-effects, which included severe depression and increased 
suicidal intention, may have been due to the actions of endogenous cannabinoids in the reward 
system. Once a better understanding of the reward system is achieved, more specific drugs 
targeting this pathway can be developed for the treatment of obesity.  
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5.4. Investigating the role of arcuate kisspeptin signalling in the control of reproduction 
Kisspeptin signals upstream of GnRH to stimulate the HPG axis, and has a vital role in the 
control of reproduction (Irwig et al., 2004; Matsui et al., 2004; Pielecka-Fortuna et al., 2008). 
Kisspeptin neurones are hypothesised to relay metabolic signals, for example leptin, to GnRH 
neurones, and hence to couple energy reserves with fertility (Castellano et al., 2005; Smith et al., 
2006a). However, recent studies suggest that leptin can influence fertility in the absence of 
kisspeptin signalling, suggesting that kisspeptin is not critical for this effect (Donato et al., 
2010).  
Kisspeptin neurones may also relay gonadal steroid signals to GnRH neurones. Within the rodent 
hypothalamus, kisspeptin neurones in the Arc are hypothesised to relay negative feedback 
signals to GnRH neurones, and to provide tonic stimulatory input to GnRH neurones. In contrast, 
kisspeptin neurones in the AVPV may relay positive feedback signals to GnRH neurones, and 
mediate the pre-ovulatory GnRH and LH surge (Smith et al., 2005a; Smith et al., 2005b; Dungan 
et al., 2007; Pineda et al., 2010).  
I used recombinant AAV expressing kisspeptin antisense cDNA to investigate the effects of 
kisspeptin down-regulation in the rat Arc on reproductive function. I chose to use a viral vector 
because it permits spatial and temporal control of gene expression, and allows the phenotype 
resulting from transgene expression to be monitored for long periods of time.  
Intra-Arc administration of rAAV-Kisspeptin-AS to adult female rats resulted in a significant 
reduction in the number of both regular and complete oestrous cycles between days 4 and 100 
post-injection. Cycle length was also significantly increased in Kisspeptin-AS animals. Plasma 
analysis revealed no statistically significant differences in levels of LH or oestradiol between 
groups.    
Kisspeptin neurones in the Arc are hypothesised to regulate the pulsatile release of GnRH into 
the pituitary portal circulation, and hence LH release from the anterior pituitary gland (Keen et 
al., 2008; Ohkura et al., 2009). It is therefore possible that the alterations in oestrous cyclicity 
observed in animals administered rAAV-Kisspeptin-AS were due to disruption of the GnRH 
pulse generator. Administration of a kisspeptin receptor antagonist into the Arc has been shown 
to suppress LH pulse frequency over 5 hours (Li et al., 2009). However, it is unclear whether this 
experiment specifically measured the effects of inhibiting Arc kisspeptin neuronal signalling, or 
whether the antagonist may, for example, have reached the median eminence and inhibited 
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kisspeptin signalling at this location. It would be interesting to monitor LH pulsatility in animals 
administered intra-Arc rAAV-Kisspeptin-AS in future studies.  
This work has begun to elucidate the physiological role of kisspeptin signalling within the Arc. 
However, further studies are required to determine the role of hypothalamic kisspeptin. I plan to 
administer rAAV-Kisspeptin-AS into the AVPV of female rats and monitor oestrous cyclicity. It 
will be interesting to determine whether the pre-ovulatory LH surge and hence ovulation is 
impaired in these animals, as might be predicted from acute studies using antagonists or 
kisspeptin antibodies  (Pineda et al., 2010; Kinoshita et al., 2005). 
I am also establishing a radioimmunoassay for kisspeptin to quantify kisspeptin peptide levels in 
the Arc and AVPV of rAAV-Kisspeptin-AS-treated animals. It would be interesting to use this 
assay in conjunction with a hypothalamic explant system to determine the responsiveness of 
kisspeptin neurones to factors for which they express receptors, for example testosterone, 
oestrogen and leptin (Smith et al., 2005b; Smith et al., 2006a), at different stages of the oestrous 
cycle.  
Kisspeptin is a promising agent for the treatment of reproductive disorders. Acute and chronic 
administration of kisspeptin-54 to women with hypothalamic amenorrhea has been shown to 
significantly increase plasma levels of LH and FSH (Jayasena et al., 2009; Jayasena et al., 2010). 
Further understanding of the kisspeptin system may therefore aid the development of novel 
agents for the treatment of infertility.   
 
5.5. Final summary  
In the work described in this thesis I have described a novel role for the neuropeptide Cbln1 in 
the control of energy homeostasis, and have begun to characterise the role of the melanocortins 
in reward pathway signalling. Further work is required to improve our understanding of both 
systems, and to determine how homeostatic and hedonic pathways interact to modulate feeding. I 
have also investigated the role of arcuate kisspeptin signalling in the control of reproduction in 
female rats, although more work is also required to further characterise this complex system.  
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Appendix I: Solutions used in this thesis 
 
5M ammonium acetate 
Dissolve 385g CH3.COONH4 in 600ml GDW and make up to 1l. 
 
Artificial cerebrospinal fluid (aCSF) 
To make 500ml aCSF, mix 100ml 0.1M NaHCO3, 100ml 0.63M NaCl, 5ml 0.09M 
Na2HPO4.2H2O, 5ml 0.59M KCl, 5ml 0.09M MgSO4.7H2O, 450mg glucose, 88mg ascorbic 
acid, 5ml aprotinin (Bayer Corp.) and 270ml GDW. Saturate with 95% O2 and 5% CO2. Add 
10ml 0.07M CaCl2.2H2O after gassing. 
 
Potassium-enriched aCSF 
To make 100ml 56mM KCl aCSF, mix 20ml 0.1M NaHCO3, 11.6ml 0.63M NaCl, 1ml 0.09M 
Na2HPO4.2H2O, 10ml 0.59M KCl, 1ml 0.09M MgSO4.7H2O, 90mg glucose, 17.6mg ascorbic 
acid, 1ml aprotinin (Bayer Corp.) and 53.4ml GDW. Saturate with 95% O2 and 5% CO2. Add 
2ml 0.07M CaCl2.2H2O after gassing. 
 
Stock solutions for aCSF: 
0.1M sodium bicarbonate: Dissolve 4.62g NaHCO3 in 500ml GDW 
0.63M sodium chloride: Dissolve 18.43g NaCl in 500ml GDW 
0.09M  disodium hydrogen orthophosphate dihydrate: Dissolve 1.56g Na2HPO4.2H2O in 100ml 
GDW 
0.59M potassium chloride: Dissolve 4.42 KCl in 100ml GDW 
0.09M magnesium sulphate heptahydrate: Dissolve 2.2g MgSO4.7H2O in 100ml GDW.  
0.07M calcium chloride dihydrate: Dissolve 1.04g CaCl2.2H2O in 100ml GDW. 
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Alkaline sodium dodecyl sulphate (SDS) 
Add 2ml 10M NaOH and 1g SDS to 100ml GDW.  
 
Antifreeze solution 
Add 30% (v/v) ethylene glycol and 20% (v/v) glycerol to 0.01M PBS 
 
Cresyl violet stain 
Mix 2g cresyl violet, 300ml GDW, 30ml 1M NaAc and 170ml acetic acid, and pH to 3.7-3.9. 
Filter before use. 
 
Caesium chloride saturated isopropanol 
Mix 100g CsCl2, 100ml GDW and 100ml isopropanol and leave to settle. 
 
Dextran-coated charcoal 
Add 2.4g charcoal and 0.24g dextran to 100ml phosphate buffer with gelatin and mix for 20 
minutes.  
 
Dextran sulphate 
Dissolve 1g dextran sulphate in 1.5ml GDW. Warm at 60ºC for 2-3 hours to dissolve and vortex 
before use.  
 
DNAse buffer 
Add 0.8ml 1M Tris/HCl pH 7.4, 120µl 1M MgCl2 and 40µl CsCl2 to 99ml GDW. 
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dNTP mix for PCR and reverse transcription 
Mix 20µl each of 100mM dGTP, dCTP, dATP and dTTP in 120µl filtered GDW. 
 
0.5M ethylenediaminetetra-acetic acid (EDTA) 
Dissolve 186.1g C10H14H2O8Na2.2H2O (EDTA) in 800ml GDW and adjust pH to 8.0. Make up 
to 1l with GDW.  
 
4% formaldehyde solution 
Dissolve 100mls 40% formaldehyde in 1l GDW.  
 
Gel loading buffer 
Mix 3.125ml 80% glycerol, 50µl 0.5M EDTA and 6.075ml GDW, and add 10mg orange G. 
 
Glucose-Tris-EDTA buffer  
Mix 2.5ml 1M Tris HCl pH 8.0, 2ml 0.5M EDTA and 5ml 18% glucose and make up to 100ml 
with GDW. Sterilise by passing through a 0.2µm filter.  
 
Kemteck buffer 
Dissolve 22.4g NaH2PO4.2H2O, 9.96g Na2HPO4.2H2O, 14.8g C10H14H2ONa2.2H2O, 1g 
C9H9HgNaO2S and 26.6ml 30% BSA in 5l GDW that has been boiled and allowed to cool. 
Adjust pH to 7.4 and store at 4ºC.  
 
Lysogeny broth 
Dissolve 10g NaCl, 10g tryptone and 5g yeast extract in 2l GDW. Sterilise by autoclaving.  
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20x MOPS 
Dissolve 83.6g 3-(N-Morpholino)propanesulphonic acid (MOPS), 8.1g sodium acetate, 7.4g 
C10H14H2O8Na2.2H2O and 2.5ml formaldehyde in 800ml water. Adjust to pH 7.0 with 10M 
sodium hydroxide and make up to 1l. 
 
Phosphate buffer 
Dissolve 48g Na2HPO4.2H2O, 4.13g KHPO4, 18.61g C10H14H2ONa2.2H2O and 2.5g NaN3 in 5l 
GDW that has been boiled and allowed to cool. Adjust pH to 7.4 and store at 4ºC.  
 
Phosphate buffer with gelatine 
The buffer is produced as above, except that 12.5g gelatine is added to the boiled water prior to 
cooling, and before addition of the other reagents. 
 
10x phosphate buffered saline (PBS) (0.1M) 
Add 80g NaCl, 2g KCl, 14.4g Na2HPO4 and 2.4g KH2PO4 to 800ml GDW. Adjust volume to 1l 
and pH to 7.4.  
 
5M potassium acetate  
Dissolve 490.6g CH3COOK in 500ml GDW and add 115ml acetic acid. Make up to 1l with 
GDW.  
 
RNase A (10mg/ml) 
Add 10mg RNAse A, 50µl 2M Tris and 30µl 5M NaCl to 9.92ml GDW. Boil for 15 minutes. 
Allow to cool and then aliquot. 
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20x saline sodium citrate (SSC) 
Add 1753g NaCl and 882g Na3C6H5O7.2H20 to 8l GDW. Adjust to pH 7.0 and make up to 10l. 
 
2M sodium acetate 
Dissolve 164.1g CH3COONa in 800ml GDW. Adjust pH to 5.2 with acetic acid and make up to 
1l with GDW.  
 
5M sodium chloride 
Dissolve 292.2g NaCl in 1l GDW.  
 
100x TE 
Dissolve 121.1g Trizma base and 3.7g C10H14H2O8Na2.2H2O in 800ml GDW and adjust pH to 
7.5. Make up to 1l with GDW.  
 
TES 
Mix 25ml 1M Tris-HCl pH 8.0, 5ml 5M NaCl, and 5ml C10H14H2O8Na2.2H2O. Make up to a 
final volume of 500ml with GDW. 
 
Transformation buffer I 
Dissolve 589mg CH3.COOK, 2.418g RbCl, 1.979g CaCl2.2H2O and 438mg MnCl2.4H2O in 
autoclaved distilled water. Add 37.5 ml 80% glycerol and adjust the volume to 200ml with 
water. Sterilise by passing through a 0.2μm filter. 
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Transformation buffer II 
Dissolve 418mg MOPS, 3.28g CaCl2.2H2O and 242mg RbCl in autoclaved distilled water. Add 
37.5ml 80% glycerol and adjust the volume to 200ml with water. Sterilise by passing through a 
0.2μm filter. 
 
1M Triethanolamine (TEA) pH 8.0 
Dissolve 7.42g C6H15NO3.HCl (triethanolamine-hydrochloride) in 30ml GDW. Add NaOH to 
pH to 8.0, then make up to 40mls with GDW.  
 
50x Tris-acetate-EDTA buffer (TAE) 
Dissolve 242g Trizma base in 843ml GDW and mix in 57ml acetic acid and 100ml 0.5M 
C10H14H2O8Na2.2H2O. 
 
2M Tris-HCl (pH 8.0) 
Dissolve 121.1g Trizma base in 450ml GDW and adjust pH to 8.0 with HCl. Make up to 500ml 
with GDW.  
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Appendix II: List of Suppliers 
Abbott Laboratories Ltd., Queenborough, Kent, UK 
Animalcare Ltd., Dunnington, Yorkshire, UK 
Associated Dental Products Ltd., Swindon, Wiltshire, UK 
ATCC, Teddington, Middlesex, UK 
Bachem, St Helens, Merseyside, UK 
Bright Instrument Company, Huntingdon, Cambridgeshire, UK 
Calbiotech, Spring Valley, California, USA 
Charles River, Margate, Kent, UK 
Clark Electromedical Instruments, Reading, Berkshire, UK 
Ecolabs Ltd., Leeds, Yorkshire, UK 
Euro-Diagnostica, Huntingdon, Cambridgeshire, UK 
Fisher Scientific, Loughborough, Leicestershire, UK 
GE Healthcare, Amersham, Buckinghamshire, UK 
Harvard Apparatus, Massachusetts, USA 
Invitrogen, Paisley, UK 
Jencons-PLS, Forest Row, East Sussex, UK 
Jet X-Ray, London, UK 
Kodak, Hemel Hempstead, Hertfordshire, UK 
Microfield Scientific Ltd., Dartmouth, Devon, UK 
MP Biomedicals Inc., Illkirch, France 
New England Biolabs, Hitchin, Hertfordshire, UK 
Nordic Pharma Ltd., Reading, UK 
Perkin Elmer, Waltham, Massachusetts, USA 
Pharmacia Diagnostics, Uppsala, Sweden 
Phoenix Pharmaceuticals Inc, Burlingame, California, USA 
Plastics One Inc., Roanoke, Virginia, USA 
Promega, Madison, Wisconsin, USA 
Schering-Plough Corp., Welwyn Garden City, Hertfordshire, UK 
Shimadzu Corporation Analytical Instruments, Shimadzu, Kyoto, Japan 
Sigma-Aldrich, Gillingham, Dorset, UK 
Special Diet Service Ltd., Witham, Essex, UK  
Stratagene Ltd., Amsterdam, The Netherlands 
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The Peptide Institute, Osaka, Japan 
Thermo Electron Corporation, Marietta, Ohio, USA 
Thermo Fisher Scientific, Epsom, Surrey, UK 
Tocris Bioscience, Bristol, UK 
VWR, Leicester, Leicestershire, UK 
Waters, Milford, Connecticut, USA 
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Appendix III: Amino acid codes 
 
Amino acid Three letter code Single letter code
Glycine        Gly  G 
Proline        Pro  P 
Alanine        Ala  A 
Valine        Val  V 
Leucine        Leu  L 
Isoleucine        Ile  I 
Methionine        Met  M 
Cysteine        Cys  C 
Phenylalanine        Phe  F 
Tyrosine        Tyr  Y 
Tryptophan        Trp  W 
Histidine        His  H 
Lysine        Lys  K 
Arginine        Arg  R 
Glutamine        Gln  Q 
Asparagine        Asn  N 
Glutamic Acid        Glu  E 
Aspartic Acid        Asp  D 
Serine        Ser  S 
Threonine        Thr  T 
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